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ABSTRACT 
Introduction and aims of the research Nitric oxide (NO) and endocannabinoids 
(eCBs) are major retrograde messengers, involved in synaptic plasticity (long-term 
potentiation, LTP, and long-term depression, LTD) in many brain areas (including 
hippocampus and neocortex), as well as in learning and memory processes. NO is 
synthesized by NO synthase (NOS) in response to increased cytosolic Ca2+ and 
mainly exerts its functions through soluble guanylate cyclase (sGC) and cGMP 
production. The main target of cGMP is the cGMP-dependent protein kinase 
(PKG). Activity-dependent release of eCBs in the CNS leads to the activation of 
the Gαi/o-coupled cannabinoid receptor 1 (CB1) at both glutamatergic and 
inhibitory synapses. The perirhinal cortex (Prh) is a multimodal associative cortex 
of the temporal lobe, critically involved in visual recognition memory. LTD is 
proposed to be the cellular correlate underlying this form of memory. Cholinergic 
neurotransmission has been shown to play a critical role in both visual recognition 
memory and LTD in Prh. Moreover, visual recognition memory is one of the main 
cognitive functions impaired in the early stages of Alzheimer’s disease. The main 
aim of my research was to investigate the role of NO and ECBs in synaptic 
plasticity in rat Prh and in visual recognition memory. Part of this research was 
dedicated to the study of synaptic transmission and plasticity in a murine model 
(Tg2576) of Alzheimer’s disease. 
Methods Field potential recordings. Extracellular field potential recordings were 
carried out in horizontal Prh slices from Sprague-Dawley or Dark Agouti juvenile 
(p21-35) rats. LTD was induced with a single train of 3000 pulses delivered at 5 Hz 
(10 min), or via bath application of carbachol (Cch; 50 µM) for 10 min. LTP was 
induced by theta-burst stimulation (TBS). In addition, input/output curves and 5Hz-
LTD were carried out in Prh slices from 3 month-old Tg2576 mice and littermate 
controls.  
Behavioural experiments. The spontaneous novel object exploration task was 
performed in intra-Prh bilaterally cannulated adult Dark Agouti rats. Drugs or 
vehicle (saline) were directly infused into the Prh 15 min before training to verify 
the role of nNOS and CB1 in visual recognition memory acquisition. Object 
recognition memory was tested at 20 min and 24h after the end of the training 
phase. 
Results Electrophysiological experiments in Prh slices from juvenile rats showed 
that 5Hz-LTD is due to the activation of the NOS/sGC/PKG pathway, whereas 
Cch-LTD relies on NOS/sGC but not PKG activation. By contrast, NO does not 
appear to be involved in LTP in this preparation.  Furthermore, I found that eCBs 
are involved in LTP induction, but not in basal synaptic transmission, 5Hz-LTD and 
Cch-LTD. Behavioural experiments demonstrated that the blockade of nNOS 
impairs rat visual recognition memory tested at 24 hours, but not at 20 min; 
however, the blockade of CB1 did not affect visual recognition memory acquisition 
tested at both time points specified. 
In three month-old Tg2576 mice, deficits in basal synaptic transmission and 5Hz-
LTD were observed compared to littermate controls.  
Conclusions The results obtained in Prh slices from juvenile rats indicate that NO 
and CB1 play a role in the induction of LTD and LTP, respectively. These results 
are confirmed by the observation that nNOS, but not CB1, is involved in visual 
recognition memory acquisition. The preliminary results obtained in the murine 
model of Alzheimer’s disease indicate that deficits in synaptic transmission and 
plasticity occur very early in Prh; further investigations are required to characterize 
the molecular mechanisms underlying these deficits. 
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1. INTRODUCTION 
1.1.  Memory and learning:  classification and short historical review 
Memory and learning have been studied since ancient times, but only in the 
last few decades the cerebral structures involved have been identified and the 
physiological and molecular mechanisms underlying these processes have begun 
to be clarified.  
Memory has been classified as explicit (facts and events) and implicit (e.g. 
classical and operant conditioning and procedural memory; Fig 1.1.). Cerebral 
areas associated with these mnemonic processes are extensively studied by 
psychologists, neurophysiologists and psychiatrists. In a situation of learning, 
many of these brain areas may be working simultaneously, each one processing 
different streams of information about the perceived event (visual, location, sound, 
emotional content, etc.). The associative learning is believed to emerge from the 
coordinated activity of different brain areas. This is how organisms, including 
humans, encode causality in the perceived world.  
Memory can also be classified as short- and long-term. Short-term memory has 
a limited temporal window (minutes) and needs to be continuously renewed to be 
maintained; long-term memory lasts longer (from hours to years). 
Different functions are associated to specific brain regions, and the same 
applies for implicit and explicit memory processes (reviewed by Squire, 2004). In 
the 1940’s, Penfield’s electrophysiological experiments on epileptic patients and 
studies of hippocampal lesions in primates and humans were some of the first 
experimental evidences supporting the idea of structure - function  relations for 
mnemonic processes (reviewed by Feindel, 1982). Before surgical ablation of the 
temporal lobe, Penfield’s patients, who were conscious throughout the procedure 
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(local anaesthesia), were electrically stimulated in different areas of the temporal 
cortex. During the stimulation, Penfield’s patients verbally referred back to past 
experiences. 
Another famous example comes from the case of patient H.M., who suffered 
from an aggressive form of epilepsy. Bilateral partial ablation of the temporal 
lobes, including both hippocampi, was performed as a treatment. After the surgery, 
H.M. suffered from a severe form of anterograde amnesia: he could recollect 
everything that happened until the day of the surgery, but from that moment 
onwards his long-term memory was severely impaired although procedural 
memory processing remained intact. 
In the coming years, lesion studies on primates and rodents demonstrated that 
the hippocampus and associated structures (perirhinal, entorhinal and 
parahippocampal cortices) are selectively involved in acquisition and consolidation 
of declarative but not implicit memory processes (reviewed by Squire, 2004).  
 
 
   
 
   
Fig 1.1. Schematic representation and functional classification of long-term memory and 
associated brain structures (modified from Squire, 2004). 
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1.2. Cellular correlates of learning and memory: synaptic plasticity 
 
What is memory from a physical point of view? In pure physical terms, memory 
is the ability of a system to acquire, store and recollect information. In a biological 
system, a complex phenomenon like memory is characterized by cellular and 
molecular mechanisms that have been the subject of extensive investigation in the 
last 40 years. Considering that most of the stored information is acquired from 
sensorial experience, the brain has to undergo many long-term functional and 
structural modifications corresponding to the mnemonic tracks left by perceived 
experiences. In his Croonian Lecture to the Royal Society in 1894, Ramòn y Cayal 
proposed that memory formation relies on reinforcement of the signalling between 
neurons in the involved areas: 
 […] it can be accepted that the mental exercise brings to a major development 
of the dendritic apparatus and of the axonic collaterals system in the mostly used 
brain areas […].  
In this concept, the notion of synaptic plasticity is already maturing: the ability of 
chemical synapses to increase or decrease the efficiency of transmission between 
neurons according to the frequency of the stimulation and to the previous history. 
 The idea that memory and learning result from the alteration of activity of 
specific synapses was further highlighted by the Canadian psychologist Donald 
Hebb in 1949 in his book titled “Organization of the behaviour”: 
“When an axon of cell A is near enough to excite B and repeatedly or 
persistently takes part in firing it, some growth process or metabolic change takes 
place in one or both cells such that A's efficiency, as one of the cells firing B, is 
increased.”  
This Hebbian rule has been formulated on pure theoretical basis, hypothesizing 
that such a mechanism could stabilize specific patterns of neuronal activity: if a 
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neuronal activity pattern corresponds to a specific behaviour, stabilizing that 
pattern means memorizing that behaviour (Hebb, 1949). 
Most part of both excitatory and inhibitory synapses show a rich repertoire of 
plastic modalities that work on time scales comprised between milliseconds and 
weeks (e.g. paired-pulse facilitation, paired-pulse depression, long-term 
potentiation, long term depression, suppression of inhibition etc.). With regards to 
the cellular and molecular basis of memory and learning, long-term potentiation 
(LTP) and long-term depression (LTD) have represented the main experimental 
model in the last 30 years. Both LTP and LTD have been observed in many brain 
structures such as hippocampus, neocortex and subcortical structures. In 1973, 
Bliss and Lømo were the first to observe that high frequency stimulation (HFS) of 
the perforant path (PP) of the hippocampus of anesthetized rabbits in vivo 
determined a significant and prolonged potentiation of synaptic transmission in the 
dentate gyrus and termed this phenomenon LTP. It has been mainly explored in 
hippocampus, but it can also be induced in other brain structures, such as the 
perirhinal cortex (Prh). LTP is characterized by a long-term (more than 3 h) 
increment of synaptic strength following a short period of coordinated neuronal 
activity, such high frequency stimulation of afferent fibres. Even if LTP is 
persistent, it’s not irreversible: the synaptic strength can be returned to basal 
levels through low frequency stimulation (LFS) of the afferent fibres 
(depotentiation, DP; Barrionuevo et al., 1980). In addition, when LFS is applied to 
a non-potentiated pathway it leads to LTD (Bear and Dudek, 1992). LTD can be 
returned to basal levels after HFS through the process termed de-depression. 
Thus, the strength of synaptic transmission can be altered in a bidirectional and 
reversible way: the dynamic storage of large amounts of information at neuronal 
level may be constantly redefined. Furthermore, these forms of Hebbian plasticity 
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act through positive feedback processes, that if left without control measures may 
destabilize the neuronal networks by driving neurons into maximal and/or minimal 
firing frequency averages: by degrading the signals that propagate through the 
network, this ultimately disrupts the ability of the neurons to encode further plastic 
changes. Homeostatic forms of synaptic plasticity should integrate negative 
feedback systems in order to keep the synaptic transmission and plasticity within a 
dynamic functional range, either increasing or decreasing the strength of all the 
synaptic inputs: this can be achieved by either keeping at the same time their 
relative weight (synaptic scaling) or by modifying the ability of the synapses to 
undergo further plastic changes (metaplasticity; reviewed by Pérez-Otaño and 
Ehlers, 2005) 
1.2.1. Long term potentiation (LTP): induction and expression 
mechanisms 
LTP is defined as the long-term increase of synaptic strength subsequent to 
the application of a HFS (usually 100 Hz) on the presynaptic fibres. A lot of what 
we know about LTP arises from experiments conducted at Schaffer Collaterals 
(SC) / CA1 glutamatergic synapses. The induction of LTP at these synapses 
involves the activation of N-methyl-D-aspartate receptors (NMDAR), a class of 
ionotropic receptors for glutamate, permeable to calcium (Ca2+) (reviewed by 
Collingridge and Bliss, 1995). HFS or presynaptic stimulation coupled to post-
synaptic depolarization removes the voltage-dependent block of the NMDAR by 
the displacement of the magnesium (Mg2+) ion placed on the extracellular side of 
the channel pore (Mayer et al., 1984). NMDAR are referred to as coincidence 
detectors, as the contemporary presence of glutamate in the synaptic cleft in 
combination with postsynaptic depolarization, determines the opening of NMDAR 
resulting in the influx of Ca2+. NMDAR are formed by hetero-oligomeric assemblies 
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of NR1 subunits with NR2 (A-D) and NR3A (Monyer et al, 1994). According to Liu 
et al., 2004, HFS applied to a glutamatergic pathway activates NR2A subunit 
containing NMDAR leading to the activation of Ca2+/calmodulin dependent Kinase 
II (CaMKII). On the other hand, if in the subunit NMDAR is comprised the NR2B 
subunit, the Ca2+ influx will result in the activation of the Ca2+/calmodulin 
dependent phosphatase calcineurin that is responsible for LTD induction (Mulkey 
et al., 1993, 1994).  
The LTP expression mechanisms are not yet fully understood. The activation of 
CaMKII triggers the insertion of further GluR1 containing α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR) on postsynaptic dendritic 
processes (Malinow and Malenka, 2002). Recent studies highlighted two other 
main signal transduction pathways responsible for the long-term modifications 
needed for the consolidation of LTP: the cAMP-dependent protein kinase (PKA) 
and the mitogen activated protein kinase (MAPK). Intracellular Ca2+ influx induces 
the activation of adenylate cyclase (AC) leading to the subsequent increase of 
intracellular cAMP which activates PKA. The expression in transgenic mice of the 
inhibitory form of the regulatory subunit of PKA R(AB) does not affect the early 
phase of LTP but disrupts its consolidation. MAPK is also termed extracellular 
signal-related kinase (ERK). In the dentate gyrus, the application of a LTP-
inducing stimulation determined rapid phosphorylation and nuclear translocation of 
MAPK (English and Sweatt, 1996; Davis et al., 2000 a). Both PKA and MAPK can 
phosphorylate and activate the transcription factor cAMP-responsive element 
binding protein (CREB) (Yin and Tully, 1996; Silva et al., 1998). CREB triggers the 
expression of genes responsible for long-term modifications (functional and 
structural) underlying the late phase of LTP. Finally, many lines of evidence have 
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consistently shown that protein synthesis blockade prevents the long-term 
expression of LTP, without affecting induction (reviewed by Blitzer et al., 2005).  
 
Many recent studies have highlighted the key role of brain-derived neurotrophic 
factor (BDNF) in both induction and expression of LTP (Lu and Gottschalk, 2000; 
Aicardi et al., 2004; Santi et al., 2006; Minichiello et al., 2009). In particular, it has 
been suggested that activity-dependent release of BDNF from the presynaptic site 
is necessary for the induction of LTP, while the activity-dependent sustained 
production and secretion from the post-synaptic site is necessary for the 
expression of LTP (Aicardi et al, 2004; Reviewed by Lu et al., 2008). Pro-BDNF is 
cleaved to mature BDNF (mBDNF) via proteolytic cleavage by the tissue 
plasminogen activator (tPA). mBDNF binds the tyrosine-kinase coupled receptor B 
(TrkB) which in turn phosphorylates various substrates, including MAPK/ERK 
resulting in the activation of MAPK/ERK kinase (MEK). TrkB activation also leads 
to phospholipase C (PLC) activation, which in turn activates both PKC and calcium 
calmodulin kinases kinase (CaMKK), subsequently resulting in CaMKIV and CREB 
activation (Reviewed by Minichiello, 2009; Fig 1.3). 
 
Fig 1.2. Schematic representation 
of LTP induction and expression 
mechanisms. The three most 
important downstream signalling 
pathways are CaMKII, MAPK and 
PKA. Ca2+ influx occurs through 
NMDAR and voltage-gated Ca2+ 
channels (VGCC). AC can also be 
activated by stimulation of Gs 
coupled receptors such as β-
adrenergic receptors (modified 
from Blitzer et al., 2005). 
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Fig 1.3. Activation of TrkB triggers three main intracellular signalling pathways. i) 
Ras–MAPK, which promotes neuronal differentiation and growth through 
MAPK/ERK kinase (MEK); ii) phosphatidylinositol 3-kinase (PI3K) cascade, which 
promotes survival and  growth of neurons and other cells through Ras or GRB-
associated binder 1 (GAB1); iii) phospholipase Cγ1, which mediates synaptic plasticity 
through CaMKII and CaMKK/CaMKIV signalling cascade (modified from Minichiello 
et al., 2009). 
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1.2.2. Long term depression (LTD): induction and expression 
mechanisms 
 
The first evidence for LTD came from the observation that LTP inducing 
protocols in hippocampal SC/CA1 synapses generated a reversible depression in 
the non tetanized pathway (Lynch et al., 1977); this phenomenon is called 
heterosynaptic plasticity. Homosynaptic depression was later shown in 
hippocampus: the application of LFS reversed LTP in a pathway previously 
tetanised; this phenomenon is now known as depotentiation (Barrionuevo et al., 
1980). Later, it was demonstrated that LFS can induce LTD in CA1 even without 
previous LTP induction (Dudek and Bear, 1992; Mulkey and Malenka, 1992).  
LTD can be induced in many brain areas other than the hippocampus including 
the visual cortex (Artola et al., 1990), striatum (Calabresi et al., 1994), perirhinal 
cortex (Ziakopoulos et al., 1999; Cho et al., 2000), amygdala (Wang and Gean, 
1999), posterior cingulus (Hedberg and Stanton, 1995) and prefrontal cortex 
(Hirsch and Crepel, 1991).  
The first studies on homosynaptic LTD showed that application of LFS 
consisting of 900 pulses delivered at 1 Hz, induces LTD that relies on the 
activation of NMDAR (Dudek and Bear, 1992; Mulkey and Malenka, 1992). 
NMDAR-dependency of LTD is often age-related (Kemp et al., 2000, Jo et al., 
2006), consistently with the developmental change in subunit composition of 
NMDAR (Monyer et al., 1994).  
It is of interest to note that LTD induction can be mediated by other receptors 
like kainate receptors (KAR), metabotropic glutamate receptors (mGluRs) and type 
I muscarinic acetylcholine receptors (M1) (reviewed by Kemp and Bashir, 2001). 
Group I and II mGluRs are involved in depotentiation in CA1 (Bashir and 
Collingridge, 1994); mGluRs agonists have been shown to induce LTD in CA1 
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(Fitzjohn et al., 2001), in the dentate gyrus (O’Mara et al.,1995a; Huang et al., 
1999) and in Prh (McCaffery et al., 1999).  
By far, the majority of AMPAR are impermeable to Ca2+, due to the editing of 
the mRNA of the glutamate receptor subunit 2 (GluR2). However, LTD in CA3 has 
been shown to require co-activation of mGluRs and Ca2+ permeable AMPA 
(Laezza et al., 1999). Increasing evidence suggests the pivotal role of AMPA 
trafficking in LTD. Activity-dependent internalization of AMPA receptors is central 
for recognition memory and LTD induction in Prh (Griffiths et al., 2008). 
KAR involvement in LTD is not yet entirely demonstrated, but it’s suggested by 
the observation that the co-application of the mGluR antagonist MCPG and the 
AMPA/KA receptor antagonist CNQX inhibits LTD induction in the hippocampus 
(reviewed by Kemp and Bashir, 2001). 
The application of LFS consisting of 3000 pulses delivered at a frequency of 5 
Hz in Prh slices of juvenile rats resulted in M1-dependent LTD (Jo et al., 2006); in 
addition, the bath application of the acetylcholine analogue carbachol (Cch) was 
shown to induce chemical M1-dependent LTD in Prh slices of adult rats (Massey 
et al., 2001). 
The central intracellular event for LTD induction is the cytosolic Ca2+ 
concentration increase, as observed for LTP (Lynch et al., 1983; Bliss and 
Collingridge, 1993): LTP-inducing stimuli determine rapid and high increases in 
intracellular Ca2+, while for LTD the increase is low and slow (Lisman, 1989). 
Presynaptic Ca2+ increase is also necessary for LTD induction (Kobayashi et al., 
1996, 1999). The source for the increase of post-synaptic Ca2+ can be both 
extracellular and intracellular. In the first case, it relies on the activation of 
NMDAR, Ca2+ permeable AMPAR or voltage-gated Ca2+ channels (VGCC; 
Cummings et al., 1996; Christie et al., 1997; Wang et al., 1997 a; Norris et al., 
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1998; Otani and Condor, 1998). In the second case, Ca2+ comes from intracellular 
stores as a consequence of the activation of Gq-coupled receptors like group I 
mGluRs or M1.  
The increase in intracellular Ca2+ determines the formation of the 
Ca2+/calmodulin (CaM) complex activating Ca2+/CaM-dependent phosphatase 
calcineurin. This happens if the Ca2+ increase is low and slow. LFS-dependent 
calcineurin activation inactivates inhibitor 1, by dephosphorylation. This results in 
the activation of phosphatase 1 and 2 (PP1/2) which results in LTD via 
dephosphorylation of various targets such as AMPAR and CaMKII (reviewed by 
Kemp and Bashir, 2001; Fig 1.4.).  
 
In the last three decades, LTD expression mechanisms have been deeply 
investigated in various brain regions. It was concluded that different induction 
mechanisms determine different expression mechanisms. Hippocampal NMDAR-
LTD in CA1 relies on the increased internalization of AMPAR via 
Fig 1.4. LTD induction requires increased intracellular calcium concentration from the 
extracellular space via NMDAR or VGCC activation or IP3-mediated opening of 
intracellular stores. The Ca2+-calmodulin complex activates the protein phosphatase 
calcineurin that dephosphorylates the phosphatase inhibitor 1 inactivating it. This 
enables the activation of protein phosphatase 1 (PP1) that dephosphorylates targets 
like CaMKII and AMPA receptors (Modified from Kemp and Bashir, 2001). 
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dephosphorylation of Ser-845 (target of PKA) and Ser-831 (target of CaMKII) of 
the GluR1 subunit, altering the conductance and the probability of opening of 
AMPARs. In addition, LFS determines increased internalization of postsynaptic 
AMPARs through a dynamin-dependent, clathrin-mediated process (Lüscher et al., 
1999; Lüthi et al., 1999; Carroll et al., 1999; Man et al., 2000; Beattie et al., 2000; 
Wang and Linden, 2000; Henley, 2003; Collingridge et al., 2004; Griffiths et al., 
2008). In specific, it has been shown that AP2, a clathrin adaptor protein, is 
important for the internalization of surface AMPARs and for the expression of 
NMDAR-dependent LTD (Lee et al., 2002).  
The last event that temporally characterizes LTD is a change in protein 
synthesis, which is essential for mGluR-dependent LTD in CA1 (Huber et al., 
2000) and for Cch-induced LTD in Prh (Massey et al., 2001): LTD induction has 
been shown to correspond to long-term changes in spine morphology, specifically 
in a reduction in spine density (Halpain et al., 1998). Fig 1.5. illustrates the main 
LTD induction pathways and related post-synaptic changes. 
It is of interest to note that the immature form of BDNF, proBDNF, has been 
demonstrated to be involved in LTD induction via activation of the pan-
neurotrophin receptor 75 (p75NTR) (Woo et al., 2005; Rösch et al., 2005). 
1.2.3. Biological relevance of LTP and LTD 
Many studies showed that both LTP and LTD can be induced in the same 
pathway depending on the frequency of firing of the presynaptic fibres (Bliss and 
Collingridge, 1993; Bear and Malenka, 1994). 
Certain properties of LTP and LTD provide support to the hypothesis that they 
underlie complex mnemonic processes. Firstly, synapses can be independently 
modified: only co-active synapses participate in the plastic change, i.e. stimulation 
does not affect surrounding synapses, thus is input-specific. This evidence 
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suggests that every single synapse can be individually used to store information. 
Since every neuron is surrounded by about 10,000 synapses and brain areas 
involved in learning and memory contain billions of neurons, the mnemonic 
capacity of the brain is extraordinary. Secondly, LTP and LTD are associative 
phenomena: this property allows for small changes in certain synapses in order to 
produce a distributed storage in a complex and organic memory within a neuronal 
network. This implies that LTP and LTD cannot be triggered by the activity of a 
single neuron, but only as a consequence of associate activation of many inputs. 
This functional need comes from the fact that both LTP and LTD induction require 
a sufficient degree of depolarization of the postsynaptic membrane (Bilkey, 1996; 
reviewed by Diamond and Rose, 1994). LTP and LTD have a reciprocal 
connection in the generation of stored memories. LTP is associated with the 
storage of new information, but, since the brain represents a system with limited 
capacity, soon the newly stored information would reach a saturation point, 
destabilizing the system and making the recollection more challenging. LTD has 
the role to improve the signal/noise ratio associated to the acquisition and 
recollection of newly stored information (reviewed by Rosenzweig and Barnes, 
2003; Fig 1.6). 
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Fig 1.6. Schematic representation of an information storage system with limited capacity. 
If we assume that a neural network coincides with a sheet of white paper, we can draw on it 
different shapes, coincident to new encoded patterns of neural activity. If the network 
contains too much information it becomes useless. Acquisition of new shapes/patterns is 
mediated by LTP. If the system keeps accumulating patterns one on another, soon every 
single shape becomes indistinguishable from others: recollection is therefore impossible and 
most of the information will be lost. The role of the LTD is to organize the patterns and select 
the stronger ones to increase memory capacity and recollection (Rosenzweig and Barnes, 
2003). 
 
Fig 1.5. Schematic representation of the main LTD induction pathways. 
Abbreviations: AC, adenylate cyclase; AA, arachidonic acid; CaMKII, 
calcium/calmodulin-dependent kinase II; CREB, cAMP responsive element binding 
protein; IP3, inositol trisphosphate; Ka, kainate receptor; mGluR, metabotropic 
glutamate receptor; MAPK, mitogen activated protein kinase; PI, phosphatidil 
inositol; PLC, phospholipase C; PKA, protein kinase A; PKC, protein kinase C; PP1/2 
A, protein phosphatase 1/2 A; TKR, tyrosine kinase receptor (Modified from Blitzer et 
al., 2004). 
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1.3. Perirhinal cortex (Prh): anatomy and functions 
At the beginning of the 1980’s, the systematic exploration of amnesia in animal 
models lead to the identification of cortical structures involved in declarative 
memory formation; these were primarily located in the medial temporal lobe, 
comprising the hippocampus, dentate gyrus, subiculum, entorhinal cortex (EC), 
parahippocampal cortex (Prp) and Prh (Zola-Morgan et al., 1986; reviewed by 
Squire and Zola-Morgan, 1991). Prh is a periallocortex, located on the ventral 
surface of the temporal lobe. In both primates and rodents, Prh comprises two 
cytoarchitectionally different regions: 35 and 36 Brodman areas (Fig. 1.8.). Area 
35 is thin and agranular (IV layer is missing) and it is located ventrally to the rhinal 
sulcus; area 36 contains a thin IV layer, in which granular cells are mixed with 
pyramidal cells from III and V layer (Burwell, 2001). 
Prh has strong reciprocal connections with the hippocampus and the 
subiculum. These connections are both direct through the lateral perforant path, 
and indirect through EC (Deacon et al., 1983; Burwell et al., 1995; Liu and Bilkey, 
1996; Naber et al., 1999). Furthermore, Prh receives both unimodal inputs from 
associative unimodal cortices (i.e. visual, somatosensory, auditory and olfactive) 
and multimodal inputs from associative multimodal cortices (i.e. medial and ventro-
lateral prefrontal cortex, cingulate anterior area, retrosplenial cortex; Fig 1.7). 
Visual information, transmitted from unimodal associative visual cortex, is then 
transmitted to the Prh (Meunier et al., 1993; Wiig and Bilkey, 1995; Ennaceur and 
Aggleton, 1997). Since a few years ago, Prh was merely considered a structure 
where sensory information was transmitted from sensory related cortices to the 
hippocampal formation, without ascribing any role in memory formation. Since the 
early 1990’s many studies highlighted that Prh interacts, directly or via integration 
with other brain areas, for various mnemonic functions, with a crucial role in visual 
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recognition memory (Buffalo et al., 1998; reviewed by Brown and Aggleton, 2001; 
Massey et al., 2001; Warburton et al., 2003; Massey et al., 2008) and fear 
conditioning (Corodimas and LeDoux, 1995). In the last decade many studies 
clarified the cellular and molecular mechanisms underlying Prh-dependent visual 
recognition memory. 
 
 
Fig 1.7. Location of the Prh in the rat brain and schematic representation of 
connections to and from other brain areas. Rat Prh network is characterized by 3 
main connections. The first one is a strong reciprocal connection with the 
hippocampal formation through lateral EC (Suzuki and Amaral, 1994). The second 
one is characterized by afferent projections from unimodal and multimodal 
associative cortices, including visual, somatosensory, auditory and olfactory 
associative areas, medial and ventro-lateral prefrontal cortex, anterior cingulus and 
retrosplenial and Prp cortices (Burwell et al., 1995). The third one is characterized by 
the reciprocal connection with the amigdaloid complex. The thickness of the arrows 
indicates the connection density (Modified from Brown and Aggleton, 2001). 
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1.3.1.Perirhinal cortex and visual recognition memory 
 
Recognition memory is a primary aspect of our ability to remember. It is based 
on the capability of both identifying and judging the prior occurrence of a visually 
perceived experience (Mandler et al., 1980).  
Recognition memory is a main component of the sort of memory lost in 
anterograde amnesia. However, it has been proposed that within the two main 
components of recognition memory, identification and judgement of prior 
occurence, only the latter is directly compromised in anterograde amnesia 
(Mandler et al., 1980; Jacoby et al., 1981; Gardiner et al., 1990; Aggleton and 
Brown, 1999).  
The visual component of recognition memory corresponds to the sensation of 
familiarity of a visual stimulus without active recollection of the attributes of that 
vision. This discrimination of familiarity is defined as ‘knowing’ (I know I’ve seen 
this thing before) whereas the active recollection of the attributes is defined as 
‘remembering’ (I actively remember the name of the object, what the material is 
made of, where I’ve seen it before etc.). There are two main models describing 
recognition memory. The first model is the single process model. In this model 
‘knowing’ and ‘remembering’ are considered a single process that differ only 
quantitatively: knowing corresponds to a weaker mnemonic trace whereas 
remembering is related to recollection and hence is related to a stronger 
mnemonic pattern. The second model is the dual process model, according to 
which ‘knowing’ and ‘remembering’ are two qualitatively distinct processes 
mediated by two distinct structures. In the dual model the hippocampus is usually 
related to ‘remembering’ because of its structural complexity and the many lines of 
evidence showing its role in recollection; on the other hand Prh has been shown to 
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be selectively involved in recognition memory. So far, the dual model is the most 
accepted (reviewed by Brown and Aggleton, 2001). 
Prh is critically involved in recognition memory as shown by several lesion 
studies in both primates and rodents (Zola-Morgan et al., 1989; Meunier et al., 
1993; Mumby et al., 1994; Meunier et al., 1996; Winters et al., 2004). Other 
evidence highlighting the pivotal role of Prh in visual recognition memory comes 
from electrophysiological recordings from the medial temporal lobe of monkeys 
performing recognition memory tasks (Brown and Wilson, 1987; Fahi et al., 1993; 
Li et al., 1993; Miller et al., 1993; Xiang et al., 1998). These studies consistently 
showed a decrease in neuronal responsiveness subsequent to the presentation of 
a previously encountered visual stimulus (Brown, 1996; Desimone, 1996; 
Eichenbaum et al., 1996; Ringo, 1996; Brown and Xiang, 1998; Suzuki and 
Eichenbaum, 2000; Eichenbaum, 2000). The decrease in the overall neuronal 
responses brings into account information about prior occurrence of a stimulus 
mediating the discrimination between familiarity or recency of that stimulus (Miller 
et al., 1993; Sobotka and Ringo, 1993; Xiang and Brown, 1998). These response 
reductions are observed in Prh (in ~25% of the recorded neurons) and rarely in the 
hippocampus (<~1%) (Brown and Wilson, 1987; Miller et al., 1993; Sobotka and 
Ringo, 1993; Xiang and Brown, 1998). In the last ten years many studies have 
aided in the clarification of the molecular mechanisms underlying the acquisition, 
consolidation and recollection of visual recognition memory. Three main 
approaches have been followed, primarily conducted in rats: 1) behavioural 
measures in animals with bilateral cannula into Prh: the local infusion of drugs or 
transfecting viruses in the Prh and the consequent deficit or enhanced 
performance in an object recognition task has teased about the roles of various 
membrane receptors and associated cellular signalling pathways involved in 
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recognition memory processes. The most applied behavioural protocol used to 
investigate visual recognition memory in rats is the spontaneous novel object 
exploration task, described in section 1.3.1.1;  2) Electrophysiological recordings 
on acute brain slices: the measure of basal synaptic transmission and synaptic 
plasticity in Prh slices has helped to define which are the cellular correlates of 
recognition memory. This in vitro approach can be carried out on: i) naive slices 
treated with various drugs ii) slices from transgenic animals iii) slices from animals 
locally transfected in Prh with viruses inducing a genetical modification, and finally 
iv) slices from animals that underwent the paired-viewing protocol (described in 
Brown and Aggleton 2001). This protocol consists in keeping the animal’s head in 
a window facing a screen showing two different images. The two images are 
projected in a manner as to occupy the monocular visual field of each eye 
independently. Sets of images are then repetitively projected. At the end of a 
period of training, a set of novel images are projected towards only one eye, in 
order to encode novelty in one hemisphere and familiarity in the other. Note that 
the visual information perceived in one eye is processed in the contralateral 
hemisphere of the brain. This treatment results in one of the hemispheres being 
conditioned with ‘familiar’ and the other hemisphere with ‘novel’ images 
respectively (Fig 1.8.). Upon surgical removal of these hemispheres, 
electrophysiological experiments (Warburton et al., 2003; Massey et al., 2008) and 
immunohistochemical studies can be performed in order to evaluate how the 
encoding of familiar or novel information influences neuronal activity. 3) 
Immunohistochemical imaging has been used for the evaluation of molecular 
changes in the Prh of rats that underwent the paired-viewing protocol; it can be 
examined in a quantitative manner by analysing the differential expression of 
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genes, e.g. the immediate early gene (IEG) c-fos levels in the ‘novel’ versus the 
‘familiar’ hemisphere. 
 
 
 
1.3.1.1. Perirhinal cortex and visual recognition memory: behavioural 
studies 
In order to better understand the cellular correlates underlying visual 
recognition memory formation, many studies evaluated the visual recognition 
performance with the spontaneous novel object exploration task on intra-Prh 
cannulated rats. This test consists of a training phase where the animal is placed 
in an arena with two identical objects where it is then left to explore. In a second 
phase of the test, a delay is introduced that varies between minutes to hours (2 
min to 24 h). During the test phase, the animal is placed back into the same arena 
with one familiar and one novel object: if the animal remembers the familiar object, 
it would preferentially explore the novel one due to innate behavioural patterns; if 
not, it would explore the novel and familiar objects equally (Warburton et al., 
Fig 1.8. In the paired-viewing protocol, a rat is exposed to two pictures simultaneously, one 
novel and one familiar. Each figure is projected on a screen in order to occupy the visual field 
of only one eye and it is therefore selectively processed in the contralateral hemisphere 
(Modified from Brown and Aggleton, 2001). 
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2003). The infusion technique can be used to analyse different stages of memory 
formation according to the different stage of the experiment when the drug is 
applied: i) acquisition: if the drug is infused before the training phase ii) 
consolidation: after the training phase iii) retrieval before the test phase (Ennaceur 
and Delacour, 1988; reviewed by Brown et al., 2010; Warburton et al., 2003).  
The reversible inactivation of Prh with the glutamatergic AMPAR antagonist 
CNQX has been shown to impair both acquisition and retrieval of visual 
recognition memory in the spontaneous novel object preference task (Winters and 
Bussey, 2005). In addition, the selective blockade of NMDAR or group I and II 
mGluRs produced an impairment at longer (24 h) but not at shorter (20 min) 
delays (Barker et al., 2006a,b), when the drug is applied before the training phase. 
This treatment however did not affect retrieval. The blockade of glutamatergic KAR 
produced deficits after a 20 min delay but not after 24 hours (Barker et al., 2006b). 
This unusual temporal pattern (amnesia and then remembering) can be perhaps 
explained because some neurons (called ‘familiarity’ or ‘slow change neurons’) in 
the Prh of monkeys responded less strongly if a novel stimulus was repeated after 
a certain amount of times (min to h); if the delay was shorter they kept responding 
strongly (Xiang and Brown, 1998). Other neurons have reduced responses in 
monkey even when stimuli are repeated after very short delays (even <1 s; Miller 
et al., 1993). Thus, two different populations of neurons within Prh provide the 
information of prior occurence of the stimulus at different time delays (20 min and 
24 h). In both cases AMPAR-dependent transmission seems to be essential for 
recognition memory, while NMDAR blockade induces a deficit in acquisition at 
longer delays and KAR at shorter delays.  
A similar pharmacological dissociation was also observed as a consequence of 
the antagonism of muscarinic or nicotinic receptors. The muscarinic antagonist 
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scopolamine was shown to impair visual recognition memory at 20 minutes but not 
at 24 hours; the opposite pattern was observed with the α 7 nicotinic antagonist 
MLA (Tinsley et al., submitted). Therefore, the muscarinic receptor and the KAR 
appear to be involved in a form of acquisition that takes place in the first 20 min, 
without however affecting the performance at longer delays.  
The role of cholinergic transmission in visual recognition has been deeply 
investigated and many studies highlight its pivotal role in this form of memory. It 
has been demonstrated that scopolamine partially impairs object recognition 
memory at 24 hours (Winters and Bussey, 2005). The selective targeting of basal 
forebrain cholinergic fibres with the immunotoxin 192 IgG-saporin caused a 
permanent cholinergic denervation of fibres targeting the Prh, impairing 
spontaneous novel object exploration in rats (Winters and Bussey, 2005). Also, it 
has been shown that scopolamine affects both visual recognition memory and 
synaptic plasticity in Prh: systemic injections or intra-Prh infusions of scopolamine 
before the test phase in the spontaneous object recognition memory task 
significantly impaired object recognition memory at 15-20 min delays, and 
disruptions in the decremental responses to familiar versus novel pictures in Prh 
neurons as measured with Fos expression were observed. Furthermore, bath 
application of scopolamine prevented in vitro LTD but not LTP in Prh slices 
(Warburton et al., 2003; Massey et al., 2001). Another study showed that intra-Prh 
infusion of scopolamine disrupted recognition memory at 24 h whereas infusion 
before the retrieval phase improved the performance, an effect probably due to the 
elimination of interferences coming from cholinergic fibres in the retrieval phase 
(Winters et al., 2006; Winters et al., 2007). To sum up, if AMPARs mediate several 
aspects of acquisition, consolidation and retrieval, NMDARs are considered crucial 
for consolidation and acquisition, whereas muscarinic cholinergic transmission in 
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Prh seems to be selectively involved in acquisiton (reviewed by Winters et al., 
2008).  
Acquisition is also influenced by the intra-Prh infusion of lorazepam (Brown and 
Brown, 1990; Wan et al., 2004) and L-type voltage-dependent calcium channel 
blockers (verapamil, diltiazem, nifedipine; Seoane et al., 2009).  
Interfering with intracellular signalling pathways that play an important role in 
Prh synaptic plasticity produces recognition memory impairments: recognition 
memory is impaired at 24 hours by blocking CaMKII (Tinsley et al., 2009) while 
blocking CaMKK has been shown to impair consolidation (Tinsley et al., 2011). Of 
interest, blocking BDNF expression via intra-Prh infusion of antisense 
oligodeoxynucleotides blocks visual recognition memory acquisition tested at 24 h 
(Seoane et al., 2010). 
Viral transduction of Prh neurons prevented the phosphorylated CREB 
(pCREB)-mediated signalling, which impaired visual recognition at 24 hours but 
not at 20 min (Warburton et al., 2005). Another recent study showed that viral 
transduction of Prh neurons with a lentivirus expressing a peptide considered able 
to block AMPAR internalization, impaired visual recognition at both 24 hours and 5 
min (Griffiths et al., 2008). When the Prh is conditioned by direct infusion of a 
transfecting virus, it is not possible to distinguish if the deficit seen is related to 
impairments in acquisition, consolidation or retrieval, since the transfection is a 
stable modification and requires days after the infusion to be expressed. 
Nonetheless, the advantage of evaluating memory deficits in an animal model 
locally transfected with a virus remains in the ability to evaluate how the 
expression of a gene, or the integrity of a pathway in a specific brain region, 
affects memory in a wild-type animal. The only alternative would consist in a 
transgenic animal model, which carries a mutation affecting every tissue of the 
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organism and therefore all brain areas. The non specificity of the transgene 
expression could possibly affect the experiment in a way not directly related to the 
functions of the brain area under examination. 
1.3.1.2. Perirhinal cortex and visual recognition memory: 
electrophysiological recordings 
As previously described (section 1.2), synaptic plasticity is thought to represent 
the cellular correlate of memory and learning. In order to better clarify the cellular 
and molecular mechanisms underlying visual recognition memory, in vitro 
electrophysiological recordings on Prh acute slices were carried out by several 
research groups, providing a collection of data complementing and enriching 
behavioural observations already described in section 1.3.1.1.  
Both LTD and LTP can be observed in Prh after the application of the 
appropriate stimulation protocol (Bilkey, 1996; Ziakopoulos et al., 1999; Cho et al., 
2000; Massey et al., 2001, 2004; Aicardi et al., 2004). Input specific LTP in Prh is 
NMDAR dependent (Bilkey, 1996). Also, LTP induction is strictly layer dependent: 
HFS (100 Hz) of the superficial layer does not cause LTP induction, whereas 
stimulation of layer II/III induces a robust LTP in the Prh and is strictly NMDAR-
dependent (Ziakopoulos et al., 1999). Further studies have shown that the NR2A 
subunit containing NMDAR is necessary for LTP induction in Prh, whilst NR2B is 
deemed necessary in LTD induction alone (Massey et al., 2004).  In addition, LTP 
induction in Prh requires BDNF-mediated activation of TrkB and the application of 
HFS (100 Hz) determines an activity-dependent increase of the basal secretion of 
BDNF in horizontal Prh slices (Aicardi et al., 2004). Finally, inhibition of pCREB-
mediated signalling blocks LTP induction in Prh (Warburton et al., 2005). 
LTP may be involved in refining stabilized patterns in Prh network: such 
synaptic changes may be necessary for long-term maintenance of visual 
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information, essential for familiarity discrimination processing: note that NMDAR 
activity (Barker et al., 2006a) and pCREB signalling (Warburton et al., 2005) are 
necessary for acquisition of visual recognition memory with a delay of 24 hours but 
not of 20 min, suggesting that LTP may indeed have a role as the cellular correlate 
of this acquisition process. Assuming that LTP plays a role in visual recognition 
memory, we have to consider that electrophysiological recordings in the Prh of 
animals performing visual recognition tasks showed a decrease in the neuronal 
responsiveness (Brown and Wilson, 1987; Fahi et al., 1993; Li et al., 1993; Miller 
et al., 1993; Xiang et al., 1998). Thus, LTD may well overrule the importance of 
LTP as cellular correlate of visual recognition memory. Some elegant 
computational studies show how LTD could represent, in an in vitro model, the 
decreased long-term neuronal responsiveness necessary to encode the 
information concerning familiarity (Brown and Bashir, 2002). Supporting this 
hypothesis, a recent study showed that both LTD and depotentiation are 
prevented in Prh slices obtained from the ‘familiar’ brain hemisphere of an animal 
that underwent the paired-viewing protocol. Interestingly, the possibility to induce 
both LTD and depotentiation was restored in this hemisphere by bath application 
of the muscarinic antagonist scopolamine, indicating a pivotal role for cholinergic 
neurotransmission in both visual recognition memory and synaptic plasticity in Prh 
(Massey et al., 2008). Several other studies have focused on the cellular 
mechanisms involved in LTD induction and expression in the Prh, leading to 
interesting results. LTD in Prh can be induced with both pharmacological (Massey 
et al., 2001) and electrical stimulation (Cho et al., 2000; Ziakopoulos et al., 2000); 
its induction relies on the activation of NMDAR, mGluRs, KAR, muscarinic 
receptor 1 (M1), depending on age, excitation level of the network and stimulation 
protocol. As observed for LTP, one form of LTD requires glutamate receptors: at 
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variance with other brain areas, LTD in Prh requires both mGluRs and NMDAR 
activation (Cho and Bashir, 2002; Cho et al., 2000; McCaffery et al., 1999). An 
elegant study by Cho et al. (2000) showed that the activation of both group I and II 
mGluRs in combination with the co-activaction of NMDAR may be necessary for 
LTD induction in Prh slices. This mechanism is voltage dependent: in resting 
conditions (-70 mV), the application of LFS (1 Hz) induced LTD relying on the co-
activation of group I and II mGluRs and NMDAR, whereas depolarization of the 
postsynaptic membrane (-40 mV) generated the condition where LTD induction 
required only group I mGluRs and NMDAR co-activation. From these results, it 
was suggested that in resting conditions the Ca2+ influx via NMDAR activation and 
intracellular Ca2+ mobilization after group I mGluR activation is insufficient for LTD 
induction, requiring the contemporary activation of group II mGluRs. In depolarized 
conditions, NMDAR are sufficiently activated in order to allow through enough Ca2+ 
influx to trigger the molecular machinery necessary for LTD induction (Cho et al., 
2000). It has also been shown that LTD of KAR-dependent synaptic transmission 
(that is different from AMPAR-dependent synaptic transmission) requires mGluR5 
activation, increased intracellular Ca2+ from internal stores, PKC activation, protein 
interacting with kinase C 1 (PICK1) and PDZ domain interactions (Park et al., 
2006). Another study showed that application of LFS consisting of 3000 pulses 
delivered at 5 Hz induces a robust LTD in Prh relying on the activation of mGluR5 
in neonatal rats (p7-12). This induction mechanism undergoes a developmental 
switch in juvenile rats (p28-35) where the same stimulation protocol induces LTD 
relying on the activation of M1. This molecular switch is mediated by sensory 
information resulting from the opening of the eyes and relies on the subsequent 
increase in M1 expression; in fact, M1 is poorly expressed in neonatal rats Prh. 
Both M1 expression in Prh and the switch from mGluR5 to M1 dependency of the 
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LFS 5Hz-induced LTD are blocked if neonatal rats are kept in the dark during 
development (Jo et al., 2006). This introduces another important factor for the 
induction of LTD: the cholinergic pathway. As previously discussed, cholinergic 
neurotransmission appears to play a pivotal role in visual recognition memory (see 
section 1.3.1.1). It has been shown that bath application of the cholinergic agonist 
charbachol (Cch) at 50 µM for 10 minutes in Prh slices induces robust LTD relying 
on M1 activation, Ca2+ release from intracellular stores and protein synthesis, and 
is independent from PKC and protein phosphatase activation (Massey et al., 
2001). Cholinergic and glutamatergic dependent synaptic plasticity within Prh are 
probably both synergistic and independent in influencing different facets of object 
recognition memory processes (Massey et al., 2008). Furthermore, it has been 
shown that L-type VGCC are involved in both LTD and depotentiation but not in 
LTP (Seoane et al., 2009). 
Recent studies tried to clarify the cellular processes involved in LTD induction 
downstream to the activation of different receptors. It was found that LTD in 
neonatal rats (p7-13) can rely on the activation of NMDAR or mGluR5 depending 
on the stimulation protocol applied. NMDAR-LTD is induced by application of LFS 
(1 Hz) in depolarized neurons (-40 mV) in Prh slices, while mGlu-LTD is induced 
by 5Hz-LFS. In both cases an increase in cytosolic Ca2+ concentration is required: 
Ca2+ acts as a second messenger, activating different Ca2+ sensors: NMDAR-LTD 
requires calmodulin, mGluR-LTD requires neuronal cell sensor protein 1 (NCS-1) 
that binds to PICK-1 through its bar domain. NCS-1/PICK-1 and PKC activation 
has been shown to be strictly involved in mGluR LTD (Jo et al., 2008). 
Furthermore, it has been demonstrated that the internalization of AMPARs is 
necessary for 5Hz LTD induction in Prh of adult animals (7-12 weeks). In this 
study adult rats were intra-Prh transfected with a recombinant lentivirus expressing 
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a peptide which blocks the interaction between the AMPAR subunit GluR2 and the 
clathrin adaptor protein 2 (AP2), necessary for endocytosis. These animals were 
both impaired in visual recognition memory and in LTD induction, but LTP 
induction was normal (Griffiths et al., 2008). Notice that in these animals 5Hz LTD 
was NMDAR dependent and not M1 dependent as observed in juvenile (p28-35) 
rats by Jo et al. (2006), suggesting a further developmental switch between 
adolescence and adulthood. Finally, it has been shown that both 1 Hz LFS and 5 
Hz LFS determine an activity-dependent decrease in the basal secretion of BDNF 
in juvenile rat Prh slices (Aicardi et al., 2004). 
These evidences strongly confirm the role of LTD as a plausible in vitro model 
for visual recognition memory acquisition, although LTP may play a role as well, 
possibly in encoding long-term modifications necessary for familiarity 
discrimination. 
1.3.1.3. Perirhinal cortex and visual recognition memory: 
immunohistochemical studies 
The study of visual recognition memory and its proposed cellular correlate, 
LTD in Prh, has been extended to the investigation of the molecular mechanisms 
underlying these processes. The basic question was: which changes in gene 
expression are induced by acquisition and consolidation of a visual recognition 
memory or by protocols inducing synaptic plasticity? The expression of C-fos, an 
IEG mainly expressed in activated neurons, was used as an indicator of neuronal 
activity (Dragunow et al., 1996; Herdegen et al., 1998): interestingly, neurons were 
found to be activated in the Prh by the novel rather than by the familiar stimulus 
(reviewed by Brown and Aggleton, 2001), and intra-Prh infusion of scopolamine 
blocked the decrease in c-fos expression observed in the ‘familiar’ hemisphere 
(Warburton et al., 2003); a similar effect was observed with the L-type VGCC 
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antagonist verapamil (Seoane et al., 2009), or by blocking the pCREB signalling 
pathway (Warburton et al., 2005). 
The results coming from this technique, together with behavioural measures 
and electrophysiological recordings, have so far confirmed the association 
between visual recognition memory and neuronal activity in the Prh, expressed as 
a decrease in neuronal responsiveness in the Prh network. LTD, the best in vitro 
model underlying this cognitive function, is induced by the activation of different 
neurotransmitter receptors depending on the state of excitation of the network, the 
developmental stage and the induction protocol. These phenomena also involve 
changes in IEG expression; in particular, visual familiarity is encoded by the 
decreased levels of c-fos expression within Prh neurons.  
1.4. Nitric oxide (NO) 
NO is a ubiquitous amphiphilic highly diffusible molecule, synthesized 
intracellularly. It is a free radical, and because of its instability and ability to freely 
diffuse through the plasma membrane it mainly acts as a paracrine modulator. NO 
is involved in many physiological and pathological processes. It emerged as a 
neuronal messenger about 20 years ago, when searches focused on endogenous 
modulators showed that NMDAR activation caused increases in cGMP 
concentration in surrounding neurons (reviewed by Garthwaite, 2008).  NO is 
involved in the regulation of peripheral organs (digestive, urogenital, respiratory) 
through nitrergic nerves, and acts as a modulator mediating relaxation of smooth 
muscle tissue (reviewed by Rand and Li, 1995; Toda and Okamura, 2003; Toda 
and Herman, 2005). It plays a major role in the regulation of blood flow: it is 
produced from endocytes and it primarily acts within smooth muscle tissue of 
blood vessels as a vasodilator. In addition, it is produced by many blood cells 
involved in immunity such as neutrophiles, macrophages and circulating 
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monocytes, eosinophiles and even platelets: it is involved in both the physiological 
regulation of the metabolism of these cells and as an inflammatory mediator. In the 
vertebrate CNS, NO-dependent transmission is involved in several neuronal 
functions and complex behaviours such as learning and memory formation, 
sensory and motor function, sleeping, feeding, and reproductive behaviours. 
Indeed, NO-dependent transmission is highly conserved in evolution as a 
modulator of behaviour. For instance, NO synthesis in the jellyfish induces cGMP 
production via activation of a receptor very similar to the mammalian soluble 
guanilate cyclase (sGC), and cGMP plays a role in swimming patterns associated 
with feeding (Moroz et al., 2004). In molluscs and insects, NO mediates olfactive, 
feeding and learning related behaviours (reviewed by Davies, 2000).  In the last 
few years many studies clarified the role of NO in vertebrate CNS functions like 
neurogenesis, neural development and differentiation (Mize and Lo, 2000; 
Contestabile and Ciani, 2004; Estrada and Murillo-Carretero, 2005), memory and 
learning (Susswein et al., 2004), and neuropathology (Contestabile et al, 2003). In 
the sections to come, I have reviewed NO-dependent transmission and its 
importance in memory and learning. 
1.4.1. Nitric oxide synthesis, receptors and downstream signalling 
 
NO is intracellularly synthesized by a group of enzymes known as NO-
synthases (NOS). NOS are complex enzymes expressed in 3 different isoforms: 
endothelial (eNOS), neuronal (nNOS) and inducible (iNOS). The first two isoforms 
(nNOS and eNOS) are constutively expressed in the CNS and they are mainly 
involved in physiological processes, whilst the third one (iNOS) is prototypically 
expressed in macrophages and glia in the CNS as a consequence of 
immunological activation. All three isoforms synthesise NO and L-citrulline from L-
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arginine, but they have different structural and functional features (reviewed by 
Alderton et al., 2001; Stuehr et al., 2004).  
nNOS was the first isoform to be cloned and purified (Bredt and Snyder, 1990; 
Bredt et al., 1991) and was first identified in the CNS, but it is widely expressed 
also in the peripheral nervous system and in skeletal muscles. nNOS is expressed 
in four splicing variants (α, β, γ and µ; see Fig 1.9.). The splice variant nNOSα is 
the most abundant in CNS, and is activated by Ca2+ associated to calmodulin. It is 
mainly localized at postsynaptic densities, where it binds the postsynaptic density 
protein 95 (PSD-95) through a PDZ domain located at the amino-terminal such as 
observed for the NMDAR subunit NR2B (Brenman et al., 1996). The physical 
association of nNOSα with NMDAR explains the preferential functional association 
between NMDAR activation and NO production (Garthwaite et al., 1988). nNOSβ 
does not have a PDZ domain so it shows less functional association with NMDAR 
activation (Gyurko et al., 2002). nNOSγ shows little or no enzymatic activity, while 
nNOSµ is similar to nNOSα with an insert around the calmodulin binding motif and 
is mainly expressed in skeletal muscles but also in the CNS where it represents 
10% of total nNOS. nNOS has allosteric modulation sites other than 
Ca2+/calmodulin binding sites. For instance, nNOS shows different putative 
phosphorylation sites for PKC, PKA, PKG and CaMKII, but they are characterized 
by mild effects on functionality (Nakane et al., 1991; Bredt et al., 1992; Dinerman 
et al., 1994). CaMKII is usually co-resident with NMDAR and nNOS at 
postsynaptic densities (Kennedy et al., 2000); it inhibits NO production by about 
50%,  via phosphorylation of nNOS at Ser-847, which most likely affects the 
binding with Ca2+/calmodulin (Komeima et al., 2000). The phosphorylation process 
on Ser-847 takes about 15 min in cultured hippocampal neurons, suggesting that 
this system is a form of long-term control. NO increases the degree of nNOS 
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phosphorylation at low concentrations (5 µM) and decreases it at higher 
concentrations (100 µM; Rameau et al., 2004). 
 
Protein kinase Akt was found to phosphorylate nNOS on Ser-1412 in cultured 
hippocampal neurones (Rameau et al., 2007); this phosphorylation is NMDAR-
dependent and it leads to an increase in nNOS activity. The dephosphorylation is 
subsequent to AMPAR and L-type VGCC activation. Phosphorylation at both Ser-
847 and Ser-1412 also occur in vivo (Hayashi et al., 1999; Rameau et al., 2007). 
Other phoshorylation sites are summarised in Table 1. nNOS has also been 
shown to interact with other proteins that may influence its activity, such as the 
intra-membrane serotonin transporter, suggesting a possible coupling between 
serotonin uptake and NO production. Also, the inhibitory protein CAPON competes 
Fig 1.9. A. Schematic representation of the genes encoding for the three isoforms of the 
NOS. Note that only nNOS has the PDZ domain for interaction with PSD-95, responsible 
for the co-localization of the enzyme with the NMDAR. B. Schematic representation of the 
sequence differences between the three isoforms (Modified from Steinert et al., 2010). 
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with PSD-95 for the binding to the PDZ-domain, without directly affecting nNOS 
catalytic activity, but interfering with coupling of NMDAR activity with nNOS 
activation and its intracellular localization (Jaffrey et al., 2002). Some studies 
highlighted that nNOS activation can also be mediated by Gq-coupled receptors 
like group I mGluRs in the striatum (Calabresi et al., 1999) or M3/M1 in the rat 
retina (Borda et al., 2005). 
eNOS is expressed in endocytes both peripherally and in the CNS (Seidal et 
al., 1997; Blackshaw et al., 2003), but many studies suggested that it is also 
expressed in astrocytes (Reviewed by Lin et al., 2007).  As nNOS, eNOS is 
Ca2+/calmodulin dependent. Notwithstanding the well known role of eNOS in blood 
flow regulation (reviewed by Toda and Okamura, 2003; Ortiz and Garvin, 2003), 
emerging evidence suggests that eNOS is also involved in vasculo-neuronal 
communication, exerting a key role in neuronal excitability as observed in the optic 
nerve (Garthwaite et al., 2006), neurogenesis (Chen et al., 2005) and synaptic 
plasticity (Bon and Garthwaite, 2003; Hopper and Gathwaite, 2006; Sergeeva et 
al., 2007). Control of eNOS is multifactorial (reviewed by Cirino et al., 2003): in 
endocytes eNOS is bound to plasma membrane through palmitoylation and it is 
localized in specialized invaginations called caveoli by interacting with caveolin-1 
and the heat-shock protein 90 (hsp-90). Ca2+/calmodulin association to eNOS 
determines dissociation from caveolin-1, which is necessary for eNOS activation. 
Hence, eNOS is usally tonically active in endocytes for the regulation of the 
smooth muscle tone of arterioles, both peripherally and in the CNS. The tonic 
activation of eNOS is due to the phosphorylation of Ser-1179 by the protein kinase 
Akt (a modification that is structurally and functionally comparable to the 
phosphorylation of Ser-1412 in nNOS) enabling eNOS activation at resting 
intracellular Ca2+ concentrations (reviewed by Garthwaite, 2008). In addition, 
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eNOS is regulated by NO itself, which inhibits its activity in resting endothelial cells 
via S-nitrosylation at Cys-94 and Cys-99 of the zinc tetrathiolate cluster, blocking 
eNOS dimerization (Erwin et al., 2005). 
iNOS expression relies on inflammatory and disease conditions; expression is 
low in physiological conditions and it has little role in maintaining vascular tone 
(Ortiz and Garvin, 2003). iNOS activation determines NO production at micromolar 
levels (whereas eNOS and nNOS produce NO at nanomolar levels); it’s a Ca2+ 
independent process involved in many pathological processes, comprising 
neurodegeneration (reviewed by Garthwaite, 2008).  
The activation of the soluble guanylate cyclase (sGC) has been recognized as 
the main transduction pathway through which NO physiologically exerts its 
functions, even before the discovery that the so called “endothelial-derived 
relaxing factor” corresponds to NO (Arnold et al., 1977; Miki et al., 1977). Latter 
studies on NO showed the preminence of this mechanism in nitrergic transmission 
(Krumenacker et al., 2004). Even if sGC is the most commonly used name for this 
receptor, it does not have much meaning in a cellular context (Chrisman et al., 
1975). It is more correct to define NO-receptors as enzyme-linked proteins, 
sometimes indirectly associated with membranes. As other receptors, NO-
receptors have a ligand-binding domain and a transduction domain. The ligand-
binding domain consists in a heme group similar to the one inserted in 
haemoglobin for molecular oxygen (O2) binding; once incorporated in the NO-
receptor protein, it shows a stunning preference for NO, notwithstanding the 
chemical similarity between the two ligands. The heme prosthetic group inserted in 
the protein component of NO-receptors allows cellular NO-dependent transmission 
in the presence of 100,000-fold higher O2 concentration (Martin et al., 2006). The 
protein component of the NO-receptor is a αβ heterodimer expressed in two 
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isoforms: α1β1 and α2β1. Both are comprised of a heme-binding domain, a 
dimerization domain and a catalytic domain where the guanosine triphosphate 
(GTP) is converted into cyclic guanosine monophosphate (cGMP). In the ligand 
binding domain, the heme group is coordinated to the protein by a histidine bond 
(Zhao et al., 1998), whilst in the inactive state the catalytic domain (that is very 
similar to the catalytic site of adenyl-cyclase) is in an open state (Dessauer et al., 
1999). 
 
The binding of NO to the heme group determines a pivot of the haem, ensuing 
dislocation of the histidine to which it is coordinated, inducing a conformational 
change that ultimately results in the closing of the catalytic domain and in the 
conversion of GTP into cGMP (Roy and Garthwaite, 2006). The two isoforms of 
Fig 1.10. Different phosphorylation sites on the three isoforms of NOS, effects of the 
phosphorylation, kinases involved and cells in which the observations were made (Modified 
from Steinert et al., 2010). 
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NO-receptors are both widely expressed in the CNS within different cell-types 
(Friebe and Koesling 2009) and subcellular localizations (Budworth et al., 1999; 
Szabadits et al., 2007). α2β1 is mainly localized at synapses, thanks to its 
association to PSD-95 through its PDZ domain (Russwurm et al., 2001) whereas 
α1β1 is mainly cytosolic but it can be transported near to the plasma membrane as 
a consequence of increased intracellular Ca2+. Immunocytochemistry of NO-
receptors (Ding et al., 2004) and of cGMP after neurons exposure to NO (deVente 
et al., 1998) underlies different levels of expression of this enzyme throughout the 
different areas of the CNS, that are complementary to nNOS expression. Different 
sites on NO-receptors have been identified as possible allosteric targets for the 
modulation of NO-cGMP signalling. In addition, many phosphorylation sites have 
also been identified on the NO-receptors, but the physiological role for such 
modifications has still to be clarified (reviewed by Pyriochou and Papapetropoulos, 
2005). It is of particular interest a recent study that shows that activation of M2 
receptors for acetylcholine on intestinal smooth muscle cells decreases cGMP 
production through Src kinase-dependent Tyr phosphorylation of the NO-receptor 
(Murthy, 2008). 
cGMP actions are exerted by direct binding on the agonist or regulatory sites of 
cyclic nucleotide gated ion channels (CNG) (reviewed by Kaupp and Seifert, 2002) 
or hyperpolarization-activated, cyclic nucleotide-modulated (HCN) channels 
(reviewed by Craven & Zagotta, 2006). Another action of cGMP is mediated by its 
binding to phosphodiesterases (PDE), a family of 11 enzymes responsible for the 
hydrolysis of cyclic nucleotides: most of them can bind and hydrolyse cGMP, in 
particular PDE 1, 2, 3, 5, 6, 9, 10 and 11 (reviewed by Bender and Beavo, 2006). 
PDE 2 and 5 once bound by cGMP have higher activity states with increased 
cGMP breakdown. The binding of cGMP to PDE3 (since this protein does not 
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hydrolyse it) results in decreased cAMP clearout and, in turn, potential increases 
in cAMP levels (reviewed by Bender and Beavo, 2006). PDE5 is mainly involved in 
hydrolysis of cGMP in cerebellum (Shimizu-Albergine et al., 2003) while PDE2 is 
mostly involved in cGMP hydrolysis in the hippocampus (van Staveren et al., 
2001; Wykes et al., 2002; Boess et al., 2004). There is an availability of selective 
inhibitors for different isoforms of PDEs that are precious tools for investigating the 
functional meaning of nitrergic transmission in different systems, comprised 
learning and memory (reviewed by Blokland et al., 2006).  
Activation of cGMP-dependent protein kinase (PKG) is the signalling system 
activated by cGMP mostly responsible for the NO-dependent cellular downstream 
signalling. There are three isoforms of PKG: PKG1a and PKG1b (splice variants) 
are derived from the expression of a gene located on human chromosome n° 10 
and finally PKGII, whose gene is located on human chromosome n° 4. While 
PKG1a and PKG1b are principally expressed in the hippocampus, dorsal root 
ganglia, cerebellum and the olfactory bulb, PKGII (which is anchored to the 
plasma membrane through myristoilation) is expressed throughout the entire CNS 
(reviewed by Feil et al., 2005; Vaandrager et al., 2005; Hofmann et al., 2006). 
PKGI is a homodimer of 76 kDa and PKGII is an homodimer of 86 kDa. All the 
PKGs contain an amino-terminal domain with 5 regulatory sites: 1) a dimerization 
site 2) self-inhibition sites, involved in the inhibition of the catalytic domain in 
absence of cGMP 3) self-phosphorylation sites that in presence of cGMP increase 
the basal catalytic activity and the affinity of the PKG for cAMP 4) a site that 
regulates the affinity and cooperativity between the cGMP binding sites 5) an 
intracellular localization site. The regulatory domain of PKG contains two binding 
sites for cyclic nucleotides that mediate the full activation of the enzyme just after 
their full occupation by two cGMP molecules. The catalytic site at the carboxi-
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terminal contains binding sites for Mg2+, ATP and the target protein (reviewed by 
Domek-Lopacinska and Strosznajder, 2005). The main target substrates for PKG 
are phosphatases, leading to the variation of phosphorylation levels of effector 
proteins (reviewed by Schlossmann and Hofmann, 2005). cGMP was also found 
extracellularly in the brain with concentration levels changing according to NO 
production (reviewed by Vincent et al., 1998; Pepicelli et al., 2004). After 
intracellular synthesis, cGMP can be transported extracellularly via multidrug 
resistance proteins (reviewed by Sager, 2004) where it can possibly act as an 
intercellular messenger (Touyz et al., 1997; Poulopoulou & Nowak, 1998; Montoliu 
et al., 1999). 
There is some evidence of cGMP independent NO-dependent transmission 
(Jacoby et al., 2001; Lev-Ram et al., 2002) suggesting other downstream 
signalling pathways triggered by NO. For example, it has been suggested that S-
nitrosation (or nitrosylation) of thiol groups on cysteine residues can be an 
alternative signal transduction system. S-nitrosation is induced by exposing 
proteins to exogenous concentrations of NO (in the order of magnitude of µM) or 
nitrosating compounds of oxygen (as N2O3) or high concentrations of Ca2+ 
(reviewed by Hogg, 2002) but to date, there is no evidence of a physiological role 
for S-nitrosation dependent transmission. In vivo, S-nitrosation has been shown to 
be involved in pathological states (Zhang and Hogg, 2005). High concentrations of 
NO (in the order of magnitude of µM), deriving from iNOS expression and 
activation, can lead to the binding of NO to the ferrous haem on the cytochrome 
oxidase in mithocondria, causing the blockade of cellular respiration and exerting 
cytotoxic effects. This phenomenon is important in chronic neurodegenerative 
diseases such as Alzheimer’s disease (AD) Parkinson’s disease (PD), multiple 
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sclerosis and other amyloid disease (reviewed by Smith and Lassmann, 2002), as 
described below (section 1.4.5.). 
Considering its reactivity, NO is usually regarded as a messenger that does not 
need a specific scavenging mechanism. At physiological concentrations (in the 
order of magnitude of nM) NO is poorly reactive (Ford et al., 1993), but it rapidly 
reacts with lipid peroxyl radicals, underlying its role in protecting the organism from 
lipid peroxidation subsequent to oxidative stress (Keynes et al., 2005). 
Remarkably, in the brain there is a mechanism for NO scavenging more efficient 
than in the rest of the organism, as evidenced by the measure of the rate of 
consumption of NO in cerebellar slices, that is significantly higher than that 
observed in dispersed cells (Hall and Garthwaite, 2006).  
Because of its amphiphillic nature and dimensions, NO freely diffuses through 
membranes, accessing any cell compartment and hence acting both as an intra- 
and inter-cellular messenger. NO acts on target neurons as a result of volume 
transmission (Steinert et al., 2008), integrating neuronal activity over a volume 
limited by diffusion, coordinating synaptic transmission and plasticity of the 
neurons comprised in that volume (Gally  and  others 1990).  A single source that 
emits NO for 10-20 seconds generates a diameter of influence of about 200 µM 
that corresponds to ~2 x 106 synapses. For multiple sources of NO, its 
concentration linearly increases with time affecting a population of active and 
inactive cells (Jacoby et al., 2001; Steinert et al., 2008). 
1.4.2. targets of NO signalling 
 
Not much is known about targets mediating NO/cGMP/PKG signalling. In fact, 
modulation of synaptic transmission, LTP and LTD do not represent ‘targets’, but 
rather integrated functions influenced by various alterations of structure/function of 
intracellular or membrane proteins, such as ion channels at both pre- and post-
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synaptic levels (reviewed by Steinert et al., 2010). Increasing evidence points to 
the fact that synaptic plasticity can also be achieved by changes in the function of 
voltage-gated ion channels, influencing neuronal excitability and, in turn, the 
efficacy of information transfer, without directly affecting synaptic strength. 
Phosphorylation or S-nitrosation of VGNC, VGCC, Ca2+ activated and ATP-
sensitive potassium (K+) channels have been proposed as possible targets 
(reviewed  by Biel  et al., 1998; Ahern et al., 2002; Sanders and Kho 2006; 
Kawano et al., 2009). The targeting of K+ channels to change neuronal excitability 
has been observed in the auditory brainstem (Steinert et al., 2008) with 
suppression of Kv3 channels and consequent increases in the neuronal excitability 
and duration of the action potentials. This action is triggered by NO-evoked 
increases in cGMP that activate PKG which in turn leads to the downstream 
dephosphorylation of the Kv3 channel expressed in CHO (Moreno et al., 2001); it 
has to be established if the same mechanism is also observable in a native 
preparation. It is worth noting that AMPAR, VGNC and NMDAR are influenced by 
NO. NO transmission has also been shown to inhibit Kv4 channels in human atrial 
and mouse ventricular myocites (Gomez et al., 2008). Kv1 activity is also inhibited 
by NO via cGMP and S-nitrosylation mediated mechanisms (Nunez et al., 2006). 
Furthermore, NO is known to interfere with AMPAR trafficking, a crucial process in 
LTP and LTD expression mechanisms, characterized by the insertion or 
internalization of AMPAR into or from the plasma membrane, respectively 
(Malinow and Malenka 2002; Song and Huganir 2002). GluR1 subunit 
phosphorylation on Ser-845 by PKGII leads to increased insertion of AMPARs at 
the cell surface (Serulle et al., 2008) as does direct nitrosylation of GluR1 and 
GluR2 (Huang et al., 2005; Selvakumar et al., 2009). On the other hand, cGMP 
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has been demonstrated to induce phosphorylation-independent inhibition of the 
AMPAR (Lei and others 2000). 
Later findings in the peripheral nervous system and at the junction between 
nitrergic nerves and the effector organs suggest new possible targets for 
NO/cGMP signalling (reviewed by Toda and Okamura, 2003; Toda & Herman, 
2005). Also, sampling of extracellular fluids suggests interactions with other 
transmission systems (reviewed by Prast by Philippu, 2001). Serotoninergic 
transmission is heavily influenced by NO/cGMP/PKG in the pond snail, Lymnaea 
stagnalis (Straub et al., 2007). It is of remarkable interest the interaction between 
NO/cGMP/PKG pathway and cholinergic neurotransmission in the brain (reviewed 
by de Vente, 2004) and in particular the role of NOS/sGC/PKG in the M1-
dependent LTD in rat prefrontal cortex slices (Huang et al., 2009). Recent studies 
highlighted the role of another important component in this machinery, the 
endocannabinoids (eCBs): in the vertebrate (lizard) neuromuscular junction, 
activation of muscarinic (M3) and consequent transient decrease in acetylcholine 
relies on eCB secretion activating the NO/cGMP/PKG pathway (Newman et al., 
2007). This mechanism is presumably presynaptic, since CB1 receptors are 
located presynaptically. In addition, depolarization-induced suppression of 
inhibition in the hippocampus in the presence of a cholinergic agonist relies on 
both NO/cGMP and eCBs (Makara et al., 2007). Furthermore, a close interplay 
between eCBs and NO in long-term plasticity at the corticostriatal excitatory 
synapses (Sergeeva et al., 2007) and spinal locomotor circuitry (Kyriakatos and El 
Manira, 2007) has been previously demonstrated. These latter evidences 
represented a key feature in the development of this project. 
The activation of the NOS/sGC/PKG pathway can also result in the 
modification of gene expression: for instance, pavlovian fear conditioning in rats 
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relies on the activation of the nNOS/sGC/PKG pathway in the lateral amygdala, 
where it activates ERK/MAP kinase (Ota et al., 2008). Furthermore, 
NOS/sGC/PKG activation mediates the late phase of LTP and induces 
phosphorylation of CREB in the hippocampus (Lu et al., 1999), while YC-1, a 
potent sGC agonist, induces the enhancement of LTP at SC-CA1 synapses and 
the phosphorylation of CREB and ERK (Chien et al., 2003). 
Even if most of the studies are focused on the action of NO on neurons, glia 
can also play an important role in NO/cGMP dependent transmission. For 
example, in the cerebellum astrocytes have the highest concentration of cGMP (de 
Vente et al., 1990; Southam et al., 1992; Southam & Garthwaite, 1993). The 
synapses are frequently interconnected with astrocyte processes, so the NO 
produced at a neuronal level may affect astrocyte metabolism. Forebrain cultures 
briefly (100 ms) exposed to NO are characterized by increased Ca2+ 
concentrations in glia (Willmott et al., 2000). Furthermore, NO/cGMP in astrocytes 
has been shown to regulate the expression of glial fibrillary acidic protein (GFAP) 
(Brahmachari et al., 2006). Fig 1.11. summarizes the main pathways of synthesis 
and signal transdution of NO. 
 52
  
 
 
Fig 1.11. Schematic representation of NO production and downstream signalling at a  
glutamatergic synapse. The main pharmacological tools used to study NO-dependent 
transmission consist in antagonism of the nNOS such as L-NMMA, 7-NI or L-NAME 
(not shown). Similarly, sGC represents a main target antagonized by molecules such as 
ODQ or NS2028 (not shown). sGC can be also be activated by the application of NO 
donors as DEA/NO or SNP. nNOS is activated by the Ca2+/calmodulin complex as a 
consequence of the NMDAR or gq-coupled receptor activation (not represented). NO 
can act both post- and presynaptically, affecting neuronal function via S-nitrosylation 
or via the NO-receptor sGC. S-GC synthesizes the second messenger cGMP that can 
directly act on CNG or Kv1 channels or indirectly by activating PKG. cGMP activity is 
negatively regulated by PDEs. Abbreviations: AP = action potential; Cav = voltage-
gated calcium channel; CNG = cyclic nucleotide-gated ion channels; DEA/NO = 
diethylamine nonoate; IKATP/h = ATP-sensitive potassium channel/hyperpolarizing 
potassium channel; Kv3.1 = voltage-gated potassium channel; L-NAME = L-ω-nitro-
arginyl-methylesther; L-NMMA = NG-methyl-L-arginine; LTD = long-term 
depression; LTP = long-term potentiation; Nav = sodium channel; NS2028 =  4H-8-
Bromo-1,2,4-oxadiazolo[3,4-d]benz[b][1,4]oxazin-1-one ODQ = 1H-
[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one; ONOO– = peroxynitrite; PDE = 
phosphodiesterase; SNP = sodium nitroprusside; 7-NI = 7-nitroindazole. (Modified 
from Steinert et al., 2010). 
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1.4.3. NO and synaptic plasticity 
 
Since synaptic plasticity is described as a variation in synaptic strength 
following a specific pattern of activity of the neural network, this concept implies 
the existence of a messenger coordinating pre- and post-synaptic changes. 
Because of its diffusibility, NO was considered a good candidate for such a 
function since the beginning; after several years of studies generating 
contradictory evidences, it is now well accepted that NO plays a key role as a 
retrograde messenger mediating both LTP and LTD induction in different brain 
areas (Garthwaite & Boulton, 1995; Holscher, 1997; Calabresi et al., 1999; Prast & 
Philippu, 2001; Susswein et al., 2004; Garthwaite et al., 2008; Steinert et al., 
2010).  
The role of NO in LTD in the cerebellum at excitatory synapses from parallel 
fibres to Purkinje cells (PC) is well established. In brief, NO is produced in parallel 
fibres or in interneurons after activation of NMDAR by parallel fibres activation 
(Shibuki and Kimura, 1997; Shin and Linden, 2005). Purkinje cells have been 
shown to express high levels of the so called PKG substrate that once 
phosphorylated works as a phosphatase inhibitor (Endo et al., 2009). This, with 
PKC activation, leads to persistent AMPAR phosphorylation, resulting in AMPAR 
internalization (Launey et al., 2004; Steinberg et al., 2006). As mentioned before, 
cerebellar LTD also relies on eCBs release that, in turn, induce NO production 
(Safo and Regehr, 2005). Carbachol (Cch)-induced LTD in rat prefrontal cortex 
relies on the activation of NO/cGMP/PKG causing a presynaptic decrease release 
of neurotransmitter (Huang et al., 2009). Hippocampal LTD at SC-CA1 synapses 
requires NO/cGMP/PKG and release of Ca2+ from ryanodine sensitive intracellular 
stores, possibly mediated by cyclic ADP-ribose (Reyes-Harde et al., 1999). In 
addition, hippocampal NMDAR-dependent, but not mGluR1-dependent LTD, relies 
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on reduction of glutamate release mediated by NOS activity (Zhang et al., 2006). 
In the hippocampus, LTP is shown to involve AMPAR insertion in the postsynaptic 
membrane (reviewed by Collingridge et al., 2004) and the NO/cGMP/PKG 
pathway is known to play a pivotal role in the insertion of AMPAR on the 
postsynaptic membrane, via the phosphorylation of Ser-845 on the AMPAR 
subunit GluR1 (Antonova et al., 2001; Wang et al., 2005; reviewed by Garthwaite 
et al., 2008). NO acts as a retrograde messenger in synaptic plasticity in 
hippocampal LTP acting via cGMP/PKG (Arancio et al., 1995; 2001), coordinating 
the increase in both post-synaptic AMPAR insertion and presynaptic 
neurotransmitter release (Wang et al., 2005). LTP induction in rat visual cortex 
requires NOS activation and cGMP production (Haghikia et al., 2007). Bath 
application of the NO donor DEA/NO (300 µM) on acute hippocampal slices has 
been demonstrated to mediate a transient depression (presumably due to the 
cytotoxic effects of the exogenous NO on the mythocondrial oxidative 
phosphorylation) followed by a stable potentiation dependent on cGMP production 
(Bon and Garthwaite, 2001). In addition, it has been previously shown that a weak 
tetanic stimulation consisting of 5 pulses delivered at 50 Hz does not induce 
plasticity, although, if coupled to the bath application of DEA/NO (3 µM; at this 
concentration it does not affect basal synaptic transmission) it induced a robust 
LTP in hippocampal SC/CA1 synapses (Bon and Garthwaite, 2003). 
NO/cGMP/PKG activation was found to potentiate glutamate release in rostral 
ventral medulla neurons acting on N-type VGCC (Huang et al., 2003). In the 
cerebellum, parallel fibres-PC synapses undergo a form of presynaptic LTP 
requiring NO and cAMP but not cGMP production (Jacoby et al., 2001). Also, in 
the cerebellum, mossy fibre–granule cell synapse LTP, relies on NO/cGMP 
production for increased presynaptic excitability (Maffei et al., 2003). In the 
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hypothalamus, NO-cGMP pathway activation leads to the reduction of extracellular 
serotonin (Kaehler et al., 1999) presumably due to the phosphorylation of a 
threonine residue located on the serotonin transporter, followed by the subsequent 
increase in serotonin uptake (Ramamoorthy et al., 2007). Furthermore, alterations 
of intrinsic neuronal excitability mediated by NO/cGMP can be responsible for 
synaptic plasticity (Smith & Otis, 2003).  
1.4.4. NO signalling in memory and learning 
 
Blocking the NO production impairs the habituation of the proboscis extension 
reflex in the honeybee (Müller and Hildebrandt 2002). In mammals, it affects 
spatial learning which is under the control of the hippocampus (Böhme et al., 
1993; Mogensen et al., 1995), and motor learning which is processed in the 
cerebellum (Allen and Steinmetz 1996; Nagao et al., 1997). The effects of NO 
blockade on hippocampal- and cerebellar-dependent learning behaviour underlie 
the role of NO in LTP and LTD in these brain areas. In other forms of learning, 
even if subsequent memory formation can be affected, blocking NO production 
does not affect the associated behaviour. For instance, NO is not involved in 
classical conditioning in the proboscis extension reflex of the honeybee (Müller et 
al., 1996) and in various learning feeding paradigms in Aplysia (Katzoff et al., 
2002) and Helyx (Teyke; 1996). NO is also involved in many forms of short-term 
memory. Short-term memory lasts not more than ten minutes following the 
learning phase, and relies on structural and functional changes of already 
synthesized proteins (phosphorylation, S-nitrosylation etc.; Kandell, 2001). These 
modifications are triggered by the production of second messenger systems, and 
when associative learning paradigms are applied, two or more second messenger 
systems are activated influencing the target neurons (Byrne 1987). The possible 
role of NO/cGMP in short-term memory was first explored and confirmed in the 
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Aplysia feeding behaviour and in the passive avoidance task in the chick (Rickard 
et al., 1998; Katzoff et al., 2002).  
Long-term memory lasts from hours to the entire lifespan of the organism and it 
is derived from the consolidation of short-term memory. It relies on the production 
of newly synthesized proteins induced by the activation of transcription factors, 
stably changing the metabolism and the structure of neurons. NO has been shown 
to affect long-term memory. In mice, blockade of NO production after training 
inhibits the consolidation of associative spatial memory tested with an inhibitory 
avoidance task (Baratti and Kopf, 1996). In Aplysia and Helyx, learning paradigms 
affecting feeding behaviour show that blockade of NO during training, but not after 
it, inhibits long-term memory formation (Katzoff et al., 2002; Teyke 1996). NO is 
also associated with the consolidation of olfactive memories: in fact, the olfactory 
bulb is particularly rich in NOS.  In rat pups, the association of an odour to a tactile 
stimulus results in the situation by which their mother’s handling generates a 
preference for the associated odour versus other odours. This kind of learning is 
blocked by blocking the NOS before, but not after the application of the paired 
stimulus (Samama and Boehm 1999). NO has also been shown to be involved in 
the Bruce effect in rat, whereby the pregnancy of the female rat caused by the 
mating with a novel male mate is blocked and the subsequent allowance of the 
pregnancy with a familiar male that impregnated the female before is known as the 
Bruce effect. This mechanism relies on an odour recognition memory: the female 
rat remembers the odour associated to the pheromones of a male that 
impregnated it beforehand. Injection of an NO donor instead of mating and the 
simultaneous exposure to the associated pheromones results in the unblockage of 
the pregnancy meaning that NO acts as a reinforcer of the original pheromone 
(Okere et al., 1996). After olfactory learning, it is possible to observe an increase 
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in the nNOS mRNA (Okere and Kaba 2000). It has been shown that 
intracerebroventricular administration of the sGC agonist YC1 into rats performing 
in the Morris water maze, a well known test of spatial learning, resulted in 
decreased escape latencies, whereas in avoidance tasks it resulted in increased 
latencies in the passive variant and decreased latencies in the active variant; 
furthermore, all these effects were reversed by the NOS antagonist L-NAME and 
the PKG antagonist KT5823, exemplifying the role of the whole NO/cGMP/PKG 
pathway in spatial memory and learning (Chien et al., 2005). The NOS inhibitor 
NO-Arg was shown to impair the retention for a single-trial step-down inhibitory 
avoidance task in rats (Bernabeu et al., 1995, 1996, 1997). A limitation to the 
interpretation of these studies is that all these effects may be non-specific to the 
learning, i.e. they are mediated by the effect of NO on cerebral blood flow.  
NOS inhibition blocks long-term memory just within a very narrow time window 
around the initial training (Müller 1996, 2000). The late phase of LTP in 
hippocampal SC-CA1 is blocked by inhibitors of gene transcription or protein 
translation (Frey et al., 1988). The late phase of LTP relies on the activation of 
inducible transcription factors via phosphorylation by kinases such as PKA (Abel et 
al., 1997) or PKG. In fact these kinases can phosphorylate CREB to pCREB 
directly (Lu et al., 1999) or via ERK (Chien et al., 2003). In particular, blocking NO 
blocks the late phase of hippocampal LTP only if the inducing protocol consists in 
three spaced pulses but it is minimally affected if there are four pulses (Lu et al., 
1999). Knock-out mice for an isoform of PKG display a reduced late phase of LTP, 
but hippocampal dependent memory and learning functions are intact (Kleppisch 
et al., 2003). Thus, it is possible that the late phase of LTP relying on the 
NO/cGMP/PKG pathway underlies only a subset of learning and memory tasks 
depending on hippocampal activity. Furthermore, studies on day-old chicks, using 
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a weaker variant of the passive inhibitory avoidance task that does not allow 
memory consolidation, showed that the co-application of the PDE5 inhibitor 
Zaprinast allowed memory consolidation (Campbell and Edwards, 2006). This 
result is consistent with the evidence, on the same model, that administration of L-
NAME at 40 minutes post training in a single trial passive inhibitory avoidance task 
blocked memory retention (Rickard et al., 1998). In addition, also cerebellar LTD is 
characterized by a protein synthesis–dependent late phase, thus also 
NO/cGMP/PKG might be involved in motor memory consolidation (Linden 1996). 
Furthermore, many lines of evidence highlighted a possible role for NO/cGMP in 
object recognition memory, which is shown to rely on activity of the Prh rather than 
the hippocampus (reviewed by Brown and Aggleton, 2001). Systemic 
administration of the PDE5 inhibitor sildenafil prior or during the training phase 
increased the retention of recognition memory in rats (Prickaerts et al., 2002, 
2005) and in mice (Rutten et al., 2005). Rats which were intraperitoneally injected 
with the unspecific NOS inhibitor L-NAME before or after the training phase 
demonstrated impaired recognition memory when tested at 24 h but not at 1 h in a 
spontaneous novel object exploration task. L-NAME administered just before the 
test phase in rats tested at 24 h rescued the delay-dependent impairment in object 
recognition memory (Boultadakis et al., 2010a). Another study showed that the 
systemic administration of a NO donor (NCX2057) antagonized the deficit in visual 
recognition memory induced by previous systemic administration of the muscarinic 
antagonist scopolamine (Boultadakis et al., 2010b). Finally, L-NAME was shown to 
antagonize the object recognition deficit induced by the NMDAR antagonist MK-
801 and ketamine (Boultadakis and Pitsikas, 2010). Intra-hippocampal blockade of 
the NO/cGMP/PKG pathway induced deficits in visual recognition memory 
suggesting a key role for this pathway in the consolidation of this memory, and 
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also showing that the NO/cGMP/PKG downstream signalling system caused the 
activation of β–adrenergic receptors that in turn induced an increase in BDNF 
expression in the hippocampus (Furini et al., 2009).  
1.4.5. Role of NO in neuropathology 
 
NO is a free radical and it can react with many molecules; therefore it is 
involved in many pathological processes. In particular, the term nitrosative stress 
is related to the ability of NO and reactive nitrogen species (RNS) to damage 
proteins, nucleic acids and lipids. NO can react with the superoxide anion O2- to 
form peroxynitrite ONOO- that also decreases NO bioavailability (Beckman and 
Koppenol 1996). NOS directly contributes to O2- production in cells deficient in the 
NOS co-factor tetrahydrobiopterin (BH4) or the substrate L-arginine because they 
inefficiently catalyse the five electron reduction of L-Arg to citrulline with the 
conversion of O2 to O2- (Xia et al., 1996). BH4 deficiency is associated to both 
Alzheimer’s (AD) and Parkinson’s disease (PD) (Kuiper et al., 1994; Foxton et al., 
2007).   
Eukaryotic cells undergo the production of reactive oxygen species (ROS) 
because of the electron leakage from the mitochondrial electron transfer chain that 
reacts with oxygen to produce O2-. This is normally metabolised by superoxide 
dismutase (SOD) to H2O2 that is further transformed by antioxidant enzymes. Both 
NO and ONOO- inhibit respiratory chain metabolism, resulting in a decreased 
production of ATP (Heales et al., 1999; Erusalimsky and Moncada 2007). Thus, 
neurodegeneration shows a complex dependency by oxidative and nitroxidative 
stress factors such as oxygen availability, antioxidant enzyme production and local 
metabolic rates (Sims et al., 2004). NO/ONOO- production determines increased 
Zn2+ from internal stores with the formation of S-nitrosothiols and neurotoxicity 
(Kroncke et al., 1994; Knoch et al., 2008). A rise in free Zn2+ leads to apoptotic 
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death via p38 MAP kinase activation and caspase-independent K+ efflux 
(Bossy-Wetzel et al., 2004). NMDAR over-activation and NO exposure can 
determine mitochondrial fragmentation and cell death (Yuan and others 2007). 
This phenomenon in response to NO was reported in Alzheimer’s disease (AD),  
amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD; Bossy-Wetzel 
et al.,2008; Knott and Bossy-Wetzel 2008, 2009; Knott et al., 2008). Also, 
fragmentation of Golgi after NMDAR activation precedes neuronal death 
(Nakagomi et al., 2008). nNOS activation is highly coupled to NMDAR activation, 
so excitotoxicity can be related to nitrergic signalling.  
iNOS expression in glia is triggered by the exposure to insult-related stimuli 
such as pathogens, ischemia, hypoxia, neurotoxic substances (comprised 
extracellular β-amyloid deposits). Oxidative and nitrosative stress are key factors 
in neurodegenerative diseases such as AD, PD, ALS, multiple sclerosis (MS), HD, 
and in brain damage coming from ischemic-reperfusion events (Bennett et al., 
2009). Enhanced nitrotyrosine immuno-reactivity and oxidative protein damage are 
evident in brains from AD  patients  (Sultana et al., 2006; Danielson and Andersen 
2008; Sultana et al., 2009); on the other hand, in β-amyloid (Aβ) mutant mice 
observations of increased H2O2 production and decreased cytocrome c oxidase 
expression were demonstrated (Manczak et al., 2006). AD patients show high 
levels of S-nitrosylated proteins in the cerebral cortex (Hensley et al., 1998) 
associated with Aβ deposition (Sultana et al., 2006) along with nitrotyrosilation of 
Tau protein (Reynolds et al., 2005) and synaptophysin in AD. Dysfunctions in the 
cholinergic transmission are also observed in AD (Tran et al., 2003). In PD 
patients and in experimental models of PD, increased expression of iNOS was 
reported (Gatto et al., 2000; Barthwal et al., 2001; Singh et al., 2005). In the 
human CNS, iNOS is mainly expressed in astrocytes rather than microglia. 
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Reports of increased iNOS astroglia immunoreactivity in post-mortem brain 
samples from patients affected by MS (Bo et al., 1994), AD (Wallace et al., 1997), 
and PD were demonstrated (Hunot et al., 1996). 
Since NO is also involved in many physiological functions, it has to be clarified 
what the determinant factor is that decides its respective role in either pathological 
or physiological functions. Other than factors such as malfunctioning in NO 
generation or compensatory cellular responses, vascular dysfunction is an 
important condition that importantly contributes to the pathogenesis of many 
diseases. The involvement of nitrergic signalling in neurodegenerative diseases 
relies then on the generation of RNS, immune signalling, spill-over from 
endothelium and its involvement in oxidative stress. Chronic cerebral 
hypoperfusion and microvascular abnormalities can contribute to AD (Marlatt et 
al., 2008; Aliev et al., 2009; de la Torre 2009). Hypoperfusion and enhanced ROS 
generation in AD (Sultana et al., 2009; 2010) can be both responsible for 
increased iNOS expression as a consequence of a subclinical increase in 
inflammatory tone. In fact Aβ causes vasoconstriction of human cerebral arteries, 
with inflammation as a direct consequence, including the synthesis of other 
vasoconstrictors such as PGE2 and PGF2a (Townsend et al., 2002). In late-onset 
AD it is possible to observe increased plasma concentrations of the vascular cell 
adhesion molecule–1 (VCAM-1), related to endothelial activation (Zuliani et al., 
2008). Furthermore, in the cerebrospinal fluid of AD patients it is possible to 
observe increased concentration of vascular-endothelial growth factor (VEGF; 
Tarkowski et al., 2002; Yang et al., 2004) that is pro-inflammatory (Ryu et al., 
2009)  and is involved in β-amyloidogenesis (Burger et al., 2009). VEGF activates 
microglial cells increasing NO production to micromolar levels by increasing iNOS 
expression (Moncada and Bolanos 2006; Kurauchi et al., 2009).  Analogue 
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inflammatory pathways contribute to the neurodegeneration of nigro-striatal 
dopaminergic fibres in PD (Miller et al., 2009; Nanhoe-Mahabier et al., 2009).  
1.5. Endocannabinoids (eCBs) 
 
eCBs or endogenous cannabinoids (eCBs) take their name from the major 
psychoactive compound present in marijuana, ∆9- tetrahydrocannabinol (THC; 
Gaoni et al., 1964). The effect of THC is due to its action on the CB1 and CB2 
receptors: while CB2 are mostly expressed in the peripheral nervous system, CB1 
is the most expressed G-coupled receptor (GPCR) in the CNS, in structures such 
as the hippocampus, Prh, postrhinal and temporal cortices (Liu et al., 2003c).  CB1 
was first isolated, cloned and characterized as a GPCR associated to αi/o (Devane 
et al., 1988; Matsuda et al., 1990). A few years later, the eCBs anandamide (AEA) 
and 2-arachydonyl glycerol (2-AG) were isolated and characterized (Devane et al., 
1992; Stella et al., 1997). The role of eCBs in brain function soon emerged, with 
central roles in the modulation of synaptic transmission and plasticity, mainly 
acting as retrograde messengers at CB1 (reviewed by Freund et al., 2003). In the 
last 10 years the role of eCBs in short- and long-term depression has been well 
characterized, consistent with their involvement in the modulation of many 
cognitive functions and behaviours, comprised memory and learning (Reviewed by 
Heyfetts and Castillo, 2009). The actions of eCBs are usually associated to LTD 
mechanisms, but recent evidence has demonstrated a possible role of eCBs also 
in LTP (see below section 1.5.1.). Furthermore, certain studies have shown that 
many neuropathologies such as PD and AD are correlated to alterations in eCB-
dependent neurotransmission: therefore eCB receptors now represent a new 
pharmacological target for the treatment of these diseases (reviewed by Micale et 
al., 2007). 
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1.5.1. Endocannabinoid-mediated long term depression (eCB-LTD) 
The first evidence of eCB-mediated LTD (eCB-LTD) emerged in excitatory 
synapses in the dorsal striatum (Gerdeman et al., 2002). eCB-LTD is also present 
in the amygdala (Marsicano et al., 2002), nucleus accumbens (Robbe et al., 
2002), hippocampal CA1 at both inhibitory (Chevaleyre and Castillo, 2003) and 
excitatory inputs (Yasuda et al., 2008) and in many other areas as summarized in 
Fig 1.12.   
1.5.2. Induction of eCB-LTD 
eCB-LTD is usually triggered by the increase in glutamate release from afferent 
fibres and the consequent release of eCBs from the target neuron (postsynaptic). 
The released eCBs work in a retrograde manner, acting at presynaptic CB1 
(homosynaptic eCB-LTD) and on CB1 located on nearby afferents (heterosynaptic 
eCB-LTD). The induction protocols of eCB-LTD vary between different brain 
areas, with frequencies of stimulation comprised between 1 and 100 Hz, including 
theta burst stimulation (TBS) as shown in Fig 1.12. Moreover, alternating induction 
of action potentials at both post- and presynaptic neurons with variable time 
intervals in between can induce the so called spike timing-dependent plasticity 
(STDP). STDP can consist of both potentiation and depression paradigms (t-LTP 
and t-LTD), depending on the time intervals and brain areas under consideration 
(reviewed by Caporale and Dan, 2008). In the case of CB1 dependent STDP, only 
t-LTD is observed (eCB-t-LTD). This form of eCB-LTD is not distinguishable by the 
one purely induced by afferent stimulation (Chevaleyre et al., 2007). 
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eCBs release is mediated by two distinct processes: postsynaptic neuron 
depolarization and neurotransmitter release. For example, glutamate release from 
the presynaptic site can trigger eCB release from the postsynaptic neuron by 
stimulating group I mGluRs, that are Gαq/11 coupled receptors (Varma et al., 2001; 
Jung et al., 2005). On the other hand, postsynaptic neuron depolarization has 
shown to generate increases in intracellular Ca2+ concentration  via VGCC and 
NMDAR activation that, in turn, stimulates eCBs synthesis and release in the 
intersynaptic cleft through a mechanism that is not yet well understood (reviewed 
by Piomelli, 2003). Many evidences underlie that eCB release does not strictly 
depend on the activation of a particular metabotropic receptor or on a specific 
source of Ca2+; other than group I mGluRs, metabotropic dopamine 2 (D2), 
muscarinic acetylcholine 1/3 (M1/3), metabotropic serotonin 2 (5HT2), orexin and 
cholecistochinin receptor activation are all effective stimuli for eCBs production. 
Fig 1.12. eCB-LTD: brain structures, synapses and stimulation protocols (modified 
from Heifetts and Castillo, 2009). 
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Most of these receptors are coupled to αq/11, engaging phospholipase C (PLC) that 
generates the substrate for diacylglycerol lipase (DGL) which results in the 
production of 2-AG. Moreover, other mechanisms have been proposed; in the 
amygdala, AEA is synthesized after mGluR1-dependent adenylate cyclase (AC) 
activation which generates increases in cAMP production and PKA activation 
(Azad et al., 2004). In cortico-striatal synapses, induction of eCB-LTD relies on D2 
activation, that is associated to αi/o and selectively induces AEA synthesis through 
a mechanism not yet understood (Giuffrida et al., 1999; reviewed by Piomelli, 
2003). Ca2+-dependent eCB release is not always required, but it still covers a 
pivotal role in eCB-LTD (Gerdeman et al., 2002). Ca2+ influx from NMDAR, L-type 
and T-type VGCC and from internal stores was reported to drive to eCB release 
(Nevian and Sackman, 2006; Bender et al., 2006; Isokawa and Alger 2006; 
Beierlein and Regehr, 2006; Adermark and Lovinger, 2007; Ohno-Shosaku et al., 
2007). The two mechanisms can both operate independently and synergistically 
(Ohno-Shosaku et al., 2002; Kreitzer and Malenka, 2005; Brenowitz and Regehr, 
2005; Hashimotodani et al., 2005).  
The degradation of eCBs is mediated by enzymes that may represent a good 
target for the modulation of eCB-LTD; these include monoacylglycerol lipase 
(MGL) and fatty acid amide hydrolase (FAAH) (reviewed by Piomelli, 2003). MGL 
is highly expressed in the presynaptic neuron near the CB1, supporting the view 
that this enzyme plays an important role in eCB-LTD. In fact, the inhibition of MGL 
leads to the induction of eCB-LTD after sub-threshold stimulation in the prefrontal 
cortex (Lafourcade et al., 2007). Recently, the topic of a putative postsynaptic 
membrane eCB transporter (EMT) responsible of eCBs efflux (an important step in 
eCBs mediated plasticity) has been raised. In the dorsal striatum, after the loading 
of the postsynaptic medium spiny neurons (MSN) with eCBs, the application of 
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paired stimuli (0.1 Hz) was shown to induce eCB-LTD not dependent on group I 
mGluR mediated postsynaptic Ca2+ increases or postsynaptic membrane 
depolarization (Ronesi et al., 2004; Ademark and Lovinger, 2007). This 
phenomenon was also observed in the somatosensory cortex (Bender et al., 
2006).  
Presynaptic activity is an important regulating factor for eCB activity.  For 
example, eCB-t-LTD induced in L5 pyramidal neurons in prefrontal cortex requires 
presynaptic NMDAR activation: application of exogenous eCBs induces LTD only 
if the presynaptic neuron is activated at a relatively high frequency; this form of 
depression is blocked by the NMDAR antagonist D-APV (Sjöstrom et al., 2003). It 
is still to be clarified how presynaptic NMDAR and CB1 co-operate in the induction 
of eCB-LTD. Furthermore, many lines of evidence underlie that direct stimulation 
of CB1 alone is not enough to induce eCB-LTD; it requires simultaneous 
presynaptic activity (Sjöstrom et al., 2003; Bender et al., 2006). This data suggests 
the need of some sort of signal integration on the presynaptic terminal for eCB-
LTD induction, probably in order to provide a control system under eCB spill-over 
conditions (Singla et al., 2007). The depolarization-driven stimulation of the 
afferent fibres could be necessary for eCB-LTD induction at the test synapse as 
supplementary activity or to release a co-factor. In the hippocampus, maximal eCB 
release is not enough to allow eCB-LTD induction, unless CB1 stimulation is 
paired to the activation of interneurons connected to the homologous synapse 
(Heyfets et al., 2008). The presynaptic activation, coming from both afferent firing 
and interneuron activation, is then necessary for eCB-LTD induction presumably 
because it mediates increases in presynaptic Ca2+ concentration, via presynaptic 
NMDAR and VGCC. It is still to be clarified how this Ca2+ increase mediates 
decreases in neurotransmitter release. It was hypothesised that presynaptic Ca2+ 
 67
increases integrates the CB1 signalling by activating the phosphatase calcineurin 
(reviewed by Heyfets and Castillo, 2009).  
To sum up: 1) eCB induction relies on the synthesis and secretion of eCBs 
from the postsynaptic neuron as a consequence of a postsynaptic metabotropic 
receptor activation (usually a Gαq/11 coupled receptor) and after activity-dependent 
Ca2+ increases at the same site 2) the eCBs spreading within the synaptic cleft 
bind CB1, causing decreased cAMP levels at the presynaptic terminal 3) in order 
to be effective, CB1 activation must be coupled to presynaptic activation, meaning 
presynaptic NMDAR or VGCC activation with consequent presynaptic increases in 
Ca2+ concentration 4) the combined activation of CB1 and a target of Ca2+ in the 
presynaptic site (presumably calcineurin) leads to long-term suppression of 
neurotransmitter release (summarised in Fig 13.). 
1.5.3. Expression of eCB-LTD 
 
Expression mechanisms of eCB-LTD have just begun to be explored. It has 
been shown that CB1 activation is not necessary for eCB-LTD long-term 
consolidation (Chevaleyre and Castillo, 2003; Sjöstrom et al., 2003; Ronesi et al., 
2004). Long-term modifications determining decreased neurotransmitter release 
probably consist in the modified excitability of the afferent fibre, resulting in 
decreased Ca2+ inlet during action potential firing or changes in the downstream 
release machinery. In eCB-LTD, CB1 activity lasts several minutes (Chevaleyre et 
al., 2006) unlike what happens in short-term eCB mediated plasticity, such as 
depolarization dependent suppression of inhibition/excitation (DSI/DSE). In fact, 
CB1 dependent DSI in the hippocampus relies on decreased activity of VGCC, 
likely mediated by Gβγ subunits (Wilson et al., 2001; Varma et al., 2002). For eCB-
LTD of inhibitory synapses (I-LTD), the activation of Gαi/o is necessary and may 
reflect the need of prolonged activation of the receptor and subsequent inhibition 
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of the cAMP/PKA pathway (Howlett et al., 1986; Childers and Deadwyler, 1996). 
Continuous activation of AC has been shown to inhibit I-LTD but not eCB-
dependent DSI (Chevaleyre et al., 2007). In addition, the postsynaptic inhibition of 
PKA and calcineurin do not affect both I-LTD and DSI, thus these modifications on 
the balance between phosphatases/kinases occur only presynaptically in eCB-
dependent plasticity. The dependency of eCB-LTD expression on the cAMP/PKA 
pathway involvement was observed in many brain areas like the striatum 
(Calabresi et al., 1994), hippocampus, amygdala (Azad et al., 2004) and the 
nucleus accumbens (Mato et al., 2008).   
As in many other forms of synaptic plasticity, the modulation of the cAMP/PKA 
pathway influences the downstream release machinery. For example, the active 
zone protein RIM1α is a target for PKA. Its phosphorylation is involved in many 
forms of synaptic plasticity such as LTP at mossy fibres/CA3 (Castillo et al., 2002) 
and at the SC/CA1 (Huang et al., 2005) synapses in hippocampus or parallel 
fibres/PC synapses in the cerebellum (Castillo et al., 2002). RIM1α is necessary 
for eCB-LTD in the hippocampus and the amygdala as shown by experiments on 
RIM1α knock-out mice (Azad et al., 2004). According to the PKA/RIM1α model, 
prolonged CB1 activation would lead to the dephosphorylation of RIM1α and the 
consequent decrease in neurotransmitter release. However, a recent study 
showed that in transgenic mice in which RIM1α was mutated (Ser413Ala) 
rendering RIM1α insensitive to PKA-dependent phosphorylation, eCB-LTD was 
still present in the hippocampus. Therefore, PKA regulation of neurotransmitter 
release in eCB-LTD relies on PKA activity on other proteins besides RIM1α. In the 
nucleus accumbens, it has been shown that blockade of P/Q-type, but not L- or N-
type VGCC occluded eCB-LTD (Mato et al., 2008), whereas in the amygdala the 
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amphetamine-induced eCB-LTD was coupled to the suppression of P/Q-type 
VGCC (Huang et al., 2003).  
A third mechanism that can underlie the expression of eCB-LTD is the 
reduction of presynaptic excitability. Heterosynaptic eCB-LTD in CA1 hippocampal 
synapses of the developing rat is associated with a decreased amplitude of fibre 
volleys; this phenomenon is blocked by K+ channels antagonists (Yasuda et al., 
2008). 
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Fig 1.13. a) Calcium influx into the postsynaptic cell through VDCC as a consequence of 
depolarization triggers ECB release b) presynaptic firing and simultaneous activation of 
CB1 determines ECB-dependent decrease in neurotransmitter release; c) schematic 
representation of the cellular mechanism mediating eCB-LTD: the activation of a gq- 
coupled receptor determines activation of DGL with production of ECBs and subsequent 
release in the inter-synaptic cleft through the putative EMT. The activation of presynaptic 
CB1 determines a decrease in PKA activity resulting in turn to decreased neurotransmitter 
release (modified from Heyfetts and Castillo, 2009) 
c 
 71
1.5.4. eCBs in memory and learning 
 
 The ubiquitous expression of CB1 in the CNS indicates that exogenous 
ligands of this receptor may interact with many brain functions, ranging from 
homeostatic regulation of feeding to associative memory (Herkenham et al., 1990; 
Tsou et al., 1998). The role of CB1 modulation in neuropsychiatric disorders and 
neurodegenerative diseases has also been investigated (see below section 
1.5.5.). 
LTD is the main model to explain the loss of connectivity after sensorial 
deprivation in the related brain area (Glazewski and Fox, 1996; Rittenhouse et al., 
1999; Allen et al., 2003; reviewed by Chklovski et al., 2004; reviewed by Hensch 
2005). The LTD-like phenomena observed in denervated somatosensory and 
visual cortex resembles the induction and expression mechanisms observed in 
eCB-LTD. Whisker removal in the rat determines weakening of L4 and L2/3 
synapses in barrel cortex by the decrease in presynaptic activity as a result of 
sensory information deprivation (Bender et al., 2006). Furthermore, monocular 
deprivation (MD) is known to depress visually evoked responses in the visual 
cortex (Trachtenberg et al., 2000); this phenomenon is probably related to the LTD 
induced at L4/L2-3 synapses in visual cortex that relies on CB1 activation (Crozier 
et al., 2007). In addition, short-term CB1 driven depression (DSI/DSE) could 
underlie these forms of cortical plasticity (Fortin et al., 2004; Bodor et al., 2005).  
Many lines of evidence underlie the role of eCBs and eCB-LTD in hippocampal 
and amygdale-dependent associative memory. The first studies employed the 
Morris water maze and cued fear conditioning on CB1 -/- transgenic animals or 
wild-type animals treated with CB1 agonists/antagonists (Marsicano et al., 2002; 
Varvel and Lichtman, 2002). These studies demonstrated that CB1 activation is 
necessary for the extinction of these memories but not for their acquisition. Also, 
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FAAH inhibitors were found to improve extinction of a cued-shock association and 
of the memory of the position of a hidden platform in Morris water maze (Chhatval 
et al., 2005; Varvel et al., 2007). However, eCBs modulate the excitability and the 
induction of LTP in the amygdala and the hippocampus, a phenomenon mostly 
related to memory acquisition rather than extinction (Chevaleyre and Castillo, 
2003; Azad et al., 2004; Chevaleyre and Castillo, 2004). 
eCBs are usually involved in LTD-like phenomena, but recent studies have 
shown that this is probably a narrow vision. Intraperitoneal administration of the 
CB1 antagonist AM251, the CB1/2 unselective agonist WIN55,212-2, or the 
inhibitor of eCBs reuptake and breakdown AM404, result in impairment of LTP 
induction at SC/CA1 synapses. Furthermore, AM404 was shown to significantly 
enhance LTD, while AM251 and WIN did not affect it. Finally, intra-hippocampal 
infusion of AM251 was demonstrated to block extinction in an inhibitory avoidance 
conditioning and extinction task, while AM404 and WIN55,212-2 facilitated the 
extinction. It is worth noting that none of these compounds affect the acquisition of 
this conditioning. Considering the functional antagonism of these compounds, it 
appears that eCB modulation of synaptic plasticity and of memory and learning is 
a complex phenomenon which is not limited to a specific inhibitory activity (Abush 
and Akirav, 2009). A recent study further underlined the multiple roles of eCBs in 
modulating synaptic plasticity: eCBs definitely induce eCB-LTD by acting on 
presynaptic CB1, but they can also be responsible for potentiation if they act on 
astrocytic CB1, the latter of which determines increases in the intra-astrocytic Ca2+ 
concentration which in turn increases the release of glutamate from the astrocyte 
itself. Astrocyte released glutamate acts on presynaptic mGluR1s determining an 
increased release of neurotransmitter and subsequent potentiation of synaptic 
transmission (Navarrete and Araque, 2010). These two latter studies underlie the 
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complexity of the eCBs modulation of synaptic activity, revealing new directions in 
the study of the activity of these endogenous molecules. 
1.5.5. eCBs in neuropathology 
 
eCB signalling is involved in many neuropathological states, from mood 
disorders to neurodegenerative diseases (reviewed by Micale et al., 2007). Recent 
data show the role of eCB dysfunctions in the pathogenesis of neurodegenerative 
diseases such as PD, AD and HD.  
The pathogenesis of PD arises from the neurodegeneration of nigrostriatal 
dopaminergic neurons. In the striatum, MSNs express D2 but not D1 receptors for 
dopamine. The dominant therapeutic strategy of PD relates to the compensation of 
the lack of dopamine (i.e. L-DOPA). Considering that corticostriatal eCB-LTD 
relies on D2-dependent decrease of neurotransmitter release, this form of synaptic 
plasticity could represent a major target in PD therapy. The FAAH inhibitor 
URB597 administered together with a D2 agonist reduced the motor deficit 
observed in PD in an animal model of the disease (Giuffrida et al., 1999; Kreitzer 
and Malenka, 2007).  
The eCB system plays a double role in the pathophysiology of AD: it inhibits 
Ach release (cholinergic loss is one of the main characteristics of AD) whilst 
having anti-inflammatory properties. Many studies have discussed the possible 
role of the eCB system in AD because of their role in the modulation of 
inflammation. CB1 expression in glia is regulated by the exposure to inflammatory 
stimuli: in particular eCBs exert neuroprotective effects by limiting microglia 
activation during inflammation (Iravani et al., 2002; Jantzen et al., 2002; Xie et al., 
2002; Benito et al., 2003; Ramirez et al., 2005). CB1 are less expressed in the 
frontal cortex of AD patients (Ramirez et al., 2005) while in the hippocampus 
increased DGLα activity was seen, resulting in the compensatory up-regulation of 
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2-AG synthesis in these patients (Farooqui et al., 1988). Considering that CB1 
activation increases Erk activity and BDNF expression (Marsicano et al., 2003), 
eCBs probably exert neuroprotective activity through CB1 activation. The 
neuroprotective effect of CB1 activation is supported by AEA-dependent inhibition 
of Aβ42 mediated toxicity in an AD in vitro model (Milton, 2002). On the other 
hand, activation of CB1 in the hippocampus decreases Ach release generating 
cognitive deficits: the CB1 antagonist rimobanant decreased the cognitive deficit 
induced in rodents treated with soluble β-amyloid peptide oligomers. This animal 
model is characterized by progressive Aβ-plaques deposition, extensive 
hippocampal damage and decreased retention of newly acquired memories 
(Mazzola et al., 2003; van der Stelt et al., 2006). Interestingly, CB2 that in 
physiological conditions are mostly expressed in the peripheral nervous system, 
are overexpressed in the CNS of AD patients and Aβ-42 treated rats (Benito et al., 
2003; Ramirez et al., 2005; van der Stelt et al., 2006), especially in microglia 
where they may exert a compensatory anti-inflammatory activity. A recent study 
further highlighted the neuroprotective role of eCBs: repeated administration (12 
days) of the eCB reuptake antagonist VDM-11 reversed hippocampal damage and 
loss of memory retention tested in passive inhibitory avoidance task in rats 
previously administered with Aβ42 fragments.  By contrast, if the administration of 
VDM-11 is limited to 5 days, starting 7 days after exposition to Aβ42, no 
neuroprotective effect is observed, once again highlighting the importance of the 
intervention in the early stages of AD (van der Stelt et al., 2006).  
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1.6. Alzheimer’s Disease (AD): epidemiology, clinical features, 
pathogenesis, and molecular profile 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly, 
accounting for 50-60% of all cases. AD affects less than 1% of individuals aged 
between 60-64 years, but cases increase exponentially with age: and at 85 years 
of age, the prevalence is comprised between 24% and 33% in Western countries 
(Ferri et al., 2005). Thus, AD is becoming more common, representing a major 
public health concern and a relevant social cost. In 2001, more than 24 million 
people were diagnosed with dementia and as a direct consequence of the 
increased life expectancy, it is expected to double every 20 years (Ferri et al., 
2005). Other than ageing, epidemiological studies have suggested other not-
genetically related risk factors such as low educational and occupational status, 
low mental ability in early life, reduced mental and physical activity during later life 
(Mayeux, 2003; Mortimer et al., 2003). Other risk factors are related to vascular 
diseases, including hypercholesterolaemia, hypertension, atherosclerosis, 
smoking, obesity and diabetes (Mayeux, 2003).  
AD is a multifactorial disorder and thus environmental factors might increase 
the risk of its sporadic form; although this disease also has a strong genetic 
background. A large population-based study showed that the extent of heritability 
for the sporadic disease is almost 80% (Gatz et al., 2007). 
First of all, it has to be stated that even if AD is a multifactorial disease, a 
familial form with a prevalence of less than 0.1% does exist (Harvey et al., 2003). 
Familial AD is an autosomal dominant disorder with onset typically before 65 years 
of age. There are several mutations on the amyloid precursor protein (APP) gene 
on chromosome 21 that explain only a few cases of familial AD. Although, 
mutations on the genes for presenilin 1 (PS1) and presenilin 2 (PS2) account for 
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most cases of the familial disease (Sherrington et al., 1995; Levy-Lahad et al., 
1995). The sporadic form of AD is the most diffuse one, and it still maintains a 
strong genetic background. Apolipoprotein E (ApoE) ε4 allele is associated with 
AD pathogenesis: it increases the risk 3 times in heterozygotes and 15 times in 
homozygotes (Cordier et al., 1993; Porrier et al., 1993; Farrer et al., 1997). ApoE 
acts as a cholesterol transporter in the brain and ApoE4 is less efficient in lipid 
transport and neuronal repair (Poirier, 1994). ApoE is essential for amyloid β (Aβ) 
deposition, promoting Aβ fibrilisation and plaque formation (Holtzman et al., 2000), 
possibly acting as a pathological chaperone. The ApoE ε4 allele has been 
calculated to account for most of the genetic risk in sporadic AD (Raber et al., 
2004). Other genetic factors can be mentioned but their involvement is difficult to 
assess, because this form of the disease is complex and probably several 
susceptibility genes act in concert, each conferring a minor increase in risk in an 
integrated interaction with environment factors. 
AD is a progressive neurodegenerative disorder, with an ambiguous onset 
whereby impairments in episodic memory, aphasia, apraxia and agnosia are 
observed with generalised issues in cognition such as impaired judgement, 
decision-making and orientation. Based on histopathological observations that 
plaques and tangles are present in the brains of AD patients and in those with 
senile dementia, these mutifactorial disorders have been considered one 
homogeneous disease, in the later phases. The cardinal signs including plaque 
formation, tangle load and cholinergic deficits in combination with the cognitive 
impairments described above are more severe in early-onset rather than in late-
onset AD (Roth, 1986; Blennow et al., 1991). In younger patients with AD there is 
a strong correlation between the severity of dementia and plaque and tangle 
accumulation, which is not found in elderly patients with the disease (Prohovnik et 
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al., 2006). These early clinical signs highlight the difference between AD and 
senile dementia. It is still uncertain if these diseases are separate, one, or a 
continuous intensification of the ageing process (Mann et al., 1984; Brayne et al., 
1988).  
Neurodegeneration in AD is estimated to start 20-30 years before clinical onset 
(Davies et al., 1988). During this preclinical phase, the plaque and tangle load 
increase to a threshold level until the appearance of the first symptoms. The early 
clinical phase is termed as mild cognitive impairment (MCI; Petersen, 2004), 
delineated on the basis of subjective reports of memory loss that are verified by 
close personal informants and by objective measures adjusted for age and 
education (Petersen, 2004). MCI does not prefigure onset of AD in all patients, but 
all patients with AD had MCI, highlighting that MCI can also underlie other 
etiological origins like normal ageing or cerebrovascular disorders (Gauthier et al., 
2006). In MCI, the conversion rate to AD is 10-15% per year (Petersen, 2004; 
Visser et al., 2005).  
The pathogenesis of AD is characterized at the microscopic level by hallmark 
lesions: amyloid plaques and neurofibrillary tangle accumulation (Fig 1.13.) in the 
medial temporal lobe and prefrontal cortex, with degeneration of neurons and 
synapses which have particular relevance for cholinergic neurotransmission. 
These changes are the result of different pathogenetic mechanisms, including Aβ 
aggregation and deposition with the development of plaques, tau 
hyperphosphorylation with tangle formation, neurovascular dysfunction and other 
mechanisms like cell-cycle abnormalities, inflammation, oxidative stress and 
mitochondrial dysfunction. Plaque deposition is highly related to the severity of the 
disease (Blessed et al., 1998). β-amyloid is constitutively produced by neurons in 
physiological conditions (Haass et al., 1992). Aβ is the result of the cleveage of the 
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amyloid precursor protein (APP) that is processed by two enzymes, β-secretase 
and γ-secretase (Fig 1.14.). 
 
γ-secretase is an intramembranous protease complex, composed of four 
components. β-secretase activity is triggered by an integral membrane aspartyl 
protease called β-site APP-cleaving enzyme 1 (BACE1) (Vassar et al., 1999). 
Another APP cleavage pathway is non-amyloidogenic and it’s characterized by 
two proteases with α-secretase activity belonging to the ADAM family of disintegrin 
and metalloproteinases (Buxbaum et al., 1998; Lammich et al., 1999). In 
Fig 1.13. Plaques and tangles in the cerebral cortex in AD. Plaques are extracellular 
deposits of Aβ surrounded by dystrophic neurites, reactive astrocytes, and microglia, 
whereas tangles are intracellular aggregates composed of a hyperphosphorylated form of 
the protein tau (modified from Blennow et al., 2006). 
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physiological conditions Aβ is degraded by the following peptidases: insulin-
degrading enzyme, neprilysin, and endothelin-converting enzyme (Carson et al., 
2002). The clearance of Aβ is mediated by the alteration in the balance between 
efflux (via low-density lipoprotein receptor-related protein) and the influx (via the 
receptor for advanced glycation end products) across the blood–brain barrier 
(Tanzi et al., 2004). The etiopathology of AD is mainly centred on the amyloid 
cascade hypothesis (Fig 1.14.) stating that an imbalance between Aβ production 
and clearance exists. This pathogenetic pattern triggers a cascade in which Aβ 
production is enhanced and keeps accumulating, forming soluble oligomers. Aβ 
soluble oligomers affect synaptic function (transmission and plasticity) and are 
therefore probably related to the mild cognitive impairment observed in the early 
stages of AD (Walsh and Selkoe, 2004; Puzzo et al., 2005; Jacobsen et al., 2006). 
Aβ oligomers composed of 12 Aβ peptides are related to memory loss in AD 
transgenic mice models (Lesne et al., 2006). The mutations responsible for the 
familal form of AD on the APP, PS1 and PS2 genes, have a pivotal role in Aβ 
generation: this evidence support the amyloidogenic hypothesis of the AD 
pathogenesis. Mutations on these genes determine increase in Aβ42 (the 
fibrillogenic isoform of Aβ) production. Duplication of the APP locus in families with 
familial AD lends support to the notion that life-long APP over-expression results in 
Aβ deposition. In time, soluble Aβ oligomers keep accumulating, undergoing a 
conformational change to high β-sheet containing oligomers that are insoluble.  
Insoluble Aβ oligomers start to aggregate first in fibrils and then in extracellular 
plaques (Fig 1.15.). 
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Fig 1.14. APP is a transmembrane protein. The Aβ domain is partly embedded in the 
plasma membrane and includes the 28 residues just outside the membrane and the first 
12–14 residues in the transmembrane domain. APP can be processed along: 1) the α-
secretase pathway that precludes Aβ aggregation since the cleveage domain is within the 
Aβ segment; 2) the β-secretase pathway releasing the β containing APP (βsAPP); γ-
secretase cleaves the remaining C-term releasing the free 40 or 42 aminoacid containing 
Aβ peptide, the amyloidogenic form of amyloid protein (modified from Blennow et al., 
2006). 
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As observed in other amyloidogenic neuropathologies, fibrillogenic Aβ42 isoform 
transmits the misfolding to other soluble Aβ peptides, accelerating the plaque 
formation and deposition (Jarret et al., 1993). In parallel with the accumulation of 
Aβ plaques, the pathogenesis of AD is characterized by intracellular tangles 
composed of hyperphosphorylated tau protein (Grundke-Iqbal et al., 1986; Nukina 
and Ihara, 1986). Physiologically tau is an axonal microtubule binding protein, thus 
promoting microtubule assembly and stability. Tau phosphorylation is mediated by 
the balance between multiple kinases (eg, GSK-3β and CDK5) and phosphates 
(eg, PP-1 and PP-2A; Iqbal et al., 2005). In AD, tau hyperphosphorylation is 
intracellularly triggered causing microtubule disassembly and in turn compromising 
Fig 1.15. Shematic representation of the pathogenetic stages of AD. The central event is the 
clearance imbalance of Aβ: increased production for the familial and decreased clearance 
for the sporadic form. Aβ oligomers affect synaptic plasticity: in the later stages, 
inflammation, oxidative stress and mitochondrial dysfunction participate in the 
progression of the neuronal damage. In parallel, altered kinase/phosphatase regulation 
leads to the accumulation of hyperphosphorylated tau tangles. 
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axonal transport, impairing neuronal and synaptic function (Fig 1.16.). The 
hyperphosphorylation of tau determines its aggregation into insoluble fibrils and 
then tangles. Tau hyperphosphorylation is an early event in the pathogenesis of 
AD in the transentorhinal region, spreading to the hippocampus, amygdala and 
later to neocortical association areas (Braak et al., 1999). It has still to be clarified 
if tangle formation is a consequence or a cause of AD. Furthermore, many lines of 
evidence suggest that the Aβ plaque formation cooperates with cerebrovascular 
alterations in the pathogenesis of AD (Farkas and Luiten, 2001; Mayeux, 2003). 
The neurovascular hypothesis states that the dysfunction of blood vessels in the 
CNS can contribute to cognitive dysfunction via impairment of delivery of nutrients 
to neurons and via the reduction of Aβ clearance (Iadecola, 2004). 
Cerebrovascular pathology and ischaemia result in the up-regulation of APP 
expression followed by Aβ deposition (Jendroska et al., 1995; Sadowsky et al., 
2004). Other hypotheses on the pathogenesis of AD suggest abnormalities in 
proteins regulating the cell cycle, inflammatory mechanisms, oxidative stress and 
mithocodrial dysfunction, especially in the progression of the disease and in the 
spread of the neuronal degeneration and dysfunction (Aisen, 2001; Webber at al., 
2005; Gibson and Huang, 2005; Reddy and Beal, 2005). 
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1.6.1. Alzheimer’s Disease: animal models 
One of the most important experimental approaches for the study of AD is the 
development of animal models resembling genetic, histological and clinical 
features of the disease. The multifactoriality of AD represents a major problem for 
the liability of each model. For this reason, many experimental approaches were 
used to generate different animals showing different characteristics of the disease 
in order to get as much information as possible on this pathology. Nowadays there 
are two main approaches for the development of AD animal models: the 
generation of transgenic mice expressing human genes correlated to the familial 
form of AD (La Ferla and Oddo, 2005; Jacobsen et al., 2006; reviewed by Epis et 
al., 2010) or the induction of neurodegeneration of the cholinergic fibres projecting 
Fig 1.16. A: Schematic representation of tau protein bound to a microtubule through 
microtubule-binding domains. B: Flow-chart of tau hyperphosphorylation and tangle 
formation causing disassembly of microtubules and disturbed axonal transport, 
aggregation into insoluble fibrils (paired helical filaments; PHF) and larger aggregates in 
tangles (modified from Blennow et al., 2006).  
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from Basal Forebrain Nuclei in wild type rats through intracerebroventricular 
infusion of the neurotoxin 192 IgG saporin (Aztiria et al., 2007). This latter 
approach is higly unspecific because the neurodegeneration of cholinergic fibres is 
a common characteristic of many neurodegenerative disorders, including 
Parkinson’s disease (Liselijn et al., 2008).  
The generation of transgenic animal models starts from the evidence of a 
strong genetic component in AD, both familial and sporadic. The familial form is 
extremely rare (less than 0.1% prevalence); it is an autosomal dominant disorder, 
strongly based on mutations of the genes encoding APP, PS1 and PS2. The 
sporadic form is multifactorial, and its main genetic component is represented by 
mutations on the APOE protein encoding gene. Given these premises, various 
trangenic murine models for the study of the disease were developed in order to 
carry single or multiple human alleles for these genes with single or multiple 
mutations consistent with the genotype observed in the familial form of the 
disease. APP, PS1 and PS2 are involved in both the pathological and 
physiological metabolism of the amyloid protein. Hence, AD transgenic murine 
models are characterized by the altered proteolysis of the APP. This results in the 
accumulation of soluble intracellular β-amyloid oligomers (which cause early 
impairment of synaptic and cognitive functions), leadind to progressive 
accumulation of extracellular β-amyloid plaques and neurodegeneration. The first 
transgenic AD mice were developed thanks to the designed constructs of cDNA-
based or yeast artificial chromosome, in order to induce expression of the entire 
human APP in the mouse brain (Buxbaum et al., 1993; Lamb et al., 1993). Other 
mutant alleles are: human APP751 (Moran et al., 1995; Quon et al., 1991), human 
APP695 (Yamaguchi et al., 1991), Aβ (Wirak et al., 1991) and/or the C-terminal 
fragments of APP (Sandhu et al., 1991). The APP transgene was successfully 
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expressed in the brain, but these mice did not show important neurological 
changes, with only few β-amyloid deposits. The lack of plaques observed in these 
models was generally attributed to the low expression level of the transgene. The 
following experimental approach was a mouse overexpressing mutant alleles of 
the human APP transgene: it showed an age-dependent AD-like pathology, with 
amyloid deposits in the brain parenchyma (Hsiao et al., 1996; Moechars et al., 
1999). The most known mutations include the V717I “London” mutation (Goate et 
al., 1991), V717F “Indiana” mutation (Murrell et al., 1991), K670D/M671L 
“Swedish” mutation (Mullan et al., 1992) andE693G “Arctic” mutation (Nilsberth et 
al., 2001). 
Presenilin knockout mice develop a fast and evident neurodegeneration in the 
cerebral cortex, memory impairment, and decreased synaptic function (Saura et 
al., 2004). In order to determine the role of presenilin-1 on APP cleavage, mice 
models carrying both the wild-type and mutant PS-1 encoding genes were 
developed (Duff et al., 1996). Both wild-type and mutant alleles carrying mice do 
not show significant signs of the disease, even if they show high levels of β-
amyloid (Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997; Chui et al., 
1999). The double PS1/2 mutant shows both cognitive loss and 
neurodegeneration (Saura et al., 2004). Crossing PS-1 mutant mice with APP 
mutant mice generates greatly accelerated β-amyloid aggregation into plaques 
(Holcomb et al., 1998), indicating that these genes interact synergistically. 
Because of the high production of β-amyloid plaques and the genetic similarity 
with the familial form of the disease in humans, the double PS-1/APP transgenic 
mice are the most used ones for the study of the pathogenesis of the disease 
(reviewed by Epis et al., 2010). However, these double mutant models do not 
show neurofibrillary tangles. Another generation of transgenic murine models for 
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the study of AD is represented by transgenic mice expressing the mutated form of 
the human gene encoding for tau (MAPT). These mice develop neurophibrillay 
tangles and show cognitive deficits and neurodeneration (Ramsden et al., 2005), 
but do not show amyloid plaques. It is important to underlie that so far no 
mutations have been identified on MAPT in the familial form of the disease: the 
mutated MAPT allele used in these mice was found in frontotemporal dementia 
(Ballatore et al., 2007). These studies were then extended by generating a triple 
transgenic murine model (3xTg-AD), bearing the following mutations: presenilin-
1M146V, APPSwe and MAPT (P301L) (Oddo et al., 2003b). This most recent and 
integrated model presents itself with both extracellular β-amyloid plaque 
accumulation and intracellular hyperphosphorylated tau tangles which are the 
main histopathological features of the disease. These lesions are correlated to 
age-dependent synaptic dysfunctions, including LTP and memory deficits (Oddo et 
al., 2003a; Billings et al., 2005). 
One of the most studied models is the Tg2576 mouse, characterized by the 
human allele of APP bearing the Swedish mutation (Lys -670-Asn; Met-671-Leu). 
Six month old Tg2576 mice are characterized by a deficit in spatial memory, a 
form of declarative memory known to be hippocampal dependent. The cognitive 
deficit is associated with impairment in synaptic transmission and LTP induction at 
Schaffer collaterals-CA1 synapses; at this age, this model also shows 
immunopositivity to intracellular soluble β-amyloid oligomers (Jacobsen et al., 
2006). These features correspond to the pathological conditions of early-onset AD 
patients affected by MCI. Later in life, these animals present increased cytosolic 
concentration of soluble β-amyloid oligomers; extracellular β-amyloid plaques and 
neurodegeneration can be observed at around 18 months of age. This model has 
been widely used to clarify the pathogenetic mechanims of the disease (Dong et 
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al., 2005; Dong et al., 2008; Sanchez-Ramos et al., 2009; Dong et al., 2009; 
Tampellini et al., 2010). 
1.7. Aims of the research 
The main aim of the present study was to identify a potential retrograde 
messenger involved in synaptic plasticity in the Prh of the rat. NO and eCBs have 
been extensively studied as modulators involved in synaptic plasticity, memory 
and learning and their role as retrograde messengers have been demonstrated in 
various brain structures. Therefore, in the present study I evaluated their role in 
both LTP and LTD induced in acute perirhinal slices using field potential 
recordings.  
Since Prh plays a major role in visual recognition memory, in the second part of 
the research I also evaluated the role of NO and eCBs in the acquisition of this 
form of declarative memory in vivo. The performance of adult rats was examined 
using the spontaneous novel object exploration task after intra-Prh infusions of 
vehicle or antagonists of nNOS and CB1 (NPA and AM251, respectively).  
Finally, since one of the major goals in AD research is to characterize the early 
stages of the disease in order to improve diagnostic and therapeutic tools, I 
performed field potential recordings in Prh slices from Tg2576 mice  (a model of 
AD) and from littermate controls at 3 month of age, in order to investigate possible 
very early in changes Prh synaptic transmission and plasticity.  
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2. MATERIALS AND METHODS 
2.1. Laboratories 
This project has been carried out in two different laboratories. It started at 
University of Bologna, department of Human and General Physiology, with the 
supervision of Professor Giorgio Aicardi, and it continued at University of Bristol, 
MRC centre for synaptic plasticity, Department of Physiology and Pharmacology, 
with the supervision of Professor Zafar Bashir. In both laboratories, field potential 
recordings were performed, while behavioural experiments were exclusively 
performed in Bristol. The following section will describe any experimental 
difference between the two laboratories by indicating in brackets the location 
(Bologna; Bristol). 
2.2. Electrophysiology 
Tissue preparation. Experiments were performed on horizontal brain slices 
including Prh, lateral entorhinal cortex (LEnt) and hippocampus. Slices were 
obtained from p21-35 male albino rats (Sprague Dawley strain; Charles River 
Laboratories, Milano, Italy) (Bologna) and from p28-35 male pigmented rats (Dark 
Agouti strain; Bantin and Kingman, Hull, UK) (Bristol). All efforts were made to 
reduce the number of animals used. Animals were treated according to approved 
European Union guidelines. Animals were anaesthetized with halothane (Bologna) 
or isoflurane (Bristol) and killed for decapitation. The head was placed in ice cold 
(2-4°C) cryoprotective artificial cerebrospinal fluid (aCSF) pH=7,4 containing (in 
mM): 250 glycerol, 2.5 KCl, 1.2 NaH2PO4, 1.2MgCl2, 2.4 CaCl2, 26 NaHCO3 and 
11 glucose (Bologna) or aCSF (same composition but with NaCl 125 mM instead 
of glycerol 250 mM; Bristol) and continuously bubbled with biological gas mixture 
(95% O2-5% CO2). The brain was rapidly removed and the frontal lobes and dorsal 
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part were resected with two single scalpel cuts. The sample was then glued on the 
dorsal side (ventral side up) with superglue Loctite on a stainless steel cutting 
stage. The stage was transferred into the cutting chamber of a motorized 
vibratome (WPI Europe, Berlin, DE) filled with ice cold, oxygenated, cryoprotective 
aCSF (Bologna) or aCSF (Bristol). The tissue was then sliced (400µM) at the 
maximum blade vibration speed and the minimal advance speed. Each slice was 
immediately transferred for 60-90 min into a recovery chamber filled with aCSF at 
room temperature (25°C) and gassed with biological mixture.  
Field potential recordings. After recovery, a single slice was placed into a 
recording chamber, continuously perfused with oxygenated aCSF (flow rate of 2/3 
ml/min) and maintained at T = 32-34°C. After an acclimatizing period of at least 20 
min, extracellular field excitatory post-synaptic potentials (fEPSP) were evoked by 
application of constant square current pulses (0,2 ms, 20-300 µA, 0,033Hz) on 
afferent fibers in layer II/III of Prh with a concentric bipolar stainless steel 
stimulation electrode (40-80 KΩ) connected to a stimulus generator (Master8; 
AMPI, Israel) through a stimulus isolation unit. Evoked extracellular fEPSP were 
recorded with a glass micropipette pulled at a horizontal micropipette puller (Sutter 
Instruments; Novato, USA) with a resistance of 3-5MΩ, filled with 2 M NaCl 
solution, inserted into the slice in layer II/III, ≈ 500µm distant from the stimulation 
electrode in caudal direction and connected to a DC amplifier by an Ag/AgCl 
electrode (Bologna: EPC-7; HEKA, Germany; Bristol: Axopatch 200, Axon 
Instruments, Foster City, CA). Stimulus intensity was adjusted to induce ≈60-70% 
of the maximal synaptic response. After at least 30 min of stable baseline 
recording, long-term depression (LTD) was induced by low frequency stimulation 
consisting in a single train of 3000 pulses delivered at 5Hz (5Hz-LFS) (Aicardi et 
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al., 2004). A weak LFS (5Hz-LFS 1350p) was also used, consisting in a single 
train of 1350 pulses delivered at 5Hz. Chemical LTD was induced via bath 
application of carbachol (Cch) (50 µM) for 10 min. LTP was induced by theta burst 
stimulation consisting of four trains delivered every 15 seconds, every train 
composed by 10 bursts delivered every 150 ms, every burst composed by 5 
pulses delivered every 10 ms (100 Hz) (Aicardi et al., 2004). 
 
a) 
 b)  
Data acquisition and analysis. The analogical signal was digitised with an 
analogical/digital board and transferred to a PC. During experiments, sweeps of 
1000 ms comprising artefact, presynaptic afferent volleys and fEPSP were digitally 
Fig 2.1. a) Schematic representation of 
the experimental setup. b) Schematic 
representarion of a rat brain horizontal 
slice containing Prh, lateral entorhinal 
cortex (LEnt), dentate gyrus (DG) and 
area CA1-3 of the hippocampus. As 
indicated, the stimulation (Stim) and the 
recording electrodes (Rec) were placed 
in layer II/III of Prh. 
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acquired with the software Axoscope 9.0 (Axon instruments; PA, USA) (Bologna) 
or WinLTP (University of Bristol, Bristol, UK) each time the stimulus generator 
delivered a current pulse. 
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Fig 2.2. a) Example of an extracellular fEPSP recorded sweep. The artifact reflects the square 
current pulse applied to evoke the fEPSP. The ”non synaptic peak” is due to the action 
potentials directly evoked by the current pulse in presynaptic fibres and/or in postsynaptic 
neurites.   The fEPSP amplitude (blue line) is measured between the baseline (red line) and 
the minimum value. b) Example of a typical LTP recording plot. After 30 min of a stable 
baseline, the TBS stimulation protocol was applied and the fEPSP were recorded for more 
than  60 min. 
 
Artifact 
Non synaptic peak fEPSP 
Example of an evoked fEPSP sweep 
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The fEPSP amplitude is considered the value, in mV, comprised between the 
average value of the signal recorded 10 ms before the artefact and the minimal 
value of the fEPSP peak (see Fig 2.2.A). Each sweep was offline analysed with 
Clampfit (Bologna) or directly on-line analyzed with WinLTP (Bristol); the fEPSP 
peak amplitude values (mV) were exported in an Excel file. Each amplitude value 
(mV) was normalized for the baseline value, calculated as the mean of the fEPSP 
amplitudes recorded in the last 10-30 min of baseline. All the experimental groups 
were plotted as mean values ± S.E.M. The effects of conditioning stimulation were 
measured 50-60 min after LTP or LTD induction: any variation of the normalised 
fEPSP bigger than 10% and significantly different from the baseline was regarded 
as synaptic plasticity. Significance from baseline was evaluated using paired or 
unpaired t-test, as appropriate. Comparisons between groups used one way 
ANOVA where necessary, to examine the effect of treatment with LTD- or LTP- 
inducing stimuli upon responses. 
2.3. Electrophysiological recordings on transgenic Tg2576 mice 
Subjects. Heterozygous male Tg2576 mice under the control of the prion 
promoter and WT littermates were used (Hsiao et al., 1996). Tg2576 mice express 
a mutated form of the human gene for amyloid precursor protein (APP) bearing the 
Swedish mutation (Lys-670-Asn; Met-671-Leu). The gene encodes a double 
amino acid substitution and is associated with a heritable susceptibility to 
Alzheimer’s disease (AD). Resulting phenotypic manifestations in Tg2576 include 
progressive accumulation of beta amyloid (Aβ) in the brain, analogous to classic 
“senile plaques” of human AD, and correlated synaptic and cognitive deficits.  
Tg2576 mice were kindly supplied by Italian National Centre on Aging (I.N.R.C.A.; 
Ancona, Italy). The original strain of Tg2576, model 001349, obtained on a mixed 
B6/SJL genetic background, was purchased from Taconic (Hudson, NY). 
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Subsequently a colony was raised by mating a transgenic male with a non 
transgenic female with a C57BL/6 genetic background. Three month old 
heterozigous males and littermate controls were used for the experiments. The 
transgenic offspring was selected with a genotyping procedure.  
Electrophysiological recordings. Field potential recordings were performed in 
Bologna as described above (section 2.2.) with the following particularities: 
1) semi-coronal slices were cut with a 45° angle to the dorsal axis as described 
elsewhere (Griffiths et al., 2008); 2) the composition of the crioprotective aCSF 
used during dissection was (in mM): NaCl 124, 3 KCl, 1.25 NaH2PO4, 10 MgSO4 
7H2O, 0 CaCl2, 26 NaHCO3 and 10 glucose; the aCSF used for recovery and 
recording had the same composition except: 1 MgSO4, 2 CaCl2; 3) input/output 
curves (I/O) were run recording 2 sweeps at each current intensity within 0 and 
200 µA with the following steps: 0, 20, 30, 40, 50, 100, 150, 200 µA; 4) LTD was 
induced after a 20 min stable baseline by application of 5 Hz-LFS; 5) the 
experimenter was blind as to the genetic condition of the animal. 
2.4. Behavioural experiments 
All the behavioural experiments were carried out by Dr. Gareth Barker under 
the supervision of Dr. Clea Warburton; I would like to thank both of them. 
Subjects. Male pigmented rats were used (Dark Agouti strain; Bantin and 
Kingman, Hull, UK), weighing 150–200 g at the beginning of the experiment. The 
animals were housed under a 12 h light/dark cycle. Behavioural training and 
testing were performed during the dark phase of the cycle (6:00 A.M. to 6:00 
P.M.). All efforts were made to reduce the number of animal used. Animals were 
treated according to approved guidelines.  
Cannulation surgery.  After being anhesthetized with isoflurane, the rats were 
secured in a stereotaxic frame with the incisor bar set at 3.3 mm below the 
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interaural line. Two stainless steel guide cannulas (26 gauge; Plastics One, 
Semat, UK) were implanted through burr holes in the skull at an angle of 20° to the 
vertical, using the following coordinates: antero- posterior, -5.6mm from bregma; 
lateral, ± 4.47mm; vertical, - 6.7mm from skull surface (Fig 2.3.). Two stainless 
steel screws and dental cement kept the cannulas anchored to the skull. Between 
infusions, the cannulas were closed by dummy inserts. After surgery, the rats were 
allowed for rcovery > 14 days. 
Apparatus. Exploration occurred in an open-topped arena (90 X 100 cm) with 
50 cm wood walls and a scaffold covered with black cloth to a height of 150 cm: in 
this way the animals were isolated from exteranl visual stimuli during the 
experiment. Sawdust covered the floor of the arena. The animal’s behaviour was 
monitored and recorded via an overhead camera and video recorder, for 
subsequent analysis. The stimuli were triplicate copies of objects made of plastic 
that varied in shape, color, and size (10 X 10 X 5cm to 25 X 10 X 5 cm) and were 
too heavy for the animal to displace.  
Training. After handling (1 week), each rat was habituated to the arena without 
stimuli for 10 min daily for 4 days before the beginning of the spontaneous novel 
object exploration protocol. This protocol comprised an acquisition phase (training) 
separated by a delay from a recognition test. In the training phase, duplicate 
copies of an object (e.g., A1 and A2) were placed near the two corners at either 
end of one side of the arena (10 cm from each adjacent wall). The animal was 
placed into the arena facing the centre of the opposite wall and allowed a total of 
either 40 s of exploration of A1 and A2 or 4 min in the arena. Exploratory 
behaviour was defined as the animal was directing its nose toward the object at a 
distance of < 2 cm. Other behaviours (i.e. looking around while sitting on or resting 
against the object) were not considered as exploration. The delay between the 
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phases was 20 min or 24 h. At test phase (3 min duration), the animal was placed 
again in the arena with two objects positioned at the same positions as at training: 
one object (A3) was the third copy of the object used in the sample phase, and the 
other was a novel object (B3). The positions of the objects in the test and the 
objects used as novel or familiar were counterbalanced between the animals in a 
group and between the control and drug-treated groups (Fig 2.4.). 
Drug delivery. General procedures have been already described elsewhere 
(Warburton et al., 2003). Infusions were made into the Prh through a 33 gauge 
cannula (Plastics One) inserted into the implanted cannula and attached to a 5 µl 
Hamilton syringe via polyethylene tubing. A volume of 1.0 µl was injected into each 
hemisphere over a 2 min period by infusion pump (Harvard Bioscience, Holliston, 
MA). The infusion cannula remained in place for an additional 5 min (Fig 2.3.).  
Design. The animals were tested after a 20 min or 24 h delay. Three different 
groups of rats was used to test the effects of drugs: one for NPA at 24 hours and 
another one for NPA and AM251 at 20 min and a third one to test AM251 at 24 
hours. To examine whether CB1 or nNOS were involved in the acquisition stage of 
memory, the appropriate antagonist (AM251 and NPA, respectively) or vehicle 
was infused starting 15 min before the commencement of the acquisition phase. 
After at least 7 d, the other substance (vehicle or antagonist in a crossover design) 
was infused, and the animal was tested again. The group sizes (n) were as 
follows: NPA experiments (24 h delay), n=12; NPA experiments (20 min delay), 
n=10; AM251 experiments (24 hours and 20 min delay), n=10. Data were 
analyzed only from animals that completed all phases of an experiment with 
patent, correctly placed cannulas. 
 96
a 
b 
  
Statistical analysis. The experimenter was blind to the treatment during all 
measures of exploration. The discrimination ratio (DR) was calculated as the 
difference in time spent by each animal exploring the novel compared with the 
familiar object, divided by the total time spent exploring both objects. Comparisons 
Fig 2.4. Schematic representation of an object recognition memory test. Fifteen min after 
infusion, the animal was placed in an arena with two identical objects. After a certain 
delay (20 min or 24h) the animal was placed in the same arena with the familiar and a 
novel object. If the subject remembers the familiar object, it will preferentially explore 
the novel one. 
Fig 2.3. a) Photomicrograph of a coronal brain 
section showing the track (indicated by arrow) left 
by a perirhinal cannula. Scale bar, 1 mm. 
(Modified from Warburton et al., 2003) b) 
Infusion sites. The sites within the perirhinal 
cortex at which drugs were infused are shown in 
the expanded boxes from a schematic brain 
section. The dots within the expanded boxes are 
just exemplificative and not necessarily 
representative of the real distribution of the drug. 
Hpc, Hippocampus; RS, rhinal sulcus; Th, 
thalamus (Modified from Barker et al., 2006). 
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for the vehicle- and drug- treated groups used an ANOVA with repeated measures 
with treatment (drug or vehicle) as a within- subjects factor and time as a between-
subjects factor. One-sample t tests were used to determine the significance of the 
DR (compared with zero discrimination) for each group. All tests used a 
significance level of p = 0.05 and were two-tailed.  
2.4.Drugs 
Electrophysiological recordings. The unselective NO synthetase (NOS) 
antagonist Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) was 
purchased from Sigma-Aldrich S.r.L., Italy; it was maintained at -20°C. 2 mM, 200 
µM and 50 µM L-NAME aCSF solutions were daily prepared and the slice was 
perfused with it at least 40 min before the application of the induction protocol. The 
nNOS selective antagonist NPA was purchased from Tocris (Cookson, Ellisville, 
MO), dissolved in 0.9% saline solution at a stock concentration of 20 mM and kept 
refrigerated at -20°C. Fresh solutions of NPA 20 µM containing aCSF were daily 
prepared by 1:1000 dilution of stock solution in aCSF. Slices were perfused with 
NPA 20 µM 40 min before the application of the induction protocol. 
The soluble guanilate cyclase (sGC) antagonist 4H-8-Bromo-1,2,4-
oxadiazolo[3,4-d]benz[b][1,4]oxazin-1-one (NS2028) was purchased from Sigma-
Aldrich S.r.L., Italy, dissolved in DMSO in a 20 mM stock solution and maintained 
at –20°C. Fresh solutions of NS2028 0.5 µM containing aCSF were daily prepared 
by 1:400000 dilution of stock solution in ACSF. Slices were perfused with NS2028 
0,5 µM 30 min before the application of the induction protocol as reported (Monfort 
et al., 2002).  
The cGMP-dependent protein kinase (PKG) antagonist (9S,10R,12R)-
2,3,9,10,11,12-Hexahydro-10-methoxy-2,9-dimethyl - 1 - oxo - 9, 12 - epoxy - 1 H - 
diindolo [ 1, 2, 3- fg: 3', 2', 1' -  kl]pyrrolo  [3,4i] [1,6] benzodiazocine-10-carboxylic 
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acid, methyl ester (KT5823) was purchased from Tocris (Cookson, Ellisville, MO) 
and dissolved in DMSO in a 2 mM stock solution. Fresh solutions of KT5823 2 µM 
containing aCSF were prepared daily by 1:1000 dilution of stock solution in ACSF. 
Slices were perfused with KT5823 2 µM 10-30 min before the application of the 
induction protocol. 
The NO donor 2-(N,N-Diethylamino)-diazenolate 2-oxide sodium salt hydrate 
(DEA/NO) was purchased from Sigma-Aldrich S.r.L., Italy, and it was maintained 
at –20°C. Because of the pH and temperature dependent stability of the 
compound, stock solutions 3 mM were daily prepared by dissolving DEA/NO in 
NaOH 10 mM. DEA/NO 3 µM containing aCSF was prepared immediately before 
the perfusion by 1:1000 dilution of stock solution in aCSF (t1/2 DEA/NO= 16 min 
pH=7.4 T=21°C; =2 min pH7.4 T=32°C); the slice was perfused 5 min before until 
the end of the 5Hz-LFS 1350p.  
The acetylcholinesterase (AchE) resistant cholinergic agonist 2-Hydroxyethyl 
trimethylammonium chloride carbamate (carbachol) was purchased from Sigma-
Aldrich S.r.L., Italy, and it was maintained at room temperature. 50 mM stock 
solutions were prepared by dissolving carbachol in bidistilled H2O and conserved 
up to 1 week at –20°C. 50 µM Cch containing aCSF was daily prepared by 1:1000 
dilution of stock solution in aCSF. 
The CB1 receptor selective antagonist N-(Piperidin-1-yl)-5-(4-iodophenyl) - 1 - 
(2, 4 - dichlorophenyl) - 4 - methyl - 1 H - pyrazole - 3 - carboxamide (AM251) was 
purchased from Tocris (Cookson, Ellisville, MO), dissolved in pure ethanol  in a 2 
mM stock solution and maintained at -20°C. Fresh 1 µM AM251 solutions were 
daily prepared by 1:2000 dilution of stock solution in aCSF. The slice was perfused 
with AM251 since 20 min before the application of the induction protocol.  
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The CB1 receptor selective agonist N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-
eicosatetraenamide (ACEA) was purchased from Tocris (Cookson, Ellisville, MO), 
and supplied in a 5 mg/ml stock solution pre-dissolved in pure ethanol. Fresh 1 µM 
ACEA solutions were daily prepared by dissolving the stock in aCSF. The slice 
was perfused with ACEA since 20 min before the application of the induction 
protocol in synaptic plasticity experiments and for 20 and 60 min in basal synaptic 
transmission experiments.  
The CB1/2 non-selective agonist (R)-(+)-[2,3-Dihydro-5-methyl-3-(4-  
morpholinylmethyl) pyrrolo [1,2,3-de] - 1,4 - benzoxazin -6- yl-1-
naphthalenylmethanone mesylate (WIN55,212-2) was purchased from Tocris 
(Cookson, Ellisville, MO), dissolved in pure ethanol in a 2 mM stock solution and 
maintained at -20°C. Fresh 2 µM WIN55,212-2 solutions were daily prepared by 
1:1000 dilution of stock solution in aCSF. The drug was applied for 20 min and 
then washed out. 
Behavioural experiments. The drugs used were AM251 and NPA (see above 
for details). Control infusions for NPA experiments consisted of 0,9% saline while 
for AM251 consisted of 0,1% EtOH containing 0,9% saline. NPA was infused at a 
concentration of 2 µM/side and AM251 was infused at a concentration of 10 
µM/side. For both drugs, saline controls and 0.1% EtOH sham controls the volume 
infused was 1 µL. 
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3. RESULTS 
3.1. Role of the NO and eCBs in the synaptic plasticity in Prh cortex 
In this section are reported the results of electrophysiological recordings 
performed to clarify the role of NO and eCBs in LTP and muscarinic dependent 
LTD. Since it was not observed any difference between different kind of controls 
(external, interleaved, Sham EtOH 0.1%, Sham DMSO 0.1%) in each laboratory, 
Bologna and Bristol,  all the controls are merged together. 
3.1.1. Role of the NOS/sGC/PKG pathway in the 5 Hz-induced LTD 
(Bologna) 
The first subset of experiments showed that the application of a 5 Hz LFS 
induced LTD in the Prh of male juvenile Sprague-Dawley rats in control conditions 
(Fig 3.1. A, n=11, baseline: 94.5% ± 2.5%; 60 min follow-up: 76.9% ± 6.1%; p < 
0,01) but LTD was blocked in presence of the NOS antagonist L-NAME (2 mM) 
(Fig 3.1. B, n=6, baseline: 100.6% ± 1.2%; 60 min follow-up: 94.3% ± 4.6%; p > 
0.05), of the sGC antagonist NS2028 (0.5 µM) (Fig 3.1. C, n=7, baseline: 97.4% ± 
1.7%; 60 min follow-up: 97.9% ± 3.5%; p > 0.05), and of the PKG antagonist 
KT5823 (2 µM) (Fig 3.1. D, n=4, baseline: 99.5% ± 3.7%; 60 min follow-up: 93.6% 
± 2.1%; p > 0.05). There was a significant difference between the magnitude of the 
LTD between controls and each of the other group (p < 0.01). 
In a second subset of experiments it has been shown that the application of a 
sub-threshold weak 5 Hz LFS, consisting in 1350 instead of 3000 pulses, failed in 
inducing LTD (Fig 3.2. A, n=9, baseline: 98.0% ± 1.7%; 60 min follow-up: 93.2% ± 
4.2%; p > 0.05) and the bath application of the NO donor DEA/NONOate 
(DEA/NO, 3 µM) did not affect basal synaptic transmission (Fig 3.2. B, n=4; p > 
0.05) but the co-application of the two protocols determined induction of a robust 
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LTD (Fig 3.2. C, n=9, baseline: 97.5% ± 2.5%; 60 min follow-up: 78.6% ± 5.1%; p 
< 0.01). There was a significant difference between the magnitude of the LTD 
induced with the weak 5 Hz LFS and with the co-application of that stimulation with 
DEANONOate 3 µM (p < 0.01). These results indicate a pivotal role for the 
NOS/sGC/PKG pathway in the induction of 5 Hz LTD (see section 4. for 
discussion). 
3.1.2. Role of the NOS/sGC/PKG pathway in the Cch-induced LTD 
(Bologna) 
The bath application of Cch (50 µM) for 10 min (Cch-LTD) in the Prh of male 
juvenile Sprague-Dawley rats determined the induction of a robust LTD (Fig 3.3. A, 
n = 21, baseline: 98.8% ± 1.1%; 60 min follow-up: 76.4% ± 4.2%, p<0.01). The 
NOS antagonist L-NAME (2 mM) or the sGC antagonist NS2028 (0.5 µM) co-
applied to Cch blocked Cch-LTD induction (Respectively: for L-NAME, Fig 3.3. B, 
n=8, baseline: 100.4% ± 1.0%; 60 min follow-up: 101.8% ± 4.6%, p>0.05; for 
NS2028, Fig 3.3. C, n=8, baseline: 98.4% ± 1.3%; 60 min follow-up: 94.5% ± 
5.1%, p>0.05). There was a significant difference in the magnitude of the LTD 
induced in control conditions and in presence of L-NAME or NS2028 (p < 0.05). 
These results indicate a role for NOS/sGC pathway in the induction of CCh-
LTD (see section 4. for discussion). 
The PKG antagonist KT5823 was used in another set of experiments carried 
out between Bologna and Bristol and that is going to be described in the next 
section. 
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3.1.3. Role of the NOS/sGC/PKG pathway in the Cch-induced LTD (Bristol) 
In order to confirm the data collected in Bologna, in Bristol I performed field 
potential electrophysiological recordings to verify the role of NOS and PKG in the 
Cch-LTD in the Prh of male juvenile Dark Agouti rats (see section 2.2. for 
methodological details).  
The first subset of experiments showed that 10 min Cch (50 µM) bath 
application determined LTD induction (Fig 3.4. A, n = 21, baseline: 98.8% ± 1.1%; 
60 min follow-up: 76.4% ± 4.2%, p<0.01) and that the NOS antagonist L-NAME 
successfully blocked Cch-LTD if applied at 200 µM (Fig 3.4. C, n = 9, baseline: 
104.0% ± 2.5%; 60 min follow-up: 101.7% ± 3.3%, p>0.05) and 2 mM (Fig 3.4. D, 
n = 5, baseline: 101.3% ± 2.3%; 60 min follow-up: 101.9% ± 3.8%, p>0.05) but not 
at 50 µM (Fig 3.4. B, n = 7, baseline: 98.6% ± 2.6%; 60 min follow-up: 84.0% ± 
5.3%, p<0.01). There was a significant difference in the magnitude of LTD induced 
in control conditions and in presence of L-NAME 200 µM and 2 mM (p < 0.01) but 
not 50 µM (p > 0.05). Also, I showed that the selective antagonist of the neuronal 
isoform of the NOS (nNOS) NPA (20 µM) blocked the induction of Cch-LTD (Fig 
3.4. D, n = 5, baseline: 102.8% ± 1.4%; 60 min follow-up: 94.5% ± 5.4%, p<0.01). 
There was a significant difference in the LTD induced in control conditions and in 
presence of NPA 20 µM (p < 0.05). 
The second subset of experiments showed that the PKG antagonist KT5823 (2 
µM) did not affect Cch-LTD induction (Fig 3.4. E, n = 7, baseline: 101.8% ± 1.2%; 
60 min follow-up: 84.6% ± 2.4%, p<0.01). There was not any significant difference 
in the magnitude of LTD induced in control conditions and in presence of KT5823 
(2 µM) (p > 0.05). 
These results confirm the role of NO in the induction of muscarinic dependent 
LTD, as previously verified in the first part of this study carried out in Bologna. 
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Also, Cch-LTD does not rely on the PKG activation, unlikely to what observed for 5 
Hz LTD, that’s still M1 dependent but induced with electrical instead of chemical 
stimulation (Jo et al., 2006). The possible reasons for this discrepancy are 
discussed in section 4. 
3.1.4. Role of the NOS in the TBS-induced LTP (Bristol) 
The bath application of L-NAME at both 200 µM (Fig 3.6. B, n = 3, baseline: 
102.1% ± 1.9%; 60 min follow-up: 131.6% ± 5.6%, p<0.01) and 2 mM (Fig 3.6. C, 
n = 6, baseline: 101.4% ± 1.7%; 60 min follow-up: 120.0% ± 5.3%, p<0.01) did not 
affect LTP induction compared to controls (Fig 3.6. A, n = 26, baseline: 101.4% ± 
1.7%; 60 min follow-up: 114.8% ± 2.8%, p<0,01). There was not any significant 
difference in the magnitude of the LTP induced in the three different conditions. (p 
> 0.05). These data show that NOS is not involved in the induction of LTP. For this 
reason I did not further verify the role of sGC and PKG in TBS-induced LTP since 
these two enzymes are sequentially activated after NO production. 
3.1.5. Effect of the cannabinoid receptors  CB1 and CB2 activation on the 
basal synaptic transmission (Bristol) 
The selective CB1 agonist ACEA (1 µM) did not affect basal synaptic 
transmission in the Prh of male juvenile Dark Agouti rats when bath applied for 
either 20 min (Fig 3.7. A, n = 6, p > 0.05) or 60 min (Fig 3.7. B, n = 6, p>0.05). The 
same lack of effect has been observed after the bath application of the CB1/CB2 
not selective agonist WIN55,212-2 (2 µM) for 20 min (Fig 3.7. C, n = 4, p > 0.05). 
3.1.6. Role of the CB1 activation in 5 Hz-induced LTD (Bristol) 
Both ACEA (1 µM) (Fig 3.8. B, n = 7, baseline: 98,5% ± 3.1%; 60 min follow-
up: 79.7% ± 2.5%, p<0.01) and AM251 (1 µM) (Fig 3.8. C, n = 5, baseline: 93.3% 
± 1.3%; 60 min follow-up: 76.6% ± 7.2%, p<0.01) did not affect the induction of  5 
Hz LTD compared to controls run in presence of EtOH 0,1% (Fig 3.8. A, n = 5, 
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baseline: 92.6% ± 4.9%; 60 min follow-up: 83.9% ± 1.2%, p<0.01). There was no 
significant difference in the magnitude of LTD induced in presence of EtOH 0.1%, 
ACEA (1 µM) and AM251 (1 µM) (p > 0.05). 
 3.1.7. Role of the CB1 activation in Cch-induced LTD (Bristol) 
Both ACEA (1 µM) (Fig 3.9. B, n = 6, baseline: 96.5% ± 1.4%; 60 min follow-
up: 87.6% ± 3.4%, p < 0.01) and AM251 (1 µM) (Fig 3.9. C, n = 6, baseline: 95.3% 
± 4.9%; 60 min follow-up: 81.8% ± 5.5%, p < 0.01) did not affect the induction of 
Cch-LTD compared to controls (Fig 3.9. A, n = 21, baseline: 98.8% ± 1.1%; 60 min 
follow-up: 76.4% ± 4.2%, p < 0.01). There was no significant difference in the 
magnitude of LTD induced in control conditions and in presence of ACEA (1 µM) 
and AM251 (1 µM) (p > 0.05). The results illustrated in this and the previous 
section, indicate that EC-dependent transmission is not involved in the induction of 
muscarinic dependent LTD in the Prh cortex of the rat, induced with both electrical 
and chemical stimulation (see section 4. for discussion). 
3.1.8. Role of the CB1 activation in TBS-induced LTP (Bristol) 
Application of TBS determined the induction of a robust LTP (Fig 3.10. A, n = 
26, baseline: 99.3% ± 0.7%; 60 min follow-up: 114.8% ± 2.8%, p < 0.01) in the Prh 
of juvenile male Dark Agouti rats. In order to assess the role of the EC 
transmission in the induction of TBS-LTP, the CB1 agonist ACEA (1 µM) and 
antagonist AM251 (1 µM) were bath applied. As shown in Fig 3.10., both ACEA (1 
µM) (Fig 3.10. B, n = 12, baseline: 98.9% ± 1.3%; 60 min follow-up: 103.2% ± 
4.0%, p > 0.05) and AM251 (1 µM) (Fig 3.10. C, n = 8, baseline: 96.5% ± 0.6%; 60 
min follow-up: 97.1% ± 2.8%, p > 0.05) both blocked the induction of  TBS-LTP. 
There was no significative difference in the LTP magnitude between controls and 
in presence of ACEA (1 µM) (p > 0.05) and between controls and AM251 (1 µM) (p 
> 0.05) but there was a significant difference between controls and AM251 (1 µM) 
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. These results indicate a role for EC-dependent transmission in the LTP induction 
in the Prh cortex of the rat (see section 4. for discussion). 
3.1.9. Role of the astrocytes in the TBS-induced LTP (Bristol) 
Even if eCBs are usually associated to the depression of synaptic transmission 
(see section 1.4. for details), recent studies showed that probably this is a narrow 
vision of the phenomenon, suggesting a double functional role for eCBs in both 
potentiation and depression of synaptic transmission (Abush and Akirav, 2009; 
Navarrete and Araque, 2010). Expecially, Navarrete and Araque showed in the 
CA1 of hippocampal slices that eCBs, that are activity dependently released by 
neurons, induce depression when they bind the CB1 on the presynaptic terminal, 
and potentiation when they bind the CB1 on the proximal astrocytes via increase 
in the astrocyte intracellular Ca2+ and, in turn, glutamate release and binding to the 
presynaptic mGluR1. Since in this study I observed a role for eCBs in the LTP 
induction in the Prh of juvenile male Dark Agouti rats, in this section I evaluated 
the role of astrocytes i LTP induction by applying TBS on slices pre-incubated for 
at least 50 min in aCSF added with the glial toxin fluoracetate 5 mM (FAC) 
(Henneberger et al., 2010). 
Application of TBS determined the induction of a robust LTP (A, n = 26, 
baseline: 99.3% ± 0.7%; 60 min follow-up: 114.8% ± 2.8%, p<0.01) in the Prh of 
juvenile male Dark Agouti rats. The pre-incubation of the slice in aCSF containing 
FAC (5 mM; at least 50 min) does not affect the magnitude of LTP (B, n = 6, 
baseline: 100.1% ± 1.8%; 60 min follow-up: 127.2% ± 10.9%, p<0.01). These 
results indicate that astrocytes are not involved in the induction of LTP (see 
section 4. for discussion). 
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3.2. Role of the NO and eCBs in visual recognition memory acquisition 
The behavioural experiments were kindly performed by dr Gareth Barker under 
the supervision of dr Clea Warburton. The drugs were locally infused into the Prh 
of a rat via bilaterally implanted cannulas (see section 2.4. for methodological 
details). The recognition memory was quantitatively evaluated via the spontaneous 
preferential exploration of a novel versus a familiar object (Ennaceur and 
Delacour, 1988) using delays of 20 min and 24 hours. 
 
3.2.1. Effect of the neuronal NOS (nNOS) in the acquisition of visual 
recognition memory (Bristol) 
The selective antagonist for the neuronal isoform of NOS (nNOS) N-ω- propyl 
L arginine (NPA, 2 µM) was locally infused into a rat’s Prh via bilaterally implanted 
cannulas (Warburton et al., 2003) (Fig. 2.3.). Recognition memory was assessed 
with spontaneous novel object exploration task (Ennaceur and Delacour, 1988), 
using delays of 20 min and 24 h. For each delay, NPA or vehicle was infused 
15min before the initial familiarization phase in order to test the effect of blocking 
nNOS during acquisition. Analysis of the discrimination at test revealed a 
significant drug by delay interaction [F(1,20)=12.99, p<0.01] and a significant 
effect of drug F[1,20)= 18.18, p<0.001] but no significant effect of delay [F1,20)= 
4.09, p>0.05]. Analysis of the significant main effects revealed that the NPA 
infused animals were significantly impaired compared to the vehicle infused 
animals at the 24h (p<0.001) but not the 20 min delay (p>0.1). Additional analysis 
confirmed that the vehicle infused animals discriminated between the novel and 
familiar objects at both delays tested [20min t(9)= 4.50, p<0.001; 24h t(11)= 7.07, 
p<0.001]; in contrast the NPA infused animals only showed discrimination between 
the novel and familiar object at the 20min delay [t(9)= 2.76, p<0.05] but not at the 
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24h delay [t(11)= -1.13, p>0.1]. Analysis of the time taken to complete the sample 
phase and the amount of exploration completed in the sample and test phases 
revealed no significant interaction between treatment and delay [for all F<1.0, 
p>0.1] and no significant effect of drug [time to complete sample phase F(1,20)= 
2.78, p>0.1; exploration in sample phase F<1.0, p>0.1; exploration in test phase 
F<1.0, p>0.1]. However there was a significant effect of delay on the amount of 
exploration completed in the test phase [F(1,20)= 4.88, p<0.05] which reflected the 
fact that both vehicle and NPA infused animals spent significantly more time 
exploring the objects at the 20min delay than the 24h delay; there was no 
significant effect of delay on the amount of time taken to complete the sample 
phase [F<1.0, p>0.1] and the amount of exploration completed in the sample 
phase [F(1,20)=2.36, p>0.1] (See table  3.1. for means). 
3.2.2. Effect of the cannabinoid receptor 1 (CB1) in the acquisition of 
visual recognition memory (Bristol) 
AM251 (2 µM) or vehicle was infused 15 min before the training phase, in order 
to investigate the role of CB1 in the acquisition of new visual recognition memory. 
Analysis of the discrimination at test revealed a non significant drug by delay 
interaction [F(1,18)<1.0, p>0.1] a non significant effect of drug [F(1,18)<1.0, p>0.1] 
and no significant effect of delay [F(1,18)<1.0, p>0.1]. Analysis of the significant 
main effects revealed that the AM251 infused animals were not significantly 
impaired compared to the vehicle infused animals at the 24h (p>0.01) and the 20 
min (p>0.01). Additional analysis confirmed that the vehicle infused animals 
discriminated between the novel and familiar objects at both delays tested [20min 
t(9)= 5.19, p<0.001; 24h t(9)= 8.28, p<0.001], just as the AM251 infused animals 
[20min t(9)= 2.93, p<0.05; 24h t(9)= 7.66, p<0.001]. Analysis of the time taken to 
complete the sample phase and the amount of exploration completed in the 
 108
sample and test phases revealed no significant interaction between treatment and 
delay [time to complete sample phase F(1,18)<1.0, p>0.1; exploration in sample 
phase F(1,18)=4.36, p>0.05; exploration in test phase F(1,18)<1.0, p>0.1] and no 
significant effect of drug [for all F(1,18)<1.0, p>0.1]. Also there was not a 
significant effect of delay on the time taken to complete the sample phase and the 
amount of exploration completed in the sample [time to complete sample phase 
F(1,18)= 2.16, p>0.1; exploration in sample phase F(1,18)<1.0, p>0.1]; however 
there was a significant effect of delay on the amount of exploration completed in 
the test phase [F(1,18)= 7.42, p<0.05] which reflected the fact that both vehicle 
and AM251 infused animals spent significantly more time exploring the objects at 
the 20min delay than the 24h (See table  3.1. for means). 
3.3. Early impairment in basal synaptic transmission and LTD in the 
perirhinal cortex of Tg2576 mice 
These results show an early impairment in the basal synaptic transmission and 
LTD induction in Prh of 3 month old transgenic mice carrying the Swedish 
mutation on the gene for the APP (Tg2576), an animal model widely used for the 
systematic investigation of  AD (see section 2.3. for methodological details). Field 
potential recordings were performed on Prh containing brain slices (see section 
2.3. for methodological details). I observed a significant impairment in the 
input/output (I/O) curve at 200 mV of stimulation but not at lower voltages (Fig 
3.12. A, at 200 mV, littermate controls, n=7: 1.53 mV ± 0.09 mV; Tg2576, n=8: 
1.09 mV ± 0.10 mV, p < 0.01). The application of 5 Hz LFS determines the 
induction of a robust LTD in the Prh from littermate controls (Fig 3.12. B, n = 5, 
baseline: 96.2% ± 1.2%; 60 min follow-up: 81.9% ± 4.0%, p < 0.01); the same 
stimulation protocol does not induce LTD in the Prh from Tg2576 (Fig 3.12. C, n = 
8, baseline: 104.6% ± 2.6%; 60 min follow-up: 97.9% ± 3.4%, p > 0.05). The 
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magnitude of LTD between littermate controls and Tg2576 is significantly different 
(p < 0.01). 
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Fig 3.1.   Role of NO in 5 Hz-induced LTD in Prh in brain slices from juvenile Sprague-Dawley rats.  5 Hz-induced LTD (A, n=11, p<0.01) is blocked by 
antagonists of the NOS (L-NAME; 2 mM) (B, n=6, p>0.05), sGC (NS2028; 0.5 µM) (C, n=7, p>0.05) and PKG (KT5823; 2 µM) (D, n=4, p>0.05). Black 
bar: 5Hz-LFS. In this and in the following figures data are shown as mean values ± S.E.M. Scale bar: 20 ms, 1 mV (in this and following figures) 
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 Fig 3.2. Role of NO in 5 Hz-induced LTD in Prh in brain slices from juvenile Sprague-Dawley rats.  Neither a weak 5 Hz LFS consisting in 1350 pulses (A, 
n=9, p>0.05) nor bath application of the NO donor DEA/NONOate (3 µM) (B, n=4, p>0,05) induce LTD, but the co-application of the two protocols induce 
a robust and persistent LTD (C, n=9, p<0,01).   
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 Fig 3.3. Role of the NO/sGC pathway in CCh-induced LTD in Prh in brain slices from juvenile Sprague-Dawley rats.  Bath application of Cch 50 µM for 10 
min induces LTD (A, n=21, p<0.01) in control slices, but not in slices pre-treated with the NOS antagonist L-NAME (2 mM) (B, n=8, p>0.05) or the sGC 
antagonist NS2028 (0.5 µM) (C, n=9, p>0,05).  Black bar: Cch 50 µM 
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Fig 3.4. Role of NO in CCh-induced LTD in Prh in brain slices from juvenile Dark Agouti rats.  
Bath application of Cch 50 µM for 10 min induces LTD in control slices (A, n=21, p<0.01) and in 
slices pre-treated with the NOS antagonist L-NAME 50 µM (B, n=7, p<0.01) but not in those pre-
treated with L-NAME 200 µM (C, n=9, p>0.05) or 2 mM (D, n=5, p>0.05) or with the nNOS 
selective antagonist NPA (E, n=5, p<0.01).  Black bar: Cch 50 µM 
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Fig 3.5. Role of  PKG in CCh-induced LTD in Prh in brain slices from juvenile Dark Agouti rats.  Bath application of Cch 50 µM for 10 min induces LTD in 
control slices (A, n=21, p<0.01). The PKG antagonist KT5823 (2 µM) does not affect Cch-LTD induction (B, n=7, p<0,01).  Black bar: Cch 50 µM 
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A B 
C 
Fig 3.6. Role of NO in TBS-induced LTP in Prh in brain slices from juvenile Dark Agouti rats. TBS induces a robust LTP (A, n=26, p<0,01) in control 
slices. LTP induction is not affected by the NOS antagonist L-NAME 200 µM (B, n=4, p<0,01) or 2 mM (C, n=6, p<0,01).  Black arrow: TBS 
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A B 
C 
Fig 3.7. Role of CB1 in basal synaptic transmission in Prh in brain slices from juvenile Dark Agouti rats. Basal synaptic transmission is not affected by 
bath application of the CB1 selective agonist ACEA (1 µM) for 20 min (A, n=6, p>0.05) or 60 min (B, n=6, p>0.05), or the CB1/CB2 agonist WIN55,212-2 
(2 µM) for 20 min (C, n=4, p>0.05).  
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 Fig 3.8. Role of CB1 in 5Hz-induced LTD in Prh in brain slices from juvenile Dark Agouti rats. 5Hz-induced LTD (A, n=11, p<0.01) is not affected by 
bath application of the CB1 selective agonist ACEA (1 µM) (B, n=7, p<0.01) or the CB1 selective antagonist AM251 (1 µM) (C, n=5, p<0.01). Black bar: 
5Hz-LFS 
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Fig 3.9. Role of CB1 in Cch-induced LTD in Prh in brain slices from juvenile Dark Agouti rats. Cch- LTD (A, n=21, p<0.01) is not affected by bath 
application of the CB1 selective agonist ACEA (1 µM) (B, n=7, p<0.01) or the CB1 selective antagonist AM251 (1 µM) . (C, n=5, p<0.01). Black bar: 
Cch 50 µM 
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Fig 3.10. Role of CB1 in TBS-induced LTP in Prh in brain slices from juvenile Dark Agouti rats. TBS-induced LTP (A, n=26, p<0.01) is blocked by bath 
application of the CB1 selective agonist ACEA (1 µM) (B, n=13, p>0.05) or the CB1 selective antagonist AM251 (1 µM) (C, n=8, p>0.05). Black arrow: 
TBS 
A 
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A B 
Fig 3.11. Role of astrocytes in TBS-induced LTP in Prh in brain slices from juvenile Dark Agouti rats. TBS application induces a robust LTP (A, n=26, p<0.01); 50 
min pre-incubation of the slices in aCSF containing the glial toxin FAC (5 mM) does not affect LTP induction (B, n=6, p<0.01). Black arrow: TBS 
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Fig 3.12. Role of NO and endocannabinoids in visual recognition memory acquisition in juvenile Dark Agouti rats. A. Infusion of the nNOS selective antagonist 
NPA (2 µM) in the Prh impairs longer-term (24 h) but not shorter-term (20 min) recognition memory. Data are presented, for each group, as mean (±SEM) DR 
(proportion of additional time spent exploring a novel rather than a familiar object). For control animals,  DR was significantly different from zero (i.e. they 
discriminate between novel and familiar) at both delays, whereas for NPA (2 µM) treated animals DR was significantly different from zero at 20 min but not at 
24 h. *p < 0.01 difference between the 20 min and 24 h delay within NPA-treated animals; ***p < 0.001, difference between vehicle- and NPA-treated animals at 
the 24 h delay. B. Infusion of the CB1 selective antagonist AM251 (10 µM) in the Prh does not affect recognition memory at both delays.  
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Infusion Delay Time to complete acquisition phase (s) Total exploration in 
acquisition phase (s) 
Total exploration in test 
phase 
Vehicle 20 min (n=10/group) 190 ± 14 34 ± 3 33 ± 3 
NPA 210 ± 13 34 ± 2 31 ± 2 
  F(1,20) < 1.0; NS F(1,20) < 1.0; NS F(1,20) < 1.0; NS 
Vehicle 24 hours (n=12/group) 214 ± 11 36 ± 1 26 ± 1 
NPA 227 ± 6 35 ± 1 27 ± 2 
  F(1,20) < 1.0; NS F(1,20) < 1.0; NS F(1,20) < 1.0; NS 
Vehicle 20 min (n=10/group) 174 ± 15 40 ± 0.1 30 ± 3 
AM251 191 ± 17 38 ± 1 34 ± 3 
  F(1,18) < 1.0; NS F(1,18) < 1.0; NS F(1,18) < 1.0; NS 
Vehicle 24 hours (n=10/group) 169 ± 20 36 ± 2 25 ± 3 
AM251  154 ± 18 39 ± 0.7 25 ± 2 
  F(1,18) < 1.0; NS F(1,20) < 1.0; NS F(1,18) < 1.0; NS 
 
 
Tab 3.1. Role of NO and endocannabinoids in visual recognition memory acquisition in juvenile Dark Agouti rats: effect of the nNOS selective antagonist NPA 
and CB1 selective antagonist AM251 on general exploration behaviour. No significant (NS) differences in total exploration times were observed between control 
and treated animals; hence, the drugs had no significant effect on general exploration behaviour.  
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Fig 3.13. Early impairment in basal synaptic transmission and LTD in the perirhinal cortex of Tg2576 mice. Input/output relationship revealing significant 
differences in basal synaptic transmission at 200 µA but not at lower stimulation intensities (A, 
 
 littermate controls, n=7, 
 
 Tg2576, n=8). 5 Hz LFS 
induces a robust LTD in Prh in brain slices from littermate controls (B, n=5, p<0.01) but not in those from Tg2576 mice (C, n=8, p>0.05). Black bar: 5Hz-LFS 
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4. DISCUSSION 
4.1.  Role of NOS/sGC/PKG and CB1 in rat perirhinal cortex LTD and LTP 
induction 
In the last decade many studies tried to clarify the cellular correlates underlying 
synaptic plasticity in Prh (Bilkey, 1996; Ziakopoulos et al., 1999; Cho et al., 2000; 
Massey et al., 2001, 2004; Aicardi et al., 2004; Jo et al., 2006; Jo et al., 2008; 
Griffiths et al., 2008; Seoane et al., 2009). The induction of LTD in the rat Prh has 
been shown to depend on the activation of different receptors, including glutamate 
ionotropic receptors (NMDAR; KR) (Cho et al., 2000; Park et al., 2006), 
metabotropic glutamate receptors (mGluRs) (Cho et al., 2000; reviewed by Cho 
and Bashir, 2002; reviewed by Bashir, 2002; Jo et al., 2006; Jo et al., 2008), and 
metabotropic acetylcholine (Ach) receptor (muscarinic 1; M1) (Massey et al., 2001; 
reviewed by Bashir, 2002). Several studies have highlighted that LTD may be the 
main cellular correlate of visual recognition memory. In vivo studies showed that 
the neuronal activity is reduced in the Prh of an animal performing a visual 
recognition task (Brown and Wilson, 1987; Fahi et al., 1993; Li et al., 1993; Miller 
et al., 1993; Xiang et al., 1998). This view has been confirmed by 
immunohistochemical observations: the expression of the immediate early gene c-
fos is reduced in the ‘familiar’ hemisphere of the Prh of rats that received the 
paired-viewing protocol (Zhu et al., 1996; Warburton et al., 2003; Massey et al., 
2008). Further in vitro electrophysiological studies confirmed that LTD in acute Prh 
slices represents the the neuronal event related to familiarity acquisition 
(Warburton et al., 2003; Massey et al., 2008, Griffiths et al., 2008).  
LTP induction relies on NMDAR activation (Bilkey, 1996) and requires TrkB 
activation by BDNF (Aicardi et al., 2004), even if the role of this form of synaptic 
plasticity in visual recognition memory is still not clear. 
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Cholinergic neurotransmission has been shown to have a pivotal role in visual 
recognition memory acquisition and LTD induction in the rat Prh (Massey et al., 
2001; Warburton et al., 2003; Winters and Prickaerts 2005; Winters et al., 
2006a,b; Winters et al., 2007). 
There is still lacking evidence of a retrograde messenger able to coordinate 
pre- and post-synaptic changes occurring in Prh for the induction and 
consolidation of synaptic plasticity. Here, I investigated the role of NO (and the 
associated downstream pathway, that is: sGC and PKG) and the cannabinoid 
receptor 1 (CB1) in both LTD and LTP in the Prh of juvenile rats.  
4.1.1.  Role of NOS/sGC/PKG  in LTD and LTP induction in the rat 
perirhinal cortex 
The first part of this study is focused on the role of NOS/sGC/PKG pathway in 
LTD induction in the rat Prh.  NO is a small amphiphillic molecule physiologically 
produced by the enzyme NO synthase (NOS) in response to increased 
intracellular Ca2+. NOS is expressed in three different isoforms: neuronal and 
endothelial (nNOS and eNOS, respectively), that are constitutively expressed and 
are activated by the Ca2+/calmodulin complex, and the inducible isoform (iNOS), 
which is  Ca2+ -independent and it is physiologically expressed at very low levels in 
macrophages and glia. Its expression is induced by an inflammatory insult. NO is 
widely produced throughout the body, and it mainly acts as a relaxant of the 
smooth muscles and therefore represents a major component in the regulation of 
the blood flow (reviewed by Toda and Okamura, 2003). In the vertebrate CNS, NO 
is involved in many functions: i) neuronal proliferation and development (Mize and 
Lo, 2000; Contestabile and Ciani, 2004; Estrada and Murillo-Carretero, 2005), ii) 
synaptic plasticity, memory and learning (Susswein et al., 2004; Garthwaite et al., 
2008; Steinert et al., 2010) iii) neurodegeneration (Contestabile et al, 2003). NO 
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mainly acts through the activation of the downstream enzyme soluble guanylate 
cyclase (sGC), that converts GTP in the second messenger cGMP; cGMP in turn 
activates many targets, including PKG. cGMP is hydrolised to GMP by 11 different 
isoforms of phosphodiesterases (PDEs), that therefore act as negative control 
system on the NO-dependent transmission. For a more extensive overview on NO 
see section 1.3 and subsections.  
NO is involved in the induction of both LTP and LTD in many brain areas 
including hippocampus, cerebellum and prefrontal cortex (Garthwaite & Boulton, 
1995; Holscher, 1997; Prast & Philippu, 2001; Susswein et al., 2004; Garthwaite et 
al., 2008; Steinert et al., 2010). Hippocampal LTP at SC/CA1 excitatory synapses 
requires NOS/sGC/PKG activation: here NO acts as a retrograde messenger 
(Arancio et al., 1996, 2001, Bon and Garthwaite, 2003). Similarly, NO mediates 
hippocampal LTD via Ca2+ release from cyclic ADP-ribose sensitive stores (Reyes-
Harde et al., 1999). The activation of the NOS/sGC/PKG pathawy has been 
demonstrated to be involved in cerebellar heterosynaptic LTD (Shibuki and 
Kimura, 1997; Shin and Linden, 2005) and homosynaptic LTP (Jacoby et al., 
2001).  
Cholinergic neurotransmission has been shown to play a central role in the 
acquisition of visual recognition memory (Massey et al., 2001; Warburton et al., 
2003; Winters et al., 2005, 2006, 2007). Recent studies showed the association 
between M1-dependent LTD and the activation of the NOS/sGC/PKG pathway in 
the prefrontal cortex (Huang et al., 2009), corticostriatal synapses (Centonze et al., 
2003) and lizard neuromuscular junction (Graves et al., 2004). A recent study has 
shown that NO and eCBs signalling cascades interact in the induction of the 
corticostriatal group I mGluR-dependent DHPG-LTD (Sergeeva et al., 2007). M1 is 
a gq-coupled receptor and hence its activation results in PLC activation that 
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converts the phosphatidil inositol bisphosphate (PIP2) in diacylglycerol (DAG) and 
inositol trisphosphate (IP3). DAG is usually associated with protein kinase C (PKC) 
activation while IP3 is responsible for Ca2+ release from intracellular stores. It has 
been recently shown that M1/M3 activation brings to NO production in the rat 
retina (Borda et al., 2005).  
NO synthase is highly expressed in the rat Prh (Liu et al., 2003a,b). 
Furthermore, the induction of 5Hz-LTD in the Prh of juvenile (p28-35) rats is M1- 
dependent (Jo et al., 2006). In addition, bath application of the cholinergic agonist 
carbachol (Cch, 50 µM) for 10 min results in M1-dependent LTD in rat Prh: this 
form of Cch-induced LTD (Cch-LTD) requires intracellular Ca2+ release and protein 
synthesis but does not require PKC and protein phosphatases activation (Massey 
et al., 2001). These observations suggest that M1-dependent LTD and NMDAR-
dependent LTP in Prh may rely on the activation of the NOS/sGC/PKG pathway.  
In the present work, evoked extracellular field potentials were recorded on II/III 
layer of horizontal Prh slices from juvenile (p21-35) rats. Fig 3.1 shows that the 
LTD induced by the application of a low frequency stimulation consisting in 3000 
pulses delivered at 5 Hz (5Hz-LTD) in juvenile (p21-35) Sprague-Dawley rats (A) 
is blocked by bath application of: the NOS antagonist L-NAME (2 mM) (B), the 
sGC antagonist NS2028 (0,5 µM) (C) and the PKG antagonist KT5823 (2 µM) (D). 
These data confirmed that the NOS/sGC/PKG pathway is necessary for the 
induction of 5Hz-LTD, suggesting that NO can be the retrograde messenger 
involved in this form of synaptic plasticity in the Prh of juvenile rats.  
To confirm this result, a second subset of experiments was carried out with an 
opposite approach: instead of blocking NO production, a NO donor, diethylamine 
NONOate (DEA/NO 3 µM), was bath applied. DEA/NO releases NO in a pH- and 
temperature-dependent fashion: at a pH=7.4 and T=32°C, the half-life of DEA/NO 
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is ~ 6 min (Bon and Garthwaite, 2001). Previous studies showed that DEA/NO at 3 
µM does not affect basal synaptic transmission at hippocampal SC/CA1 synapses 
(Bon and Garthwaite, 2003), but it induces a transient depression and subsequent 
potentiation at 300 µM (Bon and Garthwaite, 2001). DEA/NO (300 µM)-dependent 
transient depression does not rely on the activation of sGC; probably it is a 
consequence of the neurotoxic effect of the exogenous NO that, at those 
concentrations, can interfere with the cell oxydative phosphorylation. However,  
the subsequent potentiation has been demonstrated to require sGC activity (Bon 
and Garthwaite, 2001). DEA/NO at 3 µM does not affect basal synaptic 
transmission but causes an increase in intracellular cGMP levels. DEA/NO co-
application with a weak tetanus, unable to induce synaptic plasticity, results in the 
induction of a robust and prolonged LTP (Bon and Garthwaite, 2003). 
Consistently, DEA/NO (3 µM) does not affect basal synaptic transmission in rat 
Prh, as shown in Fig 3.2 B. Fig 3.2 A shows that the application of a weak 5Hz-
LFS consisting of 1350 instead of 3000 pulses is not strong enough to result in 
LTD induction. As shown in Fig 3.2. C, the co-application of the two protocols 
(DEA/NO 3 µM and weak 5Hz-LFS) results in the induction of a robust and 
prolonged LTD. These results suggest that low concentrations of NO are 
necessary but not sufficient for LTD induction, raising the possibility that LFS 
activates other cellular mechanisms involved in LTD, complementing the 
depressing activity of NO.  
Consistently with the work of Massey et al. (2001), I observed that bath 
application of the cholinergic agonist carbachol (Cch, 50 µM) for 10 min induced a 
robust LTD in the Prh cortex of juvenile (p21-35) Sprague-Dawley rats (Fig 3.3. A; 
3.4. A). As shown in Fig 3.3. B, the blockade of NOS by the non selective NOS 
antagonist L-NAME (2 mM) resulted in the inhibition of Cch-LTD induction. 
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Consistently with the trend observed in the 5Hz-LTD experiments, the bath 
application of the sGC antagonist NS2028 (0.5 µM) resulted in the blockade of 
Cch-LTD induction.  
As explained in section 2.1, this project has been carried out in two different 
laboratories in slightly different conditions: in Bristol the experiments were 
performed on p28-35 Dark Agouti (DA) rats instead of the p21-35 Sprague-Dawley 
rats used in Bologna (for more details on experimental differences between the 
two laboratories see section 2.1). Therefore, the first series of experiments carried 
out in Bristol was performed in order to confirm the role of NOS in Cch-LTD. As 
shown in Fig 3.4, L-NAME blocked Cch-LTD induction at 200 µM (C) and 2 mM 
(D) but not at 50 µM (B). Finally, since in physiological conditions both eNOS and 
nNOS are constitutively active, and since L-NAME is a non selective antagonist of 
both these constitutive isoforms of NOS, I verified the role of the nNOS in Cch-
LTD. Bath application of the nNOS selective antagonist NPA (20 µM) effectively 
blocked Cch-LTD compared to controls (Fig 3.4. E). This result does not exclude a 
role for eNOS in Cch-LTD, but it confirms the role of the nNOS, providing an 
interesting cellular correlate of the behavioural data discussed below (see section 
3.2 and 4.2). In order to better define the respective potential role for nNOS and 
eNOS in Cch-LTD, a good experimental strategy could be to perform experiments 
on single nNOS, eNOS or double eNOS/nNOS KO mice (Son et al., 1996; 
reviewed by Steinert et al. (2010). Finally, Fig 3.5 shows that PKG is not involved 
in Cch-LTD induction, since bath application of KT5823 did not block Cch-LTD 
induction compared to controls. This is at variance with the results obtained with 
5Hz-LFS application, that showed the involvement of the entire NOS/sGC/PKG 
pathway in LTD induction. It is plausible to assume that Cch-LTD relies on the 
activity of the second messenger cGMP on different effectors from PKG: for 
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instance, it could directly act on cyclic-nucleotide dependent channels (CNC) or on 
voltage gated potassium channels 1(Kv1). Another possible explanation is that the 
chemical protocol is much stronger than the electrical one, i.e. activates multiple 
intracellular pathways: thus, even if PKG was activated by the application of both 
induction protocols, KT5823 did not block Cch-LTD because the activation of other 
downstream Ca2+-dependent mechanisms compensated the PKG blockade. 
Further investigation is needed to explain this discrepancy.  
NO has been very well characterized  as a retrograde messenger in 
hippocampal NMDAR-dependent LTP induction (Arancio et al., 1996; 2001; Puzzo 
et al., 2005; Wang et al., 2005). Therefore, I also verified the possible role of NO in 
Prh LTP. LTP in Prh is NMDAR-dependent (Bilkey, 1996). The NMDAR activation 
is usually strongly associated with NO production. Indeed, nNOS is intracellularly 
co-localized at the postsynaptic density with NMDAR (see section 1.4.1. for 
details). Nonetheless, Fig 3.6 shows that NO is not involved in LTP in Prh, since L-
NAME (200 µM or 2 mM) does not block its induction. 
4.1.2.  Role of CB1 LTD and LTP induction in the rat perirhinal cortex 
The next step in this study was to evaluate the role of eCBs in synaptic 
plasticity in the rat Prh. As described in section 1.5, eCBs are lipidic messengers 
involved in memory, learning and synaptic plasticity, expecially LTD. Their 
production is triggered by the activation of several Gq-coupled receptors, 
includiong group I mGluRs and M1. Gq-coupled receptor activation results in PLC 
activation as a consequence of Ca2+ release from the intracellular stores mediated 
by IP3. PLC is also activated by other several sources of intracellular Ca2+ increase 
(i.e. NMDAR and/or VGCC activation). PLC activation results in the production of 
DAG that is the substrate for diacylglicerol lipase (DGL) that converts DAG in 2 
arachidonyl glicerol (2-AG). 2-AG and anandamide (whose synthetic pathway is 
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still to be clarified) represent the two known eCBs. The eCBs membrane 
transporter (EMT) mediates the eCBs release in the synaptic cleft. Here they act 
presynaptically by binding the CB1, mainly expressed in the CNS, or the CB2, 
mainly expressed in the peripheral nervous system. CB1 is a Gi/o-coupled receptor 
that mediates the decreased activation of adenylate cyclase (AC) and, in turn, 
decreased PKA activity. This should result in decreased glutamate secretion from 
the presynaptic terminals. This phenomenon is regarded as eCB-mediated LTD 
(eCB-LTD), described in many brain areas such as striatum, prefrontal cortex and 
hippocampus (see section 1.5.; reviewed by Heyfetts and Castillo, 2009).  
Since it has been observed high expression of CB1 in Prh (Tsou et al., 1998; 
Liu et al., 2003c), and since M1 is a Gq-coupled receptor, I investigated the 
possible role of eCBs in M1-dependent LTD (both electrically and chemically 
induced) in Prh. Although NO is critically involved in this form of LTD in Prh (as 
discussed in section 4.1.1.), a role of eCBs can not be excluded, since group I 
mGluR-dependent LTD in corticostriatal glutamatergic synapses relies on the 
sequential activation of CB1 and NOS (Sergeeva et al., 2007). Fig 3.7 shows that 
the selective agonist ACEA (1 µM) did not affect basal synaptic transmission in rat 
Prh slices; the same trend was observed with the CB1/2 non selective agonist 
WIN55,212-2 (2 µM). Furthermore, Fig 3.8 and 3.9 show that ACEA (1 µM) or the 
CB1 antagonist AM251 (1 µM) did not affect the induction of both 5Hz-LTD and 
Cch-LTD, compared to control. These result suggests that eCBs are not involved 
in Prh LTD in our experimental conditions. Recent studies have shown that CB1 
activation may play a role in potentiation of synaptic responses in rat hippocampus 
(Abush and Akirav, 2009; Navarrete and Arraque, 2010). It has been shown that 
intraperitoneal injection of AM251 impaired LTP induction at the SC/CA1 
synapses, while the inhibitor of the reuptake and breakdown of the eCBs AM404 
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facilitated it (Abush and Akirav, 2009). Furthermore, a recent elegant study 
showed that eCBs can both induce potentiation and depression in the SC/CA1 
synapses, depending on the cell type on which they act. More precisely, a 
neuronal depolarization results in activity-dependent release of eCBs, which bind 
the presynaptic CB1 and induce depression. But if the eCBs bind the CB1 
expressed on the astrocytes proximal to the site of neuronal depolarization, this 
results in increased Ca2+ concentration in the astrocytic cytosol, causing release of 
glutamate on the presynaptic neuron, which in turn increases glutamate release 
via activation of the presynaptic group I mGluRs (Navarrete and Araque, 2010).  
In order to investigate if a similar involvement of CB1 activation in potentiation 
also occurs in Prh, I carried out LTP experiments in presence of ACEA or AM251. 
As shown in Fig 3.10,C, AM251 (1 µM) blocked LTP, suggesting that CB1 
activation is necessary for LTP induction. On the other hand, Fig 3.10B shows that 
also the agonist ACEA (1 µM) blocks LTP.. Thus, CB1 activation appears 
necessary for LTP induction, because LTP induction is compromised when it is 
blocked. But when CB1 is continuously activated by an agonist (ACEA) LTP is 
inhibited, possibly due to a form of desensitization. This hypothesis needs to be 
verified by further experiments.  
According to the study cited above on the role of astrocytic CB1 in 
hippocampal LTP (Navarrete and Araque, 2010), in order to investigate the role of 
astrocytes in this novel form of CB1-dependent LTP in the Prh cortex of juvenile 
rats, I carried out a series of experiments on Prh slices preincubated with the 
astrocytic toxin fluoracetate (FAC, 5 mM) for at least 50 min (as described by 
Henneberger et al., 2010). As shown in Fig 3.11., the selective astrocytic 
degeneration did not affect LTP induction in the rat Prh. Hence, it remains to be 
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clarified the cellular machinery responsible for this new atypical form of synaptic 
plasticity. 
4.2. Role of nitric oxide and endocannabinoids in the acquisition of visual 
recognition memory 
As described in section 1.4.4 and 1.5.4, several behavioural studies on animal 
models confirmed the role of both NO and eCBs (and the relative signalling 
cascade) in many forms of memory and learning, consistently with the evidence of 
their involvement in synaptic plasticity. 
The cellular correlate of visual recognition memory has been extensively 
explored in the last years. The main approach consisted in the direct infusion of 
drugs into the Prh of bilaterally cannulated rats (reviewed by Brown et al., 2010). 
These drugs mainly consist in agonists or antagonists of membrane receptors. 
The visual recognition memory abilities of the animals were then assessed with 
the spontaneous novel object exploration task. In the training phase of this test, 
the animal familiarizes with two identical objects in an arena in which the animal 
should acquire visual memory. After a certain delay (20 min or 24 h), the animal is 
placed back in the arena where one of the familiar objects is replaced with a novel 
object: if it has memorized the previous objects, it tends to spend more time 
exploring the novel object rather than the familiar one. Hence, if visual recognition 
memory is intact, the ratio of the exploration time between the novel and the 
familial object is high; when visual recognition memory is compromised, the animal 
equally explore both the novel and the familiar object, and the exploration ratio will 
result low. The animals infused with a specific drug are compared with control 
animals receiving saline: the infusion of the drug at different stages of the 
experiment (before or after the training phase, or before the test phase) gives 
information about the stage of visual recognition memory (acquisition, 
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consolidation, retrieval) affected by the drug. So far it has been observed that the 
the AMPA antagonist CNQX impairs both acquisition and retrieval (Winters and 
Bussey, 2005). Futhermore, blockade of NMDAR and group I and II mGluRs 
results in the impairment of visual recognition memory acquisition when tested at 
24 h but not at 20 min (Barker et al., 2006a,b). Blockade of the kainate receptor 
(KR) impairs visual recognition memory acquisition at 20 min but not at 24 h 
(Barker et al., 2006b), just as recently observed when M1 is blocked by 
scopolamine (Tinsley et al., in submission). Also, many lines of evidence underlie 
the pivotal role of cholinergic transmission in visual recognition memory acquisition 
(Warburton et al., 2003; Winters and Prickaerts, 2005; Winters et al., 2006a,b; 
Winters et al., 2007; Massey et al., 2008).  
Recent studies showed the involvement of NO in visual recognition memory: 
the intraperitoneal injection of the non-specific NOS antagonist L-NAME, before 
and immediately after the training phase, successfully blocked visual recognition 
memory acquisition in a spontaneous novel object exploration task at 24 hours but 
not at 1 hour. Furthermore, L-NAME administered before the test phase at 24 
hours rescued the delay-dependent deficit in visual recognition memory 
(Boultadakis et al., 2010a). Another study showed that the systemic administration 
of a NO donor (NCX2057) rescues the visual recognition memory deficit caused 
by the previous systemic administration of the muscarinic antagonist scopolamine 
(Boultadakis et al., 2010b). Moreover, L-NAME systemic administration can rescue 
the visual recognition memory acquisition deficit induced by the NMDAR 
antagonist MK-801 and ketamine (Boultadakis and Pitsikas, 2010). All these 
studies have two major limits: first, L-NAME is a non selective antagonist of NOS, 
therefore it may affect a broad range of physiological functions, including blood 
flow (see section 1.4.); second, the administration was systemic and therefore the 
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drug did not selectively act on Prh. Another recent study showed that 
intrahippocampal infusion of the antagonists of the NOS/sGC/PKG pathway 
results in the impairment of the acquisition and the consolidation of visual 
recognition memory, suggesting that this pathway can exert a critical role in this 
form of memory. Interestingly, it has been shown that NOS/sGC/PKG activation 
leads to the activation of β-adrenergic receptors and, in turn, increases BDNF 
synthesis (Furini et al., 2009). This study has two main limits: the first one is that 
they used Wistar rats, which are characterized by low visual acuity; second, they 
worked on hippocampus, that is not specifically involved in visual recognition 
memory (reviewed by Brown et al., 2001; Brown et al., 2010). 
In order to overwhelm these limits, in the present study I included some 
behavioural results obtained in collaboration with Dr. Clea Warburton. The 
experiments were kindly performed by Dr. Gareth Barker. These experiments 
evaluated the role of NO in visual recognition memory. A selective antagonist for 
the nNOS, N-ω-propyl L arginine (NPA, 2 µM), was bilaterally infused into the Prh 
of Dark-Agouti adult rats. Since nNOS is selectively expressed in neurons and 
does not have a role in the blood flow regulation, we used of a specific antagonist 
for nNOS to avoid possible artifacts due to reduced blood flow in the infused area. 
Furthermore, we used Dark-Agouti rats which are characterized by a relatively 
high visual acuity, compared to other strains. Finally, the intra-Prh injections 
allowed us to evaluate the behavioural effects of the drug selectively acting on the 
brain area of interest. The dose of 2 µM in 1 µL was chosen in order to selectively 
act on the nNOS, since at higher concentrations NPA can lose specificity (supplier 
data, Tocris). As shown in Fig 3.12A, bilateral intra-Prh infusion of NPA (2 µM) 15 
min before the training phase successfully blocked visual recognition memory 
when tested at a delay of 24 hours but not at 20 min. This behavioural evidence is 
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consistent with present electrophysiological data (nNOS is necessary for Cch-LTD, 
see Fig 3.4 E) and with previous studies showing that cholinergic 
neurotransmission in Prh is necessary for visual recognition memory acquistion 
(Warburton et al., 2003; Winters and Bussey, 2005; Winters et al., 2006a,b; 
Winters et al., 2007; Massey et al., 2008).  
A recent study has shown that intra-Prh infusion of scopolamine generates a 
deficit in visual recognition memory acquisition when tested at 20 min but not at 24 
h; the opposite temporal pattern (deficit at 24 h but not at 20 min) was observed 
for the α7 nicotinc antagonist MLA (Tinsley et al., in preparation). The reciprocal 
involvement of muscarinic and nicotinic receptors in visual recognition memory 
acquisition tested at short and long term, is similar to what observed for glutamate 
metabotropic receptors (Barker et al., 2006a,b). Assuming that nNOS is activated 
by M1 activation, my observation that NPA blocks acquisition of visual recognition 
memory when tested at 24 h but not at 20 min appears in temporal contrast with 
data obtained with scopolamine. 
In a second subset of behavioural experiments it has been evaluated the role 
of the CB1 receptor in acquisition of visual recognition memory tested at 20 min 
and 24 h. As shown in Fig. 3.12. B, the CB1 antagonist AM251 (10 µM) did not 
affect visual recognition memory acquisition tested at both time points. This result 
is consistent with the electrophysiological evidence that CB1 is not involved in LTD 
induction. On the other hand, the functional relevance of the observed CB1 
involvement in LTP induction remains to be elucidated, because the relationship 
between LTP in Prh and visual recognition memory is still not defined. 
Interestingly, Abush and Akirav (2009) observed that intra-hippocampal infusion of 
the CB1 antagonist AM251 and the CB1/2 agonist WIN55,212-2 does not affect 
the performance in an inhibitory avoidance test, while the endocannabinoid 
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reuptake and breakdown antagonist AM404 enhances it. Furthermore, in Morris 
water maze test, animals treated both intra-hippocampally and systemically with 
WIN55,212-2, AM251 or AM404, are all impaired in spatial memory compared to 
controls. Also, many studies investigating the role of eCBs in memory and learning 
suggest that CB1 is mainly involved in memory extinction phenomena (Chhatval et 
al., 2005; Varvel et al., 2007). Therefore, the finding that CB1s is not involved in 
visual recognition memory acquisition it’s not surprising. Further investigations are 
required to evaluate the possible role of eCBs in consolidation, retrieval and delay-
dependent impairment of visual recognition memory. Finding an active role for 
CB1 in visual recognition memory might, in turn, help to understand the 
physiological role of LTP in this brain region. 
4.3. Early deficit in the synaptic transmission and plasticity in the 
perirhinal cortex of an Alzheimer’s disease murine model 
Most of the studies on AD carried out on transgenic murine models, including 
the Tg2576 model, have been focused on testing hippocampal functions with 
behavioural experiments on spatial memory, in vitro electrophysiological 
recordings and molecular biology studies (immunohistochemistry, western blots, 
RT-PCR). However, hippocampus is not the only area of the temporal lobe 
affected by the cholinergic loss and by the accumulation of soluble β-amyloid 
oligomers. Therefore, hippocampus-related memory is not the only impaired 
cognitive function in AD patients. In particular, visual recognition memory is highly 
impaired in the very first stages of the disease in humans affected by MCI (Didic et 
al., 2010; Viggiano et al., 2008). Prh is highly innervated by cholinergic fibres 
coming from the forebrain basal nuclei, which exert a pivotal role in Prh activity 
and visual recognition memory (reviewed by Winters et al., 2008; reviewed by 
Brown et al., 2010).  
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For these reasons, in the present study I have investigated synaptic functions 
(transmission and plasticity) in Prh slices from 3 month old Tg2576 mice and from 
littermate controls. The input/output curve presented in Fig 3.13A shows a 
significant deficit in basal synaptic transmission at high intensity of stimulation. 
Furthermore, Fig 3.13B shows that 5Hz-LFS application results in the induction of 
a robust LTD in littermate control but not in Tg2576 mice Prh slices. Considering 
the relationship between LTD in Prh and visual recognition memory, one may 
suppose that the very early deficit in Prh synaptic plasticity might underlie a deficit 
in visual recognition memory. A recent study demonstrated that 5 month old 
Tg2576 mice show a deficit in visual recognition memory when tested in a 
spontaneous novel object exploration task at 4 and 24 hours, but not at 2 min after 
the training phase, compared to littermate controls. The deficit observed was 
successfully reversed by the systemic administration of the calmodulin antagonist 
MK506 (Taglialatela et al., 2008). Interestingly, these results are in contrast with 
another study that showed that 14 month old Tg2576 mice did not show any visual 
recognition memory deficit when tested with the same behavioural protocol at 24 
hours (Hale and Good, 2005). This discrepancy was interpreted by Taglialatela et 
al. as a consequence of the different genetic background of the murine strains 
used to obtain the mutants. It would be worthwhile to perform the same 
experiment at 3 months of age, and to try to evaluate molecular differences 
between Tg2576 and the littermate controls.  These preliminary results suggest 
that the study of Prh alterations in AD can provide a novel experimental platform to 
better understand the etiopathology of the disease, which may lead to new 
therapeutic strategies. 
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CONCLUSIONS 
The pivotal role of Prh in visual recognition memory is well established, and in the 
last 15 years many behavioural, electrophysiological and molecular studies have 
investigated the cellular and molecular mechanisms underlying this cognitive 
function. In particular, it has been shown that LTD-like rather than LTP-like 
phenomena underlie visual recognition memory formation, and that cholinergic 
neurotransmission is a crucial component.  Although many facets of the synaptic 
functions in Prh have been clarified, there is still lacking evidence of a retrograde 
messenger coordinating pre- and post-synaptic changes in long-term potentiation 
(LTP) and long-term depression (LTD). NO and eCBs have been extensively 
investigated as retrograde messengers in synaptic plasticity in other brain areas, 
and their role in memory and learning is well estabilished.  
In the present study, an integrated behavioural-electrophysiological approach 
was used to evaluate the role of NO and eCBs in synaptic plasticity in the Prh and 
in visual recognition memory. The results obtained indicate that NO is selectively 
involved in LTD induction (both chemically and electrically induced), but not in LTP 
induction. Conversely, the eCB receptor CB1 is selectively involved in LTP, but not 
in LTD.  The latter was an upredicted result, since previous studies in other brain 
regions have shown a selective involvement of this receptor in LTD induction. The 
electrophysiological data were confirmed in behavioural experiments, which 
demonstrate that nNOS plays an important role in the acquisition of visual 
recognition memory, whereas CB1 appears not involved in this process. The role 
of this receptor in LTP induction suggests its possible involvement in other aspects 
of visual recognition memory, which need further investigation.  
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Finally, preliminary data from a transgenic murine model of AD (Tg2576) 
showed a very early impairment (3 months of age) in Prh synaptic transmission 
and plasticity. This is an interesting result, since one of the major goals in AD 
research is to characterize the early stages of the disease in order to improve 
diagnostic and therapeutic tools. Prh may provide a good experimental platform for 
the investigation of the pathogenesis of this debilitating disorder. 
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